EP4186518A1 - Polynucleotides codant l'interleukine-12 (il12) et leurs utilisations - Google Patents

Polynucleotides codant l'interleukine-12 (il12) et leurs utilisations Download PDF

Info

Publication number
EP4186518A1
EP4186518A1 EP22204799.5A EP22204799A EP4186518A1 EP 4186518 A1 EP4186518 A1 EP 4186518A1 EP 22204799 A EP22204799 A EP 22204799A EP 4186518 A1 EP4186518 A1 EP 4186518A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
cancer
sequence
hil12ab
il12b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22204799.5A
Other languages
German (de)
English (en)
Inventor
Joshua Frederick
Susannah HEWITT
Ailin Bai
Stephen Hoge
Vladimir PRESNYAK
Iain Mcfadyen
Kerry BENENATO
Ellalahewage Sathyajith Kumarasinghe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4186518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of EP4186518A1 publication Critical patent/EP4186518A1/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Definitions

  • Interleukin-12 is a pro-inflammatory cytokine that plays an important role in innate and adaptive immunity. Gately, MK et al., Annu Rev Immunol. 16: 495-521 (1998 ). IL12 functions primarily as a 70 kDa heterodimeric protein consisting of two disulfide-linked p35 and p40 subunits. IL12 p40 homodimers do exist, but other than functioning as an antagonist that binds the IL12 receptor, they do not appear to mediate a biologic response. Id.
  • the precursor form of the IL12 p40 subunit (NM_002187; P29460; also referred to as IL12B, natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2) is 328 amino acids in length, while its mature form is 306 amino acids long.
  • the precursor form of the IL12 p35 subunit (NM_000882; P29459; also referred to as IL 12A, natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1) is 219 amino acids in length and the mature form is 197 amino acids long. Id.
  • the genes for the IL12 p35 and p40 subunits reside on different chromosomes and are regulated independently of each other.
  • IL12 protein Due to its ability to activate both NK cells and cytotoxic T cells, IL12 protein has been studied as a promising anti-cancer therapeutic since 1994. See Nastala, C. L. et al., J Immunol 153: 1697-1706 (1994 ). But despite high expectations, early clinical studies did not yield satisfactory results. Lasek W. et al., Cancer Immunol Immunother 63: 419-435, 424 (2014 ). Repeated administration of IL12, in most patients, led to adaptive response and a progressive decline of IL12-induced interferon gamma (IFN- ⁇ ) levels in blood. Id.
  • IFN- ⁇ interferon gamma
  • IFN-induced anti-cancer activity is largely mediated by the secondary secretion of IFN ⁇
  • the concomitant induction of IFN- ⁇ along with other cytokines (e.g., TNF- ⁇ ) or chemokines (IP-10 or MIG) by IL12 caused severe toxicity. Id .
  • the marginal efficacy of the IL12 therapy in clinical settings may be caused by the strong immunosuppressive environment in humans.
  • Id. To minimize IFN- ⁇ toxicity and improve IL12 efficacy, scientists tried different approaches, such as different dose and time protocols for IL12 therapy. See Sacco, S. et al., Blood 90: 4473-4479 (1997 ); Leonard, J. P. et al., Blood 90: 2541-2548 (1997 ); Coughlin, C. M. et al., Cancer Res. 57: 2460-2467 (1997 ); Asselin-Paturel, C. et al., Cancer 91: 113-122 (2001 ); and Saudemont, A. et al., Leukemia 16: 1637-1644 (2002 ). Nonetheless, these approaches have not significantly impacted patient survival. Kang, W. K., et al., Human Gene Therapy 12: 671-684 (2001 ).
  • the present disclosure provides mRNA therapeutics for the treatment of cancer.
  • the mRNA therapeutics of the disclosure are particularly well-suited for the treatment of cancer as the technology provides for the intracellular delivery of mRNA encoding immune modulating polypeptides (for example, immune stimulating polypeptides, such as IL-12, and the like, useful in immuno-oncology ("IO")), followed by de novo synthesis of functional proteins within target cells, e.g., within target cells in tumors.
  • immune modulating polypeptides for example, immune stimulating polypeptides, such as IL-12, and the like, useful in immuno-oncology ("IO")
  • IO immuno-oncology
  • the disclosure features therapeutic mRNAs having modified nucleotides to (1) minimize unwanted immune activation (e.g., the innate immune response associated with in vivo introduction of foreign nucleic acids) and (2) optimize the translation efficiency of mRNA to protein.
  • Exemplary aspects of the disclosure feature therapeutic mRNAs having a combination of nucleotide modifications to reduce the innate immune response and sequence optimization, in particular, within the open reading frame (ORF) of therapeutic mRNAs encoding immune modulating polypeptides (e.g., immune stimulating polypeptides such as IL-12) to enhance protein expression.
  • immune modulating polypeptides e.g., immune stimulating polypeptides such as IL-12
  • the mRNA therapeutic technology of the disclosure features delivery of mRNA(s) encoding immune modulating (e.g., immune stimulating) polypeptides via a lipid nanoparticle (LNP) delivery system.
  • the mRNA therapeutic technology of the disclosure features delivery of mRNA(s) encoding immune modulating polypeptides into tumors via a lipid nanoparticle (LNP) delivery system.
  • the disclosure also features novel ionizable lipid-based LNPs which have improved properties when combined with mRNA(s) encoding immune modulating (e.g., immune stimulating) polypeptides and administered in vivo, for example, cellular uptake, intracellular transport and/or endosomal release or endosomal escape.
  • the LNP formulations of the disclosure also demonstrate reduced immunogenicity associated with the in vivo administration of LNPs.
  • Certain aspects of the present disclosure are directed to a method of reducing the size of a tumor or inhibiting growth of a tumor in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising one or more polynucleotides encoding an IL-12 polypeptide, wherein the polynucleotide comprises an open reading frame (“ORF") encoding an interleukin 12 p40 subunit (“IL12B”) polypeptide and an interleukin 12 p35 subunit (“IL12A”) polypeptide.
  • ORF open reading frame
  • IL12B interleukin 12 p40 subunit
  • IL12A interleukin 12 p35 subunit
  • the method further comprises administering to the subject an effective amount of a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or an effective amount of a composition comprising a checkpoint inhibitor polypeptide.
  • the checkpoint inhibitor polypeptide inhibits PD1, PD-L1, CTLA-4, or a combination thereof.
  • the checkpoint inhibitor polypeptide comprises an antibody.
  • administering the composition activates T cells in the subject.
  • Another aspect of the present disclosure is directed to a method of activating T cells in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising one or more polynucleotides encoding an IL-12 polypeptide, wherein the polynucleotide comprises an ORF encoding an IL12B polypeptide and an IL12A polypeptide.
  • the T cell activation comprises inducing T cell proliferation.
  • the T cell activation comprises inducing T cell infiltration in the tumor or increasing the number of tumor-infiltrating T cells.
  • the T cell activation comprises inducing a memory T cell response.
  • the activated T cells comprise CD4 + T cells, CD8 + T cells, or both.
  • administering the composition alone or in combination with a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or a composition comprising a checkpoint inhibitor polypeptide increases an effector to suppressor T cell ratio in the tumor.
  • administering the composition further increases the number of activated NK cells in the subject.
  • administering the composition increases cross-presenting dendritic cells in the tumor of the subject.
  • administering the composition reduces the size of a distal tumor or inhibits growth of a distal tumor in the subject.
  • Another aspect of the present disclosure is directed to a method of increasing an effector to suppressor T cell ratio in a tumor of a subject in need thereof comprising administering to the subject an effective amount of a composition comprising one or more polynucleotides encoding an IL-12 polypeptide, wherein the polynucleotide comprises an ORF encoding an IL12B polypeptide and an IL12A polypeptide.
  • the effector to suppressor T cell ratio is a CD8 + T cells: T regulatory (Treg) cells ratio.
  • Another aspect of the present disclosure is directed to a method of increasing the number of activated Natural Killer (NK) cells in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising one or more polynucleotides encoding an IL-12 polypeptide, wherein the polynucleotide comprises an ORF encoding an IL12B polypeptide and an IL12A polypeptide.
  • NK Natural Killer
  • Another aspect of the present disclosure is directed to a method of increasing cross-presenting dendritic cells in a tumor of a subject in need thereof comprising administering to the subject an effective amount of a composition comprising one or more polynucleotides encoding an IL-12 polypeptide, wherein the polynucleotide comprises an ORF encoding an IL12B polypeptide and an IL12A polypeptide.
  • the cross-presenting dendritic cells are CD103 + cells.
  • Another aspect of the present disclosure is directed to a lipid nanoparticle comprising a polynucleotide encoding a human IL12 polypeptide, wherein the polynucleotide comprises an ORF encoding a human IL12B polypeptide operably linked to a human IL12A polypeptide.
  • the IL12B polypeptide and the IL12A polypeptide are fused directly or by a nucleic acid encoding a linker.
  • the IL12B polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, or at least 98% identical to amino acids 23 to 328 of SEQ ID NO: 48, wherein the amino acid sequence has IL12B activity.
  • the IL12A polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, or at least 98% identical to amino acids 336 to 532 of SEQ ID NO: 48, wherein the amino acid sequence has IL12A activity.
  • the polynucleotide comprises a nucleotide sequence encoding a signal peptide.
  • the signal peptide is an IL12B signal peptide.
  • the composition comprises a polynucleotide comprising an ORF encoding an IL12B polypeptide operably linked via a linker to an IL12A polypeptide.
  • the composition comprises a polynucleotide comprising an ORF encoding an IL12B signal peptide, an IL12B polypeptide, a linker and an IL12A polypeptide.
  • the linker comprises a Gly/Ser linker.
  • the IL12 polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO: 48.
  • the polynucleotide comprises a nucleotide sequence at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5 to 44, 236, and 237.
  • the polynucleotide comprises a nucleotide sequence at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO: 236 or 237.
  • the polynucleotide comprises an ORF comprising at least one chemically modified nucleoside.
  • the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and a combination thereof.
  • the chemically modified nucleosides in the ORF are selected from the group consisting of uridine, adenine, cytosine, guanine, and any combination thereof.
  • the polynucleotide comprises a miRNA binding site.
  • the miRNA binding site is a miR-122 binding site.
  • the miRNA binding site is a miR-122-3p or miR-122-5p binding site.
  • the miRNA binding site comprises a nucleotide sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% identical to aacgccauua ucacacuaaa ua (SEQ ID NO: 51), wherein the miRNA binding site binds to miR-122.
  • the miRNA binding site comprises a nucleotide sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% identical to uggaguguga caaugguguu ug (SEQ ID NO: 53), wherein the miRNA binding site binds to miR-122.
  • the miRNA binding site comprises a nucleotide sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% identical to caaacaccau ugucacacuc ca (SEQ ID NO: 54), wherein the miRNA binding site binds to miR-122.
  • the polynucleotide comprises a 5' untranslated region (UTR).
  • the 5' UTR comprises a nucleic acid sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence listed in Table 3.
  • the polynucleotide comprises a 3' untranslated region (UTR).
  • the 3' UTR comprises a nucleic acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence listed in Table 4A or 4B.
  • the polynucleotide comprises a miRNA binding site within the 3' UTR.
  • the polynucleotide comprises a nucleotide spacer sequence fused to the miRNA binding site. In some embodiments, the polynucleotide comprises a 5' terminal cap structure. In some embodiments, the polynucleotide comprises a 3' polyA tail. In some embodiments, the polynucleotide comprises a codon optimized ORF. In certain embodiments, the polynucleotide is in vitro transcribed (IVT) polynucleotide. In certain embodiments, the polynucleotide is circular.
  • IVT in vitro transcribed
  • the polynucleotide is formulated with a delivery agent.
  • the delivery agent comprises a lipidoid, a liposome, a lipoplex, a lipid nanoparticle, a polymeric compound, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a conjugate.
  • the delivery agent is a lipid nanoparticle.
  • the delivery agent comprises a compound having formula (I) or a salt or stereoisomer thereof, wherein
  • the compound is of Formula (IA): or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M 1 is a bond or M'; R 4 is unsubstituted C 1-3 alkyl, or -(CH 2 ) n Q, in which n is 1, 2, 3, 4, or 5 and Q is OH, -NHC(S)N(R) 2 , or -NHC(O)N(R) 2 ; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; and R 2 and R 3 are independently selected from the group consisting of H, C 1-14 alkyl, and C 2-14 alkenyl.
  • the compound is of Formula (II): or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; M 1 is a bond or M'; R 4 is unsubstituted C 1-3 alkyl, or -(CH 2 ) n Q, in which n is 2, 3, or 4 and Q is OH, -NHC(S)N(R) 2 , or -NHC(O)N(R) 2 ; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; and R 2 and R 3 are independently selected from the group consisting of H, C 1-14 alkyl, and C 2-14 alkenyl.
  • the compound is selected from Compound 1 to Compound 147, and salts and stereoisomers thereof.
  • the delivery agent comprises a compound having the formula (I) or a salt or stereoisomer thereof, wherein R 1 is selected from the group consisting of C 530 alkyl, C 520 alkenyl, -R*YR", -R", and R"M'R'; R 2 and R 3 are independently selected from the group consisting of H, C 114 alkyl, C 214 alkenyl, R*YR", YR", and R*OR", or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle; R 4 is selected from the group consisting of a C 36 carbocycle, (CH 2 ) n Q, -(CH 2 ) n CHQR, CHQR, CQ(R) 2 , and unsubstituted C 16 alkyl, where Q is selected from a carbocycle, hetero
  • the delivery agent further comprises a phospholipid.
  • the phospholipid is selected from the group consisting of 1,2 dilinoleoyl sn glycero 3 phosphocholine (DLPC), 1,2 dimyristoyl sn glycero phosphocholine (DMPC), 1,2 dioleoyl sn glycero 3 phosphocholine (DOPC), 1,2 dipalmitoyl sn glycero 3 phosphocholine (DPPC), 1,2 distearoyl sn glycero 3 phosphocholine (DSPC), 1,2 diundecanoyl sn glycero phosphocholine (DUPC), 1 palmitoyl 2 oleoyl sn glycero 3 phosphocholine (POPC), 1,2 di O octadecenyl sn glycero 3 phosphocholine (18:0 Diether PC), 1 oleoyl 2
  • DLPC 1,2
  • the phospholipid is selected from the group consisting of 1 myristoyl 2 palmitoyl sn glycero 3 phosphocholine (14:0-16:0 PC, MPPC), 1 myristoyl 2 stearoyl sn glycero 3 phosphocholine (14:0-18:0 PC, MSPC), 1 palmitoyl 2 acetyl sn glycero 3 phosphocholine (16:0-02:0 PC), 1 palmitoyl 2 myristoyl sn glycero 3 phosphocholine (16:0-14:0 PC, PMPC), 1 palmitoyl 2 stearoyl sn glycero 3 phosphocholine (16:0-18:0 PC, PSPC), 1 palmitoyl 2 oleoyl sn glycero 3 phosphocholine (16:0-18:1 PC, POPC), 1 palmitoyl 2 linoleoyl sn glycero 3 phosphocholine (16
  • the delivery agent further comprises a structural lipid. In some embodiments, the delivery agent further comprises a PEG lipid. In some embodiments, the delivery agent further comprises an ionizable lipid selected from the group consisting of 3 (didodecylamino) N1,N1,4 tridodecyl 1 piperazineethanamine (KL10), N1 [2 (didodecylamino)ethyl] N1,N4,N4 tridodecyl 1,4 piperazinediethanamine (KL22), 14,25 ditridecyl 15,18,21,24-tetraaza-octatriacontane (KL25), 1,2 dilinoleyloxy N,N dimethylaminopropane (DLin-DMA), 2,2 dilinoleyl 4 dimethylaminomethyl [1,3] dioxolane (DLin-K-DMA), heptatriaconta 6,9,28,31 tetraen
  • the delivery agent further comprises a quaternary amine compound.
  • the quaternary amine compound is selected from the group consisting of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-
  • DOTAP 1,2-
  • 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine DLePC
  • 1,2-distearoyl-3-trimethylammonium-propane DSTAP
  • 1,2-dipalmitoyl-3-trimethylammonium-propane DPTAP
  • 1,2-dilinoleoyl-3-trimethylammonium-propane DLTAP
  • 1,2-dimyristoyl-3-trimethylammonium-propane DMTAP
  • 1,2-distearoyl -sn-glycero-3-ethylphosphocholine DSePC
  • 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine DPePC
  • 1,2-dimyristoyl -sn-glycero-3-ethylphosphocholine DOePC
  • 1,2-di-di-di-di-sn-glycero-3-ethylphosphocholine DOe
  • the composition is formulated for in vivo delivery. In some aspects, the composition is formulated for intramuscular, subcutaneous, intratumoral, or intradermal delivery.
  • the administration treats a cancer.
  • the cancer is selected from the group consisting of adrenal cortical cancer, advanced cancer, anal cancer, aplastic anemia, bileduct cancer, bladder cancer, bone cancer, bone metastasis, brain tumors, brain cancer, breast cancer, childhood cancer, cancer of unknown primary origin, Castleman disease, cervical cancer, colon/rectal cancer, endometrial cancer, esophagus cancer, Ewing family of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gestational trophoblastic disease, Hodgkin disease, Kaposi sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer, small
  • the composition is administered by a device comprising a pump, patch, drug reservoir, short needle device, single needle device, multiple needle device, micro-needle device, jet injection device, ballistic powder/particle delivery device, catheter, lumen, cryoprobe, cannula, microcanular, or devices utilizing heat, RF energy, electric current, or any combination thereof.
  • the effective amount is between about 0.10 mg/kg to about 1,000 mg/kg.
  • the present disclosure provides a new approach to treat cancer involving the prevention or treatment of disease with substances (e.g., mRNAs encoding II,12) that stimulate the immune response, i.e., immunotherapy.
  • substances e.g., mRNAs encoding II,12
  • immunotherapy i.e., immunotherapy.
  • the disclosure relates to methods of treating cancer using a polynucleotide encoding IL12.
  • An IL12 polypeptide as disclosed herein comprises IL12A, IL12B, or both IL12A and IL12B.
  • the disclosure provides methods of treating cancer using a combination approach that features mRNAs encoding IL12 and an anti-cancer agent, e.g., an immune-checkpoint inhibitor, e.g., anti-PD-1 antibody, anti-PD-L1 antibody, and/or anti-CTLA-4 antibody.
  • an anti-cancer agent e.g., an immune-checkpoint inhibitor, e.g., anti-PD-1 antibody, anti-PD-L1 antibody, and/or anti-CTLA-4 antibody.
  • an anti-cancer immune response is possible by administering, e.g ., intratumorally, mRNAs encoding IL12 in the stimulation of, for example, T-cells and/or natural killer cells. Therefore, an mRNA encoding IL12 is believed to provide a first stimulation signal to the immune system, for example, within the tumor environment, e.g., via intratumoral injection of the mRNA. IL12 can also stimulate the production of interferon-gamma (IFN- ⁇ ) and tumor necrosis factor-alpha (TNF- ⁇ ) from T cells and natural killer (NK) cells.
  • IFN- ⁇ interferon-gamma
  • TNF- ⁇ tumor necrosis factor-alpha
  • the disclosure provides a method of treating tumor comprising administering a polynucleotide (e.g., mRNA) encoding IL12 in combination with an anti-PD-1 antibody or anti-PD-L1 antibody to block the interaction between PD-L1 and its receptor, i.e., PD-1.
  • the disclosure includes a method of treating tumor comprising administering a polynucleotide (e.g., mRNA) encoding IL12 in combination with an anti-CTLA-4 antibody.
  • the disclosure provides a method of treating tumor comprising administering a polynucleotide (e.g., mRNA) encoding IL12 in combination with an anti-PD-1 antibody or anti-PD-L1 antibody and an anti-CTLA-4 antibody.
  • a polynucleotide e.g., mRNA
  • Some aspects of the disclosure also include additional agents, e.g., OX40L, a polynucleotide encoding OX40L, or mRNA encoding an OX40L.
  • the anti-PD-1 antibody or anti-PD-L1 antibody can be administered in the form of a polynucleotide.
  • the anti-CTLA-4 antibody can be administered in the form of a polynucleotide.
  • Exemplary aspects feature treatment with lipid nanoparticle-(LNP-) encapsulated mRNAs.
  • Exemplary aspects feature intratumoral administration of mRNAs in cationic lipid-based LNPs.
  • Certain aspects of the present disclosure are directed to methods of reducing or decreasing size, mass, and/or volume of a tumor or preventing the growth of a tumor in a subject in need thereof comprising administering a polynucleotide, e.g ., mRNA, encoding an IL12B and/or IL12A polypeptide disclosed herein, or a vector or a host cell comprising the polynucleotide, or an IL12B and/or IL12A polypeptide encoded by the polynucleotide.
  • a polynucleotide e.g ., mRNA, encoding an IL12B and/or IL12A polypeptide disclosed herein
  • a vector or a host cell comprising the polynucleotide, or an IL12B and/or IL12A polypeptide encoded by the polynucleotide.
  • the polynucleotide encodes an IL-12 polypeptide, wherein the polynucleotide comprises an ORF encoding an IL12B and an IL12A polypeptides.
  • the methods of reducing the size (including mass and/or volume) of a tumor or inhibiting growth of a tumor in a subject in need thereof comprise administering to the subject an effective amount of a composition comprising one or more polynucleotides.
  • the one or more polynucleotides encode an IL-12 polypeptide.
  • the one or more polynucleotides comprise an ORF encoding an IL12B polypeptide.
  • the one or more polynucleotides comprise an ORF encoding an IL12A polypeptide. In certain embodiments, the one or more polynucleotides comprise an ORF encoding an IL12B polypeptide and an IL12A polypeptide.
  • the methods further comprise administering a second agent.
  • the second agent comprises an effective amount of a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide.
  • the second agent comprises an effective amount of a composition comprising a checkpoint inhibitor polypeptide.
  • the checkpoint inhibitor is any checkpoint inhibitor known in the art or described herein.
  • the checkpoint inhibitor is an anti-PD-1 antibody.
  • the checkpoint inhibitor is an anti-PD-L1 antibody.
  • the checkpoint inhibitor is an anti-CTLA-4 antibody.
  • the second agent comprises an effective amount of a composition comprising a polynucleotide comprising an ORF encoding OX40L.
  • the checkpoint inhibitor is selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, or a polynucleotide encoding OX40L or any other agents disclosed herein.
  • the composition comprising a checkpoint inhibitor comprises more than one checkpoint inhibitor.
  • the method comprises administering (i) an mRNA, encoding an IL12B and/or IL12A polypeptide disclosed herein, and (ii) an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody, a polynucleotide encoding OX40L, or any combination thereof.
  • the methods reduce the size of a tumor in a subject as compared to the size of the tumor before the administration.
  • the size of the tumor is reduced by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100%.
  • the subject exhibits a partial resonse. In certain embodiments, the subject exhibits a complete response.
  • the methods of the present disclosure inhibit, stop or delay tumor growth in a subject in need thereof.
  • the tumor growth is inhibited, stopped or delayed for at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 9 months, at least about 12 months, at least about 15 months, at least about 18 months, at least about 24 months, or at least about 36 months.
  • the tumor growth is inhibited indefinitely.
  • the present disclosure provides methods of promoting an anti-tumor effect (e.g. , induce T cell proliferation, induce T cell infiltration in a tumor, induce a memory T cell response, increasing the number of NK cells, etc.) by administering the polynucleotide (e.g., mRNA) encoding IL12 alone or the polynucleotide in combination with any agents disclosed herein.
  • an anti-tumor effect e.g. , induce T cell proliferation, induce T cell infiltration in a tumor, induce a memory T cell response, increasing the number of NK cells, etc.
  • the present disclosure provides a method of activating T cells in a subject in need thereof, inducing T cell proliferation in a subject in need thereof, inducing T cell infiltration in a tumor of a subject in need thereof, and/or inducing a memory T cell response in a subject in need thereof, comprising administering to the subject a composition disclosed herein, e.g., a polynucleotide (e.g., mRNA) encoding IL12, alone or in combination with composition comprising a second agent, e.g ., a checkpoint inhibitor polypeptide or a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide, e.g ., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, or a polynucleotide encoding OX40L or any other agents disclosed herein.
  • a composition disclosed herein e.g., a polynucleo
  • the intratumoral administration of the polynucleotide (e.g., mRNA) encoding IL12 alone or in combination with a second agent can increase the efficacy of the anti-tumor effect (e.g., T cell infiltration in a tumor) compared to other routes of administration.
  • the anti-tumor effect e.g., T cell infiltration in a tumor
  • the administering of the compositions described herein activates T cells in the subject.
  • T cell activation can be characterized in any way known in the art.
  • the activated T cells express CD4.
  • the activated T cells express CD8.
  • the activated T cells express CD4 and CD8.
  • the activated T cells comprise CD4 + T cells, CD8 + T cells, or both CD4 + T cells and CD8 + T cells.
  • activated T cells in the subject reduce the size of a tumor or inhibit the growth of a tumor in the subject.
  • Activation of T cells can be measured using applications in the art such as measuring T cell proliferation; measuring cytokine production with enzyme-linked immunosorbant assays (ELISA) or enzyme-linked immunospot assays (ELISPOT); or detection of cell-surface markers associated with T cell activation (e.g., CD69, CD40L, CD137, CD25, CD71, CD26, CD27, CD28, CD30, CD154, and CD134) with techniques such as flow cytometry.
  • ELISA enzyme-linked immunosorbant assays
  • ELISPOT enzyme-linked immunospot assays
  • T cell activation comprises inducing T cell proliferation.
  • T cell proliferation is increased by at least about 1.5 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 20 fold, at least about 30 fold, at least about 50 fold, or at least about 100 fold, as compared to the level of T cell proliferation prior to the administration of the IL12 encoding polynucleotide (e.g., mRNA).
  • the IL12 encoding polynucleotide e.g., mRNA
  • T cell proliferation in the subject is directed to an anti-tumor immune response in the subject.
  • the T cell proliferation in the subject reduces or decreases the size of a tumor or inhibits the growth of a tumor in the subject.
  • T cell proliferation can be measured using applications in the art such as cell counting, viability staining, optical density assays, or detection of cell-surface markers associated with T cell activation (e.g., CD69, CD40L, CD137, CD25, CD71, CD26, CD27, CD28, CD30, CD154, and CD134) with techniques such as flow cytometry.
  • T cell activation comprises induction of T cell infiltration of the tumor.
  • T cell infiltration in the tumor is increased by at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 20 fold, at least about 30 fold, at least about 50 fold, or at least about 100 fold, as compared to the level of T cell infiltration of the tumor prior to the administration of the IL12 encoding polynucleotide (e.g., mRNA).
  • the IL12 encoding polynucleotide e.g., mRNA
  • T cell activation comprises increasing the number of tumor-infiltrating T cells.
  • the number of tumor-infiltrating T cells in the tumor is increased by at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 20 fold, at least about 30 fold, at least about 50 fold, or at least about 100 fold, as compared to the number of tumor infiltrating T cells in the tumor prior to the administration of the IL12 encoding polynucleotide (e.g., mRNA)
  • the IL12 encoding polynucleotide e.g., mRNA
  • T cell infiltration in a tumor of the subject is directed to an anti-tumor immune response in the subject.
  • the T cell infiltration in a tumor of the subject reduces or decreases the size of a tumor or inhibits the growth of a tumor in the subject.
  • T cell infiltration in a tumor can be measured using applications in the art such as tissue sectioning and staining for cell markers, measuring local cytokine production at the tumor site, or detection of T cell-surface markers with techniques such as flow cytometry.
  • T cell activation comprises inducing a memory T cell response in a subject in need thereof.
  • the memory T cell response is increased by at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 20 fold, at least about 30 fold, at least about 50 fold, or at least about 100 fold, as compared to the memory T cell response prior to the administration of the IL12 encoding polynucleotide (e.g., mRNA).
  • the IL12 encoding polynucleotide e.g., mRNA
  • the memory T cell response in the subject is directed to an anti-tumor immune response in the subject.
  • the memory T cell response in the subject reduces or decreases the size of a tumor or inhibits the growth of a tumor in the subject.
  • a memory T cell response can be measured using applications in the art such as measuring T cell markers associated with memory T cells, measuring local cytokine production related to memory immune response, or detecting memory T cell-surface markers with techniques such as flow cytometry.
  • the administering of the compositions described herein increases an effector to suppressor T cell ratio in the tumor.
  • the effector to suppressor T cell ratio is characterized by the ratio of (i) CD8+, CD4+, or CD8+/CD4+ T cells to (ii) Treg cells in a subject.
  • the increase in the effector to suppressor T cell ratio correlates with an increase in the number of CD8+ T cells.
  • the increase in the effector to suppressor T cell ratio correlates with an increase in the number of CD4+ T cells. In some embodiments, the increase in the effector to suppressor T cell ratio correlates with an increase in the number of CD8+/CD4+ T cells. In some embodiments, the increase in the effector to suppressor T cell ratio correlates with a decrease in the number of Treg cells.
  • the effector to suppressor T cell ratio e.g., the CD8 + T cell to Treg cell ratio
  • the IL12 encoding polynucleotide e.g., mRNA
  • an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody, or a polynucleotide encoding OX40L is at least about 1.5:1, at least about 2:1, at least about 2.5:1, at least about 3:1, at least about 3.5:1, at least about 3.5:1, at least about 4:1, at least about 4.5:1, at least about 5:1, at least about 6:1, at least about 7:1, at least about 8:1, at least about 9:1, at least about 10:1, at least about 15:1, at least about 20:1, at least about 25:1, at least about 30:1, at least about 35:1, at least about 40:1, at least about 45:1, at least about 50:1, at least about 60:1, at least about 70:1,
  • the effector to suppressor T cell ratio e.g., the CD8 + T cell to Treg cell ratio
  • the IL12 encoding polynucleotide e.g., mRNA
  • an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody, or a polynucleotide encoding OX40L is at least about 1.5, at least about 2, at least about 2.5, at least about 3, at least about 3.5, at least about 3.5, at least about 4, at least about 4.5, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 110, at least about 120, at least about 130, at least about 140
  • the increase in the effector to suppressor T cell ratio in the tumor is directed to an anti-tumor immune response in the subject.
  • the increase in the effector to suppressor T cell ratio in the tumor reduces or decreases the size of a tumor or inhibits the growth of a tumor in the subject.
  • the effector to suppressor T cell ratio in the tumor can be measured using applications in the art such as measuring the ratio of CD8+, CD4+, or CD8+/CD4+ T cells to Treg cells, using any methods known in the art including IHC and/or flow cytometry.
  • the activated T cells by the present methods are CD4 + cells, CD8 + cells, CD62 + (L-selectin + ) cells, CD69 + cells, CD40L + cells, CD137 + cells, CD25 + cells, CD71 + cells, CD26 + cells, CD27 + cells, CD28 + cells, CD30 + cells, CD45 + cells, CD45RA + cells, CD45RO + cells, CD11b + cells, CD154 + cells, CD134 + cells, CXCR3 + cells, CCR4 + cells, CCR6 + cells, CCR7 + cells, CXCR5 + cells, Crth2 + cells, gamma delta T cells, or any combination thereof.
  • the activated T cells by the present methods are Th 1 cells.
  • the T cells activated by the present methods are Th 2 cells.
  • the T cells activated by the present disclosure are cytotoxic T cells.
  • the infiltrating T cells by the present methods are CD4 + cells, CD8 + cells, CD62 + (L-selectin + ) cells, CD69 + cells, CD40L + cells, CD137 + cells, CD25 + cells, CD71 + cells, CD26 + cells, CD27 + cells, CD28 + cells, CD30 + cells, CD45 + cells, CD45RA + cells, CD45RO + cells, CD11b + cells, CD154 + cells, CD134 + cells, CXCR3 + cells, CCR4 + cells, CCR6 + cells, CCR7 + cells, CXCR5 + cells, Crth2 + cells, gamma delta T cells, or any combination thereof.
  • the infiltrating T cells by the present methods are Th 1 cells. In other embodiments, the infiltrating T cells by the present methods are Th 2 cells. In other embodiments, the infiltrating T cells by the present disclosure are cytotoxic T cells.
  • the memory T cells induced by the present methods are CD4 + cells, CD8 + cells, CD62 + (L-selectin + ) cells, CD69 + cells, CD40L + cells, CD137 + cells, CD25 + cells, CD71 + cells, CD26 + cells, CD27 + cells, CD28 + cells, CD30 + cells, CD45 + cells, CD45RA + cells, CD45RO + cells, CD1 1b + cells, CD154 + cells, CD134 + cells, CXCR3 + cells, CCR4 + cells, CCR6 + cells, CCR7 + cells, CXCR5 + cells, Crth2 + cells, gamma delta T cells, or any combination thereof.
  • the memory T cells by the present methods are Th 1 cells.
  • the memory T cells by the present methods are Th 2 cells.
  • the memory T cells by the present disclosure are cytotoxic T cells.
  • the disclosure includes a method of inducing an adaptive immune response, an innate immune response, or both adaptive and innate immune response against tumor comprising administering a polynucleotide, e.g ., mRNA, encoding IL12 alone or in combination with a second agent, e.g., a checkpoint inhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, a polynucleotide encoding OX40L, and/or any other agents disclosed herein.
  • a polynucleotide e.g ., mRNA
  • encoding IL12 alone or in combination with a second agent, e.g., a checkpoint inhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody
  • a polynucleotide encoding OX40L e.g., a second
  • the present disclosure further provides a method of increasing the number of Natural Killer (NK) cells in a subject in need thereof comprising administering a polynucleotide comprising an mRNA encoding IL12 alone or in combination with a second agent, e.g., a checkpoint inhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, a polynucleotide encoding OX40L, and/or any other agents disclosed herein.
  • a checkpoint inhibitor e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody
  • the increase in the number of NK cells in the subject is directed to an anti-tumor immune response in the subject.
  • the increase in the number of NK cells in the subject reduces or decreases the size of a tumor or inhibits the growth of a tumor in the subject.
  • Increases in the number of NK cells in a subject can be measured using applications in the art such as detection of NK cell-surface markers (e.g., CD335/NKp46; CD336/NKp44; CD337/NPp30) or intracellular NK cell markers (e.g., perforin; granzymes; granulysin).
  • NK cell-surface markers e.g., CD335/NKp46; CD336/NKp44; CD337/NPp30
  • intracellular NK cell markers e.g., perforin; granzymes; granulysin.
  • the administering of the compositions described herein e.g., a polynucleotide (e.g., mRNA) encoding an IL12, alone or in combination with a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or a composition comprising a checkpoint inhibitor polypeptide, increases the number of activated NK cells in the subject as compared to the number of activated NK cells prior to the administration.
  • a polynucleotide e.g., mRNA
  • a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or a composition comprising a checkpoint inhibitor polypeptide increases the number of activated NK cells in the subject as compared to the number of activated NK cells prior to the administration.
  • the number of activated NK cells is increased by at least about 1.5 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 15 fold, at least about 20 fold, at least about 25 fold, at least about 30 fold, at least about 35 fold, at least about 40 fold, at least about 45 fold, at least about 50 fold, at least about 60 fold, at least about 70 fold, at least about 80 fold, at least about 90 fold, or at least about 100 fold.
  • the increase in activated NK cells is maintained for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, or at least about 28 days.
  • the administering of the compositions described herein e.g., a polynucleotide (e.g., mRNA) encoding an IL12, alone or in combination with a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or a composition comprising a checkpoint inhibitor polypeptide, increases the number of cross-presenting dendritic cells in the tumor of the subject as compared to the number of cross-presenting dendritic cells in the tumor prior to the administration.
  • a polynucleotide e.g., mRNA
  • a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or a composition comprising a checkpoint inhibitor polypeptide increases the number of cross-presenting dendritic cells in the tumor of the subject as compared to the number of cross-presenting dendritic cells in the tumor prior to the administration.
  • the number of cross-presenting dendritic cells in the tumor is increased by at least about 1.5 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 15 fold, at least about 20 fold, at least about 25 fold, at least about 30 fold, at least about 35 fold, at least about 40 fold, at least about 45 fold, at least about 50 fold, at least about 60 fold, at least about 70 fold, at least about 80 fold, at least about 90 fold, or at least about 100 fold.
  • the increase in cross-presenting dendritic cells in the tumor is maintained for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, or at least about 28 days.
  • the present disclosure is also directed to a method of increasing IFN ⁇ expression in a subject having tumor comprising administering a polynucleotide, e.g., mRNA, encoding IL12 alone or in combination with a second agent, e.g., a checkpoint inhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, a polynucleotide encoding OX40L, and/or any other agents disclosed herein.
  • a polynucleotide e.g., mRNA
  • encoding IL12 alone or in combination with a second agent, e.g., a checkpoint inhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody
  • a polynucleotide encoding OX40L e.g., a polynucleotide encoding IL
  • inventions also include a method of increasing expression of IFN ⁇ , TNF ⁇ , IL-10, IL-13, IL-15/15R, IL-27, MIP-1 ⁇ , MIP-1 ⁇ , MCP-1, MCP-3, M-CSF, IL-4, IL-5, or any combination thereof in a subject having tumor comprising administering a polynucleotide, e.g., mRNA, encoding IL12 alone or in combination with another agent disclosed herein.
  • the methods of the present disclosure can include methods of inducing expression of GM-CSF, IL-18, IL-3, RANTES, IL-6, or any combination thereof.
  • the polynucleotide encoding IL12 can be formulated as a pharmaceutical composition that is suitable for administration either directly or indirectly to tumors.
  • tumor is used herein in a broad sense and refers to any abnormal new growth of tissue that possesses no physiological function and arises from uncontrolled usually rapid cellular proliferation.
  • tumor as used herein relates to both benign tumors and to malignant tumors.
  • Certain aspects of the disclosure provide methods of intratumorally administering a single administration dose of a polynucleotide, e.g., mRNA, encoding IL12 alone or in combination with any agents disclosed herein.
  • a polynucleotide e.g., mRNA, encoding IL12
  • an mRNA encoding IL12 can be administered only once while the other agent can be administered regularly, following its regular dosing schedule.
  • a checkpoint inhibitor e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, is administered prior to administration of a polynucleotide, e.g ., mRNA, encoding IL12.
  • the polynucleotide is formulated in a lipid nanoparticle, e.g ., Compound 18, disclosed herein.
  • a lipid nanoparticle e.g ., Compound 18, disclosed herein.
  • the intratumoral delivery of a polynucleotide encoding IL12 and/or the lipid nanoparticle formulation disclosed herein allow single dose administration that is sufficient for the dose to trigger anti-tumor efficacy and treat tumor. Given the potential toxicity of IFN ⁇ induced by IL-12, this single dosing regimen of the disclosed polynucleotide can be beneficial to the subjects in need of the treatment.
  • the method comprises administering a single dose of a polynucleotide encoding IL12 in combination with a second agent, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, which can be given also in single administration or multiple administrations following its regular ( e.g., approved) schedule.
  • a second agent e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody
  • the method comprises not more than two administrations of a polynucleotide encoding IL12, not more than three administrations of a polynucleotide encoding IL12, not more than four administrations of a polynucleotide encoding IL12, or not more than five administrations of a polynucleotide encoding IL12, optionally in combination with a checkpoint inhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, or a polynucleotide encoding an OX40L polypeptide.
  • a checkpoint inhibitor e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, or a polynucleotide encoding an OX40L polypeptide.
  • the present methods can result in abscopal effects, e.g., a treatment of tumor where localized treatment of a tumor, e.g., intratumoral delivery, by a polynucleotide, e.g., mRNA, encoding IL12 causes not only a shrinking of the treated tumor, but also a shrinking of tumors outside the scope of the localized treatment ("distal tumor").
  • abscopal effects e.g., a treatment of tumor where localized treatment of a tumor, e.g., intratumoral delivery, by a polynucleotide, e.g., mRNA, encoding IL12 causes not only a shrinking of the treated tumor, but also a shrinking of tumors outside the scope of the localized treatment ("distal tumor").
  • the administering of the compositions described herein e.g., a polynucleotide encoding an IL12 polypeptide, alone or in combination with a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or a composition comprising a checkpoint inhibitor polypeptide, reduces the size of a distal tumor.
  • the administering is intratumoral to a first tumor, and the administering reduces the size of a second, distal tumor.
  • the size of the distal tumor is reduced by at least about 10%, at least about 20% at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100%.
  • the administering of the compositions described herein e.g., a polynucleotide encoding an IL12 polypeptide, alone or in combination with a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide or a composition comprising a checkpoint inhibitor polypeptide, inhibits the growth of a distal tumor.
  • the administering is intratumoral to a first tumor, and the administering inhibits the growth of a second, distal tumor.
  • the growth of the distal tumor is inhibited for at least about 7 days, at least about 14 days, at least about 21 days, at least about 28 days, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, at least about 36 months, at least about 4 years, or at least about 5 years.
  • compositions for intratumoral administration disclosed herein can:
  • a decrease in leakage can be quantified as decrease in the ratio of polypeptide expression in the tumor to polypeptide expression in non-tumor tissues, such as peritumoral tissue or to another tissue or organ, e.g., liver tissue.
  • Delivery of a polynucleotide encoding IL12 to a tumor involves administering a pharmaceutical composition disclosed herein, e.g., in nanoparticle form, including the polynucleotide encoding IL12 to a subject, where administration of the pharmaceutical composition involves contacting the tumor with the composition.
  • a translatable mRNA upon contacting a cell in the tumor with the pharmaceutical composition, a translatable mRNA may be translated in the cell to produce a polypeptide of interest.
  • mRNAs that are substantially not translatable may also be delivered to tumors.
  • Substantially non-translatable mRNAs may be useful as vaccines and/or may sequester translational components of a cell to reduce expression of other species in the cell.
  • the pharmaceutical compositions disclosed herein can increase specific delivery.
  • specific delivery means delivery of more (e.g., at least 1.5 fold more, at least 2-fold more, at least 3-fold more, at least 4-fold more, at least 5-fold more, at least 6-fold more, at least 7-fold more, at least 8-fold more, at least 9-fold more, at least 10-fold more) of a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides by pharmaceutical composition disclosed herein ( e.g., in nanoparticle form) to a target tissue of interest (e.g., a tumor) compared to an off-target tissue (e.g., mammalian liver).
  • a target tissue of interest e.g., a tumor
  • off-target tissue e.g., mammalian liver
  • the level of delivery of a nanoparticle to a particular tissue may be measured, for example, by comparing
  • Specific delivery to a tumor or a particular class of cells in the tumor implies that a higher proportion of pharmaceutical composition including a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides is delivered to the target destination (e.g., target tissue) relative to other off-target destinations upon administration of a pharmaceutical composition to a subject.
  • target destination e.g., target tissue
  • the present disclosure also provides methods to deliver intratumorally a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides when a pharmaceutical composition comprising the polynucleotides disclosed herein ( e.g., in nanoparticle form) are administered to a tumor.
  • the intratumoral administration can show one or more properties selected from the group consisting of:
  • a decrease in leakage can be quantified as decrease in the ratio of polypeptide expression in the tumor to polypeptide expression in non-tumor tissues, such as peritumoral tissue or to another tissue or organ, e.g., liver tissue.
  • another property in delivery caused as a result of using the pharmaceutical compositions disclosed herein is a reduction in immune response with respect to the immune response observed when other lipid components are used to deliver the same a therapeutic agent or polynucleotide encoding a therapeutic agent.
  • the present disclosure provides a method of increasing retention of a therapeutic agent (e.g., a polynucleotide or a polypeptide administered as part of the pharmaceutical composition or a polypeptide expressed as a result of the administration) in a tumor tissue in a subject, comprising administering intratumorally to the tumor tissue a pharmaceutical composition disclosed herein, wherein the retention of the therapeutic agent in the tumor tissue is increased compared to the retention of the therapeutic agent in the tumor tissue after administering a corresponding reference composition (e.g., MC3).
  • a therapeutic agent e.g., a polynucleotide or a polypeptide administered as part of the pharmaceutical composition or a polypeptide expressed as a result of the administration
  • a corresponding reference composition e.g., MC3
  • Also provided is a method of increasing retention of an expressed polypeptide in a tumor tissue in a subject comprising administering to the tumor tissue a pharmaceutical composition disclosed herein, wherein the pharmaceutical composition comprises a polynucleotide encoding the expressed polypeptide, and wherein the retention of the expressed polypeptide in the tumor tissue is increased compared to the retention of the polypeptide in the tumor tissue after administering a corresponding reference composition (e.g., MC3).
  • a corresponding reference composition e.g., MC3
  • the present disclosure also provides a method of decreasing expression leakage of a polynucleotide administered intratumorally to a subject in need thereof, comprising administering said polynucleotide intratumorally to the tumor tissue as a pharmaceutical composition disclosed herein, wherein the expression level of the polypeptide in non-tumor tissue is decreased compared to the expression level of the polypeptide in non-tumor tissue after administering a corresponding reference composition (e.g., MC3).
  • a corresponding reference composition e.g., MC3
  • a therapeutic agent e.g., a polypeptide administered as part of the pharmaceutical composition
  • Also provided is a method of decreasing expression leakage of an expressed polypeptide in a tumor in a subject comprising administering to the tumor tissue a pharmaceutical composition disclosed herein, wherein the pharmaceutical composition comprises a polynucleotide encoding the expressed polypeptide, and wherein the amount of expressed polypeptide in non-tumor tissue is decreased compared to the amount of expressed polypeptide in non-tumor tissue after administering a corresponding reference composition (e.g., MC3).
  • a corresponding reference composition e.g., MC3
  • the non-tumoral tissue is peritumoral tissue. In other embodiments, the non-tumoral tissue is liver tissue.
  • the present disclosure also provides a method to reduce or prevent the immune response caused by the intratumoral administration of a pharmaceutical composition, e.g., a pharmaceutical composition comprising lipids known in the art, by replacing one or all the lipids in such composition with a compound of Formula (I).
  • a pharmaceutical composition e.g., a pharmaceutical composition comprising lipids known in the art
  • the immune response caused by the administration of a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides in a pharmaceutical composition comprising MC3 (or other lipids known in the art) can be prevented (avoided) or ameliorated by replacing MC3 with a compound of Formula (I), e.g., Compound 18.
  • the immune response observed after a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides is administered in a pharmaceutical composition disclosed herein is not elevated compared to the immune response observed when the therapeutic agent or a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides is administered in phosphate buffered saline (PBS) or another physiological buffer solution (e.g., Ringer's solution, Tyrode's solution, Hank's balanced salt solution, etc.).
  • PBS phosphate buffered saline
  • another physiological buffer solution e.g., Ringer's solution, Tyrode's solution, Hank's balanced salt solution, etc.
  • the immune response observed after a therapeutic agent or a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides is administered in a pharmaceutical composition disclosed herein is not elevated compared to the immune response observed when PBS or another physiological buffer solution is administered alone.
  • no immune response is observed when a pharmaceutical composition disclosed herein is administered intratumorally to a subject.
  • the present disclosure also provides a method of delivering a therapeutic agent or a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides to a subject in need thereof, comprising administering intratumorally to the subject a pharmaceutical composition disclosed herein, wherein the immune response caused by the administration of the pharmaceutical composition is not elevated compared to the immune response caused by the intratumoral administration of
  • the administration treats a cancer.
  • the polynucleotide (e.g., mRNA) of the present disclosure can be administered in any route available, including, but not limited to, intratumoral, enteral, gastroenteral, epidural, oral, transdermal, epidural (peridural), intracerebral (into the cerebrum), intracerebroventricular (into the cerebral ventricles), epicutaneous (application onto the skin), intradermal, (into the skin itself), subcutaneous (under the skin), nasal administration (through the nose), intravenous (into a vein), intraperitoneal (into the peritoneum), intraarterial (into an artery), intramuscular (into a muscle), intracardiac (into the heart), intraosseous infusion (into the bone marrow), intrathecal (into the spinal canal), intraperitoneal, (infusion or injection into the peritoneum), intravesical infusion, intravitreal, (through the eye), intracavernous injection, (into the base of the penis), intra
  • the mRNA of the present disclosure is administered parenterally (e.g., includes subcutaneous, intravenous, intraperitoneal, intratumoral, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques), intraventricularly, orally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenterally e.g., includes subcutaneous, intravenous, intraperitoneal, intratumoral, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques
  • intraventricularly orally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • the polynucleotide, composition, or polypeptide is administered subcutaneously, intravenously, intraperitoneally, intratumorally, intramuscularly, intra-articularly, intra-synovially, intrasternally, intrathecally, intrahepatically, intradermally, intralesionally, intracranially, intraventricularly, orally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • the polynucleotide (e.g., mRNA) of the present disclosure is administered intratumorally.
  • the polynucleotide is delivered by a device comprising a pump, patch, drug reservoir, short needle device, single needle device, multiple needle device, micro-needle device, jet injection device, ballistic powder/particle delivery device, catheter, lumen, cryoprobe, cannula, microcanular, or devices utilizing heat, RF energy, electric current, or any combination thereof.
  • aspects of the present disclosure relate to transplantation of cells containing polynucleotides to a mammalian subject.
  • Administration of cells to mammalian subjects is known to those of ordinary skill in the art, and includes, but is not limited to, local implantation (e.g., topical or subcutaneous administration), organ delivery or systemic injection (e.g ., intravenous injection or inhalation), and the formulation of cells in pharmaceutically acceptable carriers.
  • the polynucleotide e.g., mRNA
  • the administration of the polynucleotide, pharmaceutical composition or formulation of the disclosure results in expression of II,12 in cells of the subject. In some embodiments, administering the polynucleotide, pharmaceutical composition or formulation of the disclosure results in an increase of IL12 activity in the subject.
  • the polynucleotides of the present disclosure are used in methods of administering a composition or formulation comprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides to a subject, wherein the method results in an increase of IL 12 activity in at least some cells of a subject.
  • the administration of a composition or formulation comprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides to a subject results in an increase of IL12 activity in cells subject to a level at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or to 100% or more of the activity level expected in a normal subject.
  • inventions of the disclosure also provide a method of treating a cancer in a subject in need thereof comprising administering (e.g., intratumorally, intraperitoneally, or intravenously) a polynucleotide comprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides with one or more anti-cancer agents to the subject.
  • administering e.g., intratumorally, intraperitoneally, or intravenously
  • a polynucleotide comprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides with one or more anti-cancer agents to the subject.
  • the polynucleotides e.g., mRNA
  • encoding an IL12B polypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides of the present disclosure can be used to reduce the size of a tumor or inhibit tumor growth in a subject in need thereof.
  • the tumor is associated with a disease, disorder, and/or condition.
  • the disease, disorder, and/or condition is a cancer.
  • the administration of the polynucleotide (e.g., mRNA) encoding an IL12B polypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides treats a cancer.
  • a “cancer” refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and can also metastasize to distant parts of the body through the lymphatic system or bloodstream.
  • a “cancer” or “cancer tissue” can include a tumor at various stages.
  • the cancer or tumor is stage 0, such that, e.g., the cancer or tumor is very early in development and has not metastasized.
  • the cancer or tumor is stage I, such that, e.g., the cancer or tumor is relatively small in size, has not spread into nearby tissue, and has not metastasized.
  • the cancer or tumor is stage II or stage III, such that, e.g., the cancer or tumor is larger than in stage 0 or stage I, and it has grown into neighboring tissues but it has not metastasized, except potentially to the lymph nodes.
  • the cancer or tumor is stage IV, such that, e.g., the cancer or tumor has metastasized. Stage IV can also be referred to as advanced or metastatic cancer.
  • the cancer can include, but is not limited to, adrenal cortical cancer, advanced cancer, anal cancer, aplastic anemia, bileduct cancer, bladder cancer, bone cancer, bone metastasis, brain tumors, brain cancer, breast cancer, childhood cancer, cancer of unknown primary origin, Castleman disease, cervical cancer, colon/rectal cancer, endometrial cancer, esophagus cancer, Ewing family of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gestational trophoblastic disease, Hodgkin disease, Kaposi sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer, small cell lung cancer, lung carcinoid tumor,
  • the tumor is a solid tumor.
  • a “solid tumor” includes, but is not limited to, sarcoma, melanoma, carcinoma, or other solid tumor cancer.
  • Sparcoma refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
  • Sarcomas include, but are not limited to, chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sar
  • melanoma refers to a tumor arising from the melanocytic system of the skin and other organs.
  • Melanomas include, for example, acra-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, metastatic melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
  • carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
  • exemplary carcinomas include, e.g., acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere,
  • Additional cancers that can be treated include, e.g., Leukemia, Hodgkin's Disease, Non- Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, small-cell lung tumors, primary brain tumors, stomach cancer, colon cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, papillary thyroid cancer, neuroblastoma, neuroendocrine cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, endometrial cancer, adrenal cortical cancer, prostate cancer, Müllerian cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, or uterine papillary serous carcinoma.
  • Leukemia e.g.,
  • the disclosure further includes a polynucleotide comprising an ORF (e.g., mRNA) encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptide or uses thereof as a combination therapy, i.e., with any other anti-cancer agent in combination.
  • the polynucleotide encodes an IL-12 polypeptide, wherein the polynucleotide comprises an ORF encoding an IL12B polypeptide and an IL12A polypeptide or uses thereof as a combination therapy, i.e., with any other anti-cancer agent in combination.
  • the disclosure is directed to a polynucleotide comprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptide in combination with one or more anti-cancer agents or uses of the polynucleotide in combination with one or more anti-cancer agents to the subject.
  • the combination therapy can be a combination of the polynucleotide encoding IL12 and one or more standard therapy.
  • the methods of the disclosure include two additional anti-cancer agents, three additional agents, four additional agents, etc.
  • the additional anti-cancer agents can be a protein, e.g., an antibody, or a polynucleotide, e.g., mRNA.
  • the one or more anti-cancer agents are an mRNA.
  • the one or more anti-cancer agents are an mRNA encoding a tumor antigen.
  • the one or more anti-cancer agents are not a tumor antigen or an mRNA encoding a tumor antigen.
  • the one or more anti-cancer agents are a protein, e.g., an antibody.
  • the one or more anti-cancer agents are an approved agent by the United States Food and Drug Administration. In other embodiments, the one or more anti-cancer agents are a pre-approved agent by the United States Food and Drug Administration.
  • IL12 IL12
  • any other agents e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, or OX40L as polynucleotides and/or proteins.
  • the present disclosure encompasses combination therapy of (i) a polynucleotide (e.g., mRNA) encoding IL12 and a protein comprising an anti-PD-1 antibody or an anti-PD-L1 antibody; (iii) a polynucleotide (e.g., mRNA) encoding IL12 and a second protein comprising an anti-CTLA-4 antibody, or (iv) a polynucleotide (e.g., mRNA) encoding IL12 and a second protein comprising OX40L.
  • the IL12 can also be administered as a protein.
  • the additional agents can be formulated together with the polynucleotide encoding IL12, e.g., mRNA, or separately. Moreover, even when formulated separately, the additional agents can be administered concurrently with the polynucleotide encoding IL12 or sequentially. In one embodiment, the polynucleotide encoding IL12 is administered prior to the second agent. In another embodiment, the polynucleotide encoding IL12 is administered after the second agent.
  • the additional agents e.g., any antibody disclosed herein or a polynucleotide encoding OX40L
  • the second agents e.g., any antibody disclosed herein or a polynucleotide encoding OX40L
  • are administered via different routes e.g., intravenously, subcutaneously, intraperitoneally, etc.
  • the subject for the present methods or compositions has been treated with one or more standard of care therapies. In other aspects, the subject for the present methods or compositions has not been responsive to one or more standard of care therapies or anti-cancer therapies.
  • the subject has been previously treated with an IL12 protein or an IL12 DNA gene therapy.
  • the subject is treated with an anti-PD-1 antagonist or an anti-CTLA-4 antagonist prior to the polynucleotide of the present disclosure.
  • the subject has been treated with a monoclonal antibody that binds to PD-1 prior to the polynucleotide of the present disclosure and/or a monoclonal antibody that binds to CTLA-4 prior to the polynucleotide of the present disclosure.
  • the subject has been treated with an anti-PD-1 monoclonal antibody and/or anti-CTLA-4 monoclonal antibody therapy prior to the polynucleotide of the present methods or compositions.
  • T cell regulation i.e., activation or inhibition is mediated via co-stimulatory or co-inhibitory signals. This interaction is exerted via ligand/receptor interaction.
  • T cells harbor a myriad of both activating receptors, such as OX40, and inhibitory receptors (i.e., immune checkpoints) such as programmed death receptor 1 (PD-1) or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) ( Mellman et al. 2011 Nature.;480:480-489 ).
  • PD-1 programmed death receptor 1
  • CTLA-4 cytotoxic T lymphocyte-associated protein 4
  • the methods of reducing the size of a tumor or inhibiting growth of a tumor in a subject in need thereof comprise administering to the subject an effective amount of a composition comprising one or more polynucleotides.
  • the one or more polynucleotides encode an IL-12 polypeptide.
  • the one or more polynucleotides comprise an open reading frame ("ORF") encoding an IL12B polypeptide.
  • the one or more polynucleotides comprise an ORF encoding an IL12A polypeptide.
  • the one or more polynucleotides comprise an ORF encoding an IL12B polypeptide and an IL12A polypeptide.
  • the methods further comprise administering a second agent.
  • the second agent comprises an effective amount of a composition comprising a polynucleotide comprising an ORF encoding a checkpoint inhibitor polypeptide.
  • the second agent comprises an effective amount of a composition comprising a checkpoint inhibitor polypeptide.
  • the checkpoint inhibitor is any checkpoint inhibitor known in the art or described herein.
  • the checkpoint inhibitor is an anti-PD-1 antibody.
  • the checkpoint inhibitor is an anti-PD-L1 antibody.
  • the checkpoint inhibitor is an anti-CTLA-4 antibody.
  • the second agent comprises an effective amount of a composition comprising a polynucleotide comprising an ORF encoding OX40L.
  • the checkpoint inhibitor is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, a polynucleotide encoding OX40L any other agents disclosed herein, and any combination thereof.
  • the composition comprising a checkpoint inhibitor comprises more than one checkpoint inhibitor.
  • the method comprises administering (i) an mRNA, encoding an IL12B and/or IL12A polypeptide disclosed herein, and (ii) an anti-PD-L1 antibody, an anti-PD-1 antibody, anti-CTLA-4 antibody, a polynucleotide encoding OX40L, or any combination thereof.
  • the checkpoint inhibitor comprises an antigen binding fragment of an antibody.
  • the antibody is an anti-CTLA-4 antibody or antigen-binding fragment thereof that specifically binds CTLA-4, an anti-PD-1 antibody or antigen-binding fragment thereof that specifically binds PD-1, an anti-PD-L1 antibody or antigen-binding fragment thereof that specifically binds PD-L1, or a combination thereof.
  • the antibody is an anti-CTLA4 antibody or antigen-binding fragment thereof that specifically binds CTLA4.
  • the antibody is an anti-PD-1 antibody or antigen-binding fragment thereof that specifically binds PD-1.
  • the antibody is an anti-PD-L1 antibody or antigen-binding fragment thereof that specifically binds PD-L1.
  • Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being investigated in clinical trials for cancers including melanoma, head and neck squamous cell carcinoma (HNSCC). Data available from these trials indicate substantial activity accompanied by a favorable safety and toxicity profile in these patient populations.
  • HNSCC head and neck squamous cell carcinoma
  • checkpoint inhibitors have been tested in clinical trials for the treatment of melanoma.
  • phase III clinical trials have revealed that therapies such as ipilimumab and pembrolizumab, which target the CTLA-4 and PD-1 immune checkpoints, respectively, have raised the three-year survival of patients with melanoma to ⁇ 70%, and overall survival (>5years) to ⁇ 30%.
  • checkpoint inhibitors have been tested in clinical trials for the treatment of head and neck cancer.
  • PD-L1 programmed death ligand 1
  • the subject has been previously treated with a PD-1 antagonist prior to the polynucleotide of the present disclosure.
  • the subject has been treated with a monoclonal antibody that binds to PD-1 prior to the polynucleotide of the present disclosure.
  • the subject has been treated with an anti-PD-1 monoclonal antibody therapy prior to the polynucleotide of the present methods or compositions.
  • the anti-PD-1 monoclonal antibody therapy comprises nivolumab, pembrolizumab, pidilizumab, or any combination thereof.
  • the subject has been treated with a monoclonal antibody that binds to PD-L1 prior to the polynucleotide of the present disclosure.
  • the subject has been treated with an anti-PD-L1 monoclonal antibody therapy prior to the polynucleotide of the present methods or compositions.
  • the anti-PD-L1 monoclonal antibody therapy comprises durvalumab, avelumab, MEDI473, BMS-936559, aezolizumab, or any combination thereof.
  • the subject has been treated with a CTLA-4 antagonist prior to treatment with the compositions of present disclosure.
  • the subject has been previously treated with a monoclonal antibody that binds to CTLA-4 prior to the compositions of the present disclosure.
  • the subject has been treated with an anti-CTLA-4 monoclonal antibody prior to the polynucleotide of the present disclosure.
  • the anti-CTLA-4 antibody therapy comprises ipilimumab or tremelimumab.
  • the disclosure is directed to a method of treating cancer and/or a method of immunotherapy in a subject in need thereof comprising administering to the subject (e.g., intratumorally, intraperitoneally, or intravenously) the polynucleotide (e.g., RNA, e.g., mRNA) encoding an IL12 polypeptide in combination with a PD-L1 antagonist, e.g., an antibody or antigen-binding portion thereof that specifically binds to PD-L1, e.g., an anti-PD-L1 monoclonal antibody, e.g., an anti-PD-L1 monoclonal antibody comprises Durvalumab, Avelumab, MEDI473, BMS-936559, Atezolizumab, or any combination thereof.
  • the polynucleotide e.g., RNA, e.g., mRNA
  • a PD-L1 antagonist e.g., an antibody or antigen-bind
  • the anti-PD-L1 antibody useful for the disclosure is MSB0010718C (also called Avelumab; See US 2014/0341917 ) or BMS-936559 (formerly 12A4 or MDX-1105) (see, e.g., U.S. Patent No. 7,943,743 ; WO 2013/173223 ).
  • the anti-PD-L1 antibody is atezolizumab (also known as TECENTRIQ ® ).
  • the anti-PD-L1 antibody is MPDL3280A (also known as atezolizumab, TECENTRIQ ® , and RG7446) (see, e.g., Herbst et al.
  • the disclosure is directed to a method of treating cancer and/or a method of immunotherapy in a subject in need thereof comprising administering to the subject (e.g., intratumorally, intraperitoneally, or intravenously) the polynucleotide (e.g., RNA, e.g., mRNA) encoding an IL12 polypeptide, in combination with a PD-1 antagonist, e.g., an antibody or antigen-binding portion thereof that specifically binds to PD-1, e.g., an anti-PD-1 monoclonal antibody.
  • a PD-1 antagonist e.g., an antibody or antigen-binding portion thereof that specifically binds to PD-1, e.g., an anti-PD-1 monoclonal antibody.
  • the anti-PD-1 antibody (or an antigen-binding portion thereof) useful for the disclosure is pembrolizumab.
  • Pembrolizumab also known as "KEYTRUDA ® ", lambrolizumab, and MK-3475
  • KEYTRUDA ® a humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1).
  • Pembrolizumab has been approved by the FDA for the treatment of relapsed or refractory melanoma and advanced NSCLC.
  • the anti-PD-1 antibody useful for the disclosure is nivolumab.
  • Nivolumab also known as "OPDIVO ® "; formerly designated 5C4, BMS-936558, MDX-1106, or ONO-4538
  • OPDIVO ® is a fully human IgG4 (S228P) PD-1 immune checkpoint inhibitor antibody that selectively prevents interaction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking the down-regulation of antitumor T-cell functions
  • U.S. Patent No. 8,008,449 Wang et al., 2014 Cancer Immunol Res. 2(9):846-56 .
  • Nivolumab has shown activity in a variety of advanced solid tumors including renal cell carcinoma (renal adenocarcinoma, or hypernephroma), melanoma, and non-small cell lung cancer (NSCLC) (Topalian et al., 2012a; Topalian et al., 2014; Drake et al., 2013; WO 2013/173223 .
  • renal cell carcinoma renal adenocarcinoma, or hypernephroma
  • NSCLC non-small cell lung cancer
  • the anti-PD-1 antibody is MEDI0680 (formerly AMP-514), which is a monoclonal antibody against the PD-1 receptor.
  • the anti-PD-1 antibody is BGB-A317, which is a humanized monoclonal antibody.
  • BGB-A317 is described in U.S. Publ. No. 2015/0079109 .
  • a PD-1 antagonist is AMP-224, which is a B7-DC Fc fusion protein.
  • the disclosure includes a method of treating cancer and/or a method of immunotherapy in a subject in need thereof comprising administering to the subject (e.g., intratumorally, intraperitoneally, or intravenously) the polynucleotide (e.g., RNA, e.g., mRNA) encoding an IL12 polypeptide together with an antibody or an antigen binding portion thereof that specifically binds to PD-1, e.g., an anti-PD-1 monoclonal antibody, e.g., an anti-PD-1 monoclonal antibody comprises Nivolumab, Pembrolizumab, Pidilizumab, or any combination thereof.
  • the polynucleotide e.g., RNA, e.g., mRNA
  • an antigen binding portion thereof that specifically binds to PD-1
  • an anti-PD-1 monoclonal antibody e.g., an anti-PD-1 monoclonal antibody comprises Nivolumab, Pembroli
  • the disclosure is directed to a method of treating cancer and/or a method of immunotherapy in a subject in need thereof comprising administering to the subject (e.g., intratumorally, intraperitoneally, or intravenously) the polynucleotide (e.g., RNA, e.g., mRNA) encoding an IL12 polypeptide in combination with a CTLA-4 antagonist, e.g., an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, e.g., an anti-CTLA-4 monoclonal antibody, e.g., an anti-CTLA-4 monoclonal antibody comprises Ipilimumab or Tremelimumab, or any combination thereof.
  • the polynucleotide e.g., RNA, e.g., mRNA
  • CTLA-4 antagonist e.g., an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, e.g., an anti-CT
  • An exemplary clinical anti-CTLA-4 antibody is the human mAb 10D1 (now known as ipilimumab and marketed as YERVOY ® ) as disclosed in U.S. Patent No. 6,984,720 .
  • Another anti-CTLA-4 antibody useful for the present methods is tremelimumab (also known as CP-675,206).
  • Tremelimumab is human IgG2 monoclonal anti-CTLA-4 antibody. Tremelimumab is described in WO/2012/122444 , U.S. Publ. No. 2012/263677 , or WO Publ. No. 2007/113648 A2 .
  • a first polynucleotide e.g. a first mRNA
  • a second polynucleotide e.g., a second mRNA
  • an OX40L polypeptide are administered in combination.
  • the first polynucleotide e.g. a first mRNA
  • the second polynucleotide e.g.
  • a second mRNA) encoding an OX40L polypeptide are administered in combination with an antibody or an antigen-binding portion thereof which specifically binds to CTLA-4, an antibody or antigen-binding portion thereof which specifically binds to a PD-1 receptor, or an antibody or antigen-binding portion thereof which specifically binds to a PD-L1 receptor.
  • a first polynucleotide e.g. a first mRNA
  • a second polynucleotide e.g. a second mRNA
  • an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 or PD-L1 receptor or a polynucleotide encoding the same.
  • a first polynucleotide e.g. a first mRNA
  • a second polynucleotide e.g. a second mRNA
  • an antibody or an antigen-binding portion thereof that specifically binds to a CTLA-4 or a polynucleotide encoding the same.
  • a first polynucleotide e.g. a first mRNA
  • a second polynucleotide e.g. a second mRNA
  • an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 or PD-L1 receptor
  • an antibody or an antigen-binding portion thereof that specifically binds to a CTLA-4 (or polynucleotides of the same).
  • compositions disclosed herein comprise (i) a first polynucleotide (e.g. a first mRNA) encoding IL12 and (ii) a second polynucleotide (e.g. a second mRNA) encoding an antibody or an antigen binding portion thereof which specifically binds to CTLA-4 in a single formulation.
  • a first polynucleotide e.g. a first mRNA
  • a second polynucleotide e.g. a second mRNA
  • compositions disclosed herein comprise a polynucleotide encoding IL12 and a polynucleotide encoding an OX40L protein in a single formulation.
  • OX40L Human OX40L was first identified on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I) by Tanaka et al. ( Tanaka et al., International Journal of Cancer (1985), 36(5):549-55 ).
  • OX40L is the ligand for OX40 (CD134).
  • OX40L has also been designated CD252 (cluster of differentiation 252), tumor necrosis factor (ligand) superfamily, member 4, tax-transcriptionally activated glycoprotein 1, TXGP1, or gp34.
  • Human OX40L is 183 amino acids in length and contains three domains: a cytoplasmic domain of amino acids 1 - 23; a transmembrane domain of amino acids 24 - 50, and an extracellular domain of amino acids 51 - 183.
  • a polynucleotide encoding OX40L that can be combined with the polynucleotide encoding IL12 comprises an mRNA encoding a mammalian OX40L polypeptide.
  • the mammalian OX40L polypeptide is a murine OX40L polypeptide.
  • the mammalian OX40L polypeptide is a human OX40L polypeptide.
  • the OX40L polypeptide comprises an amino acid sequence set forth in Table 1.
  • each polynucleotide of the disclosure comprises an mRNA, i.e., an mRNA encoding an IL12 polypeptide and an mRNA encoding an OX40L polypeptide.
  • the mRNA encoding an IL12 polypeptide encodes a mammalian IL12 polypeptide.
  • the mRNA encoding an OX40L polypeptide encodes a mammalian OX40L polypeptide.
  • the mRNA encoding an IL12 polypeptide encodes a murine IL12 polypeptide.
  • the mRNA encoding an OX40L polypeptide encodes a murine OX40L polypeptide. In some embodiments, the mRNA encoding an IL12 polypeptide encodes a human IL12 polypeptide. In some embodiments, the mRNA encoding an OX40L polypeptide encodes a human OX40L polypeptide.
  • the IL12 polypeptide comprises a human amino acid sequence set forth in Table 4 .
  • the OX40L polypeptide comprises a human amino acid sequence set forth in Table 1.
  • the OX40L polypeptide comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to an amino acid sequence listed in Table 1 or an amino acid sequence encoded by a nucleotide sequence listed in Table 1, wherein the amino acid sequence is capable of binding to an OX40 receptor.
  • the OX40L polypeptide encoded by a polynucleotide of the disclosure comprises an amino acid sequence listed in Table 1 with one or more conservative substitutions, wherein the conservative substitutions do not significantly affect the binding activity of the OX40L polypeptide to its receptor, i.e., the OX40L polypeptide binds to the OX40 receptor after the substitutions.
  • a nucleotide sequence i.e., mRNA
  • a sequence is written in DNA form (containing thymidine) in the present application, the corresponding RNA sequence would contain uridine instead of thymidine.
  • the polynucleotide (e.g ., mRNA) useful for the methods and compositions comprises an open reading frame encoding an extracellular domain of OX40L.
  • the polynucleotide (e.g ., mRNA) comprises an open reading frame encoding a cytoplasmic domain of OX40L.
  • the polynucleotide (e.g ., mRNA) comprises an open reading frame encoding a transmembrane domain of OX40L.
  • the polynucleotide (e.g ., mRNA) comprises an open reading frame encoding an extracellular domain of OX40L and a transmembrane of OX40L.
  • the polynucleotide (e.g ., mRNA) comprises an open reading frame encoding an extracellular domain of OX40L and a cytoplasmic domain of OX40L.
  • the polynucleotide e.g ., mRNA
  • Table 1 presents, e.g ., precursor and mature sequences for OX40L as well as constructs comprising the OX40L sequences. Furthermore, a construct comprising a polynucleotide encoding OX40L and further comprising components such 3' UTR and 5' UTR would be considered an OX40L encoding polynucleotide.
  • a person of skill in the art would understand that in addition to the native signal sequences and propeptide sequences disclosed in Table 1 (sequences present in the precursor for and absent in the mature corresponding form) and the non-native signal peptide disclosed in Table 1, other signal sequences can be used.
  • references to an OX40L polypeptide or polynucleotide according to Table 1 encompass variants in which an alternative signal peptide (or encoding sequence) known in the art has been attached to the OX40L polypeptide (or polynucleotide). It is also understood that references to the sequences disclosed in Table 1 through the application are equally applicable and encompass orthologs and functional variants (for example polymorphic variants) and isoforms of those sequences known in the art at the time the application was filed.
  • Table 1 OX40L Polypeptide and Polynucleotide sequences Encoded Polypeptide Description Sequence SEQ ID NO: OX40L (TNFSF4) Tumor necrosis factor ligand superfamily member 4 isoform 1 [Homo sapiens] NP 003317 SEQ ID NO: 178 183 aa OX40L (TNFSF4) TNFSF4 isoform 2 [Homo sapiens] NP_00128449 1 SEQ ID NO: 179 133 aa OX40L (TNFSF4) TNFSF4 [Mus musculus] NP_033478 SEQ ID NO: 180 198 aa OX40L (TNFSF4) TNFSF4, ORF [Homo sapiens] SEQ ID NO: 181 552nts OX40L (TNFSF4) TNFSF4, transcript variant 1, mRNA NM_003326 SEQ ID NO: 182 3484 nts OX40L (TNFSF4) Mus musculus Tn
  • IL12 (also shown as IL-12) is a pleiotropic cytokine, the actions of which create an interconnection between innate and adaptive immunity.
  • IL12 functions primarily as a 70 kDa heterodimeric protein consisting of two disulfide-linked p35 and p40 subunits.
  • the precursor form of the IL12 p40 subunit (NM_002187; P29460; also referred to as IL12B, natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2) is 328 amino acids in length, while its mature form is 306 amino acids long.
  • the precursor form of the IL12 p35 subunit (NM_000882; P29459; also referred to as IL12A, natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1) is 219 amino acids in length and the mature form is 197 amino acids long.
  • the genes for the IL12 p35 and p40 subunits reside on different chromosomes and are regulated independently of each other. Gately, MK et al., Annu Rev Immunol. 16: 495-521 (1998 ). Many different immune cells (e.g ., dendritic cells, macrophages, monocytes, neutrophils, and B cells) produce IL12 upon antigenic stimuli.
  • the active IL12 heterodimer is formed following protein synthesis. Id.
  • IL12 is composed of a bundle of four alpha helices. It is a heterodimeric cytokine encoded by two separate genes, IL12A (p35) and IL12B (p40).
  • the active heterodimer (referred to as 'p70'), and a homodimer of p40 are formed following protein synthesis.
  • the IL12 polypeptide of the present disclosure comprises a single polypeptide chain comprising the IL12B and IL12A fused directly or by a linker.
  • the IL12 polypeptide of the present disclosure comprises two polypeptides, the first polypeptide comprising IL12B and the second polypeptide comprising IL12A.
  • the disclosure provides an IL12A polypeptide and an IL12B polypeptide, wherein the IL12A and IL12B polypeptides are on the same chain or different chains.
  • the IL12A or IL12B polypeptide of the disclosure is a variant, a peptide or a polypeptide containing a substitution, and insertion and/or an addition, a deletion and/or a covalent modification with respect to a wild-type IL12A or IL12B sequence.
  • sequence tags such as epitope tags, e.g., a V5 tag
  • amino acids can be added to the sequences encoded by the polynucleotides of the disclosure (e.g ., at the N-terminal or C-terminal ends), e.g., for localization.
  • amino acid residues located at the carboxy, amino terminal, or internal regions of a polypeptide of the disclosure can optionally be deleted providing for fragments.
  • the IL12A and/or IL12B polypeptide encoded by a polynucleotide of the disclosure comprises a substitutional variant of an IL12A and/or IL12B sequence, which can comprise one, two, three or more than three substitutions.
  • the substitutional variant can comprise one or more conservative amino acids substitutions.
  • the variant is an insertional variant.
  • the variant is a deletional variant.
  • the IL12A and/or IL12B polypeptide encoded the polynucleotide comprises a linker fusing the IL12A and IL12B polypeptides.
  • linkers are disclosed elsewhere herein.
  • lipid nanoparticle comprising a polynucleotide (e.g ., mRNA) encoding a human IL12 polypeptide, wherein the polynucleotide comprises an ORF encoding a human IL12B polypeptide operably linked to a human IL12A polypeptide.
  • the IL12B polypeptide is operably linked to the IL12A polypeptide by a peptide linker.
  • the IL12B polypeptide is located at the 5' terminus of the IL12A polypeptide or the peptide linker.
  • the IL12A polypeptide is located at the 5' terminus of the IL12B polypeptide or the peptide linker.
  • IL12 protein fragments, functional protein domains, variants, and homologous proteins are also considered to be within the scope of the IL12 polypeptides of the disclosure.
  • Nonlimiting examples of polypeptides encoded by the polynucleotides of the disclosure are shown in FIGs. 1 to 2 .
  • Table 2 shows the correlating amino acid numbering in SEQ ID NOs, nucleotide numbering in SEQ ID NOs, and the 5' UTR, IL12B signal peptide, mature IL12A and IL12B peptides, and linker.
  • Table 2 shows the correlating amino acid numbering in SEQ ID NOs, nucleotide numbering in SEQ ID NOs, and the 5' UTR, IL12B signal peptide, mature IL12A and IL12B peptides, and linker.
  • Table 2 shows the correlating amino acid numbering in SEQ ID NOs, nucleotide numbering in SEQ ID NOs, and the 5' UTR, IL
  • the disclosure provides polynucleotides (e.g ., a RNA, e.g., an mRNA) that comprise a nucleotide sequence (e.g., an ORF, e.g., mRNA) encoding one or more IL12 polypeptides.
  • a nucleotide sequence e.g., an ORF, e.g., mRNA
  • the polynucleotides encode an IL-12 polypeptide, wherein the polynucleotides comprise a single ORF encoding an IL12B polypeptide and an IL12A polypeptide.
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure encodes a single IL12 polypeptide chain comprising an IL12B polypeptide and an IL12A polypeptide, which are fused directly or by a linker, wherein the IL12B polypeptide is selected from the group consisting of:
  • the polynucleotide (e.g ., a RNA, e.g., an mRNA) of the disclosure encodes two polypeptide chains, the first chain comprising an IL12B polypeptide and the second chain comprising an IL12A polypeptide, wherein the IL12B polypeptide is selected from the group consisting of:
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure encodes a mammalian IL12 polypeptide, such as a human IL12 polypeptide, a functional fragment or a variant thereof.
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide is introduced to the cells in vitro. In some embodiments, the polynucleotide is introduced to the cells in vivo.
  • the polynucleotides e.g., a RNA, e.g., an mRNA
  • the polynucleotides of the disclosure comprise a nucleotide sequence (e.g ., an ORF) that encodes a wild-type human IL12B and/or IL12A, (see FIG. 1 ).
  • the polynucleotide e.g., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure comprises a codon optimized nucleic acid sequence, wherein the open reading frame (ORF) of the codon optimized nucleic sequence is derived from a wild-type IL12A and/or IL12B sequence.
  • the polynucleotides e.g., a RNA, e.g., an mRNA
  • the polynucleotides comprise a nucleotide sequence encoding IL12B and/or IL12A having the full length sequence of human IL12B and/or IL12A (i.e., including the initiator methionine and the signal peptides).
  • the initiator methionine and/or signal peptides can be removed to yield a "mature IL12B" and/or "mature IL12A" comprising amino acid residues of SEQ ID NO: 1 and SEQ ID NO: 3, respectively.
  • SEQ ID NO: 1 corresponds to amino acids 23 to 328 of SEQ ID NO: 48
  • SEQ ID NO: 3 corresponds to amino acids 336 to 532 of SEQ ID NO: 48, respectively.
  • the teachings of the present disclosure directed to the full sequence of human IL12B and/or IL12A are also applicable to the mature form of human IL12B and/or IL12A lacking the initiator methionine and/or the signal peptide.
  • the polynucleotides (e.g., a RNA, e.g., an mRNA) of the disclosure comprise a nucleotide sequence encoding IL12B and/or IL12A having the mature sequence of human IL12B and/or IL12A.
  • the polynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure comprising a nucleotide sequence encoding IL12B and/or IL12A is sequence optimized.
  • the polynucleotides e.g., a RNA, e.g., an mRNA
  • the polynucleotides of the disclosure comprise a nucleotide sequence (e.g ., an ORF) encoding a mutant IL12B and/or IL12A polypeptide.
  • the polynucleotides of the disclosure comprise an ORF encoding an IL12B and/or IL12A polypeptide that comprises at least one point mutation, at least two point mutations, at least three mutations, at least four mutations, at least five mutations, at least six mutations, at least seven mutations, at least eight mutations, at least nine mutations, or at least ten mutations in the IL12B and/or IL12A sequence and retains IL12B and/or IL12A enzymatic activity.
  • the mutant IL12B and/or IL12A polypeptide has an IL12B and/or IL12A activity which is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% of the IL12B and/or IL12A activity of the corresponding wild-type IL12B and/or IL12A ( i.e., the same IL12B and/or IL12A but without the mutation(s)).
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure comprising an ORF encoding a mutant IL12B and/or IL12A polypeptide is sequence optimized.
  • the polynucleotide (e.g ., a RNA, e.g., an mRNA) of the disclosure comprises a nucleotide sequence (e.g ., an ORF) that encodes an IL12B and/or IL12A polypeptide with mutations that do not alter IL12B and/or IL12A enzymatic activity.
  • a mutant IL12B and/or IL12A polypeptides can be referred to as function-neutral.
  • the polynucleotide comprises an ORF that encodes a mutant IL12B and/or IL12A polypeptide comprising one or more function-neutral point mutations.
  • the mutant IL12B and/or IL12A polypeptide has higher IL12B and/or IL12A enzymatic activity than the corresponding wild-type IL12B and/or IL12A. In some embodiments, the mutant IL12B and/or IL12A polypeptide has an IL12B and/or IL12A activity that is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% higher than the activity of the corresponding wild-type IL12B and/or IL12A ( i.e., the same IL12B and/or IL12A but without the mutation(s)).
  • the polynucleotides e.g., a RNA, e.g., an mRNA
  • the polynucleotides of the disclosure comprise a nucleotide sequence (e.g ., an ORF) encoding a functional IL12B and/or IL12A fragment, e.g ., where one or more fragments correspond to a polypeptide subsequence of a wild type IL12B and/or IL12A polypeptide and retain IL12B and/or IL12A enzymatic activity.
  • a nucleotide sequence e.g ., an ORF
  • the IL12B and/or IL12A fragment has an IL12B and/or IL12A activity which is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% of the IL12 activity of the corresponding full length IL12B and/or IL12A.
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure comprising an ORF encoding a functional IL12B and/or IL12A fragment is sequence optimized.
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure comprises a nucleotide sequence (e.g ., an ORF) encoding an IL12B and/or IL12A fragment that has higher IL12B and/or IL12A enzymatic activity than the corresponding full length IL12B and/or IL12A.
  • the IL12B and/or IL12A fragment has an IL12B and/or IL12A activity which is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% higher than the IL12B and/or IL12A activity of the corresponding full length IL12B and/or IL12A.
  • the polynucleotide (e.g ., a RNA, e.g., an mRNA) of the disclosure comprises a nucleotide sequence (e.g ., an ORF) encoding an IL12B and/or IL12A fragment that is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or 25% shorter than wild-type IL12B and/or IL12A.
  • a nucleotide sequence e.g ., an ORF
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure comprises a nucleotide sequence (e.g ., an ORF) encoding an IL12B polypeptide, which has:
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure comprises a nucleotide sequence (e.g ., an ORF) encoding an IL12A polypeptide, which has:
  • the polynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure comprises a single ORF encoding IL12B and IL12A, wherein the ORF comprises a sequence that has:
  • the polynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure comprises a first ORF encoding IL12B and a second ORF encoding IL12A or , wherein the first ORF comprises a sequence that has:
  • the polynucleotide sequence comprises an ORF comprising the sequence set forth as hIL12AB_002 (SEQ ID NO: 6) or a nucleotide sequence at least about 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to hIL12AB_002 (SEQ ID NO: 6).
  • the first nucleotide sequence (e.g,. first ORF) encoding the IL12B polypeptide and the second nucleotide sequence (e.g ., second ORF) encoding the IL12A polypeptide are fused directly or by a linker.
  • the first nucleotide sequence (e.g,. first ORF) encoding the IL12B polypeptide and the second nucleotide sequence (e.g ., second ORF) encoding the IL12A polypeptide are not fused to each other.
  • the polynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure comprises a nucleotide sequence (e.g ., an ORF) encoding an IL12B-IL12A fusion polypeptide (e.g ., the wild-type sequence, functional fragment, or variant thereof), wherein the nucleotide sequence has at least about 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 5 to 44. See Table 4.
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • the polynucleotide of the disclosure comprises a nucleotide sequence (e.g ., an ORF) encoding an IL12B-IL12A fusion polypeptide (e.g ., the wild-type sequence, functional fragment, or variant thereof), wherein the nucleotide sequence has 70% to 100%, 75% to 100%, 80% to 100%, 85% to 100%, 70% to 95%, 80% to 95%, 70% to 85%, 75% to 90%, 80% to 95%, 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 100%, sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 5 to 44. See Table 4.
  • the polynucleotide (e.g ., a RNA, e.g., an mRNA) of the disclosure comprises from about 900 to about 100,000 nucleotides (e.g ., from 900 to 1,000, from 900 to 1,100, from 900 to 1,200, from 900 to 1,300, from 900 to 1,400, from 900 to 1,500, from 1,000 to 1,100, from 1,000 to 1,100, from 1,000 to 1,200, from 1,000 to 1,300, from 1,000 to 1,400, from 1,000 to 1,500, from 1,083 to 1,200, from 1,083 to 1,400, from 1,083 to 1,600, from 1,083 to 1,800, from 1,083 to 2,000, from 1,083 to 3,000, from 1,083 to 5,000, from 1,083 to 7,000, from 1,083 to 10,000, from 1,083 to 25,000, from 1,083 to 50,000, from 1,083 to 70,000, or from 1,083 to 100,000).
  • nucleotides e.g ., from 900 to 1,000,
  • the polynucleotide of the disclosure (e.g ., a RNA, e.g., an mRNA) comprises a nucleotide sequence (e.g ., an ORF) encoding an IL12B-IL12A fusion polypeptide ( e.g ., the wild-type sequence, functional fragment, or variant thereof), wherein the length of the nucleotide sequence ( e.g ., an ORF) is at least 500 nucleotides in length ( e.g ., at least or greater than about 500, 600, 700, 80, 900, 1,000, 1,050, 1,083, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900,
  • the polynucleotide of the disclosure e.g ., a RNA, e.g., an mRNA
  • a nucleotide sequence e.g ., an ORF
  • an IL12B and/or IL12A polypeptide e.g ., the wild-type sequence, functional fragment, or variant thereof
  • at least one nucleic acid sequence that is noncoding, e.g., a miRNA binding site.
  • the polynucleotide of the disclosure e.g., a RNA, e.g., an mRNA
  • a nucleotide sequence e.g ., an ORF
  • IL12B and/or IL12A polypeptide that is single stranded or double stranded.
  • the polynucleotide of the disclosure comprising a nucleotide sequence (e.g., an ORF) encoding an IL12B and/or IL12A polypeptide (e.g., the wild-type sequence, functional fragment, or variant thereof) is DNA or RNA.
  • the polynucleotide of the disclosure is RNA.
  • the polynucleotide of the disclosure is, or functions as, a messenger RNA (mRNA).
  • the mRNA comprises a nucleotide sequence (e.g ., an ORF) that encodes at least one IL12B and/or IL12A polypeptide, and is capable of being translated to produce the encoded II,12B and/or IL12A polypeptide in vitro, in vivo, in situ or ex vivo.
  • a nucleotide sequence e.g ., an ORF
  • the polynucleotide of the disclosure e.g., a RNA, e.g., an mRNA
  • a sequence-optimized nucleotide sequence e.g ., an ORF
  • an IL12B and/or IL12A polypeptide e.g ., the wild-type sequence, functional fragment, or variant thereof
  • the polynucleotide comprises at least one chemically modified nucleobase, e.g ., 5-methoxyuracil.
  • the polynucleotide further comprises a miRNA binding site, e.g., a miRNA binding site that binds to miR-122.
  • the polynucleotide disclosed herein is formulated with a delivery agent, e.g., a compound having Formula (I) , e.g., any of Compounds 1-147 or any of Compounds 1-232.
  • a delivery agent e.g., a compound having Formula (I) , e.g., any of Compounds 1-147 or any of Compounds 1-232.
  • the polynucleotides e.g., a RNA, e.g., an mRNA
  • One such feature that aids in protein trafficking is the signal sequence, or targeting sequence.
  • the peptides encoded by these signal sequences are known by a variety of names, including targeting peptides, transit peptides, and signal peptides.
  • the polynucleotide e.g ., a RNA, e.g., an mRNA
  • a nucleotide sequence e.g., an ORF
  • encodes a signal peptide operably linked a nucleotide sequence that encodes an IL12B and/or IL12A polypeptide described herein.
  • the "signal sequence” or “signal peptide” is a polynucleotide or polypeptide, respectively, which is from about 9 to 200 nucleotides (3-70 amino acids) in length that, optionally, is incorporated at the 5' (or N-terminus) of the coding region or the polypeptide, respectively. Addition of these sequences results in trafficking the encoded polypeptide to a desired site, such as the endoplasmic reticulum or the mitochondria through one or more targeting pathways. Some signal peptides are cleaved from the protein, for example by a signal peptidase after the proteins are transported to the desired site.
  • the polynucleotide of the disclosure comprises a nucleotide sequence encoding an IL12B and/or IL12A polypeptide, wherein the nucleotide sequence further comprises a 5' nucleic acid sequence encoding a native signal peptide.
  • the polynucleotide of the disclosure comprises a nucleotide sequence encoding an IL12B and/or IL12A polypeptide, wherein the nucleotide sequence lacks the nucleic acid sequence encoding a native signal peptide.
  • the polynucleotide of the disclosure comprises a nucleotide sequence encoding an IL12B and/or IL12A polypeptide, wherein the nucleotide sequence further comprises a 5' nucleic acid sequence encoding a heterologous signal peptide.
  • the polynucleotide further comprises a nucleic acid sequence encoding a signal peptide that is located at the 5' terminus of the first ORF.
  • the first ORF comprises a nucleic acid sequence encoding a signal peptide.
  • the signal peptide is a human IL12B signal peptide.
  • the signal peptide comprises a sequence at least about 80%, at least about 90%, at least about 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to amino acids 1 to 22 of SEQ ID NO: 48.
  • RNA sequences e.g., conversion of uracil to thymine.
  • RNA sequence e.g., conversion of thymine to uracil.
  • the polynucleotide of the disclosure e.g ., a RNA, e.g., an mRNA
  • polynucleotides of the disclosure comprise a single ORF encoding an IL12B and/or IL12A polypeptide, a functional fragment, or a variant thereof.
  • the polynucleotide of the disclosure can comprise more than one nucleotide sequence, for example, a first nucleotide sequence encoding an IL12B polypeptide (a first polypeptide of interest), a functional fragment, or a variant thereof, a second nucleotide sequence encoding an IL12A polypeptide (a second polypeptide of interest), a functional fragment, or a variant thereof, and a third nucleotide sequence expressing a third polypeptide of interest (e.g ., a polypeptide heterologous to IL12).
  • the third polypeptide of interest can be fused to the IL12B polypeptide directly or by a linker.
  • the third polypeptide of interest can be fused to the IL12A polypeptide directly or by a linker. In other embodiments, the third polypeptide of interest can be fused to both the IL12B polypeptide and the IL12A polypeptide directly or by a linker.
  • the polynucleotide of the disclosure can comprise more than three nucleotide sequences, for example, a first nucleotide sequence encoding an IL12B polypeptide (a first polypeptide of interest), a functional fragment, or a variant thereof, a second nucleotide sequence encoding an IL12A polypeptide (a second polypeptide of interest), a functional fragment, or a variant thereof, a third nucleotide sequence expressing a third polypeptide of interest, and a fourth nucleotide sequence expressing a fourth polypeptide of interest.
  • the third polypeptide of interest is fused to the IL12A polypeptide directly or by a linker
  • the fourth polypeptide of interest is fused to the IL12B polypeptide directly or by a linker.
  • two or more polypeptides of interest can be genetically fused, i.e., two or more polypeptides can be encoded by the same nucleotide sequence.
  • the polynucleotide can comprise a nucleic acid sequence encoding a linker (e.g ., a G 4 S peptide linker or another linker known in the art) between two or more polypeptides of interest.
  • a polynucleotide of the disclosure e.g ., a RNA, e.g., an mRNA
  • a polynucleotide of the disclosure can comprise two, three, four, or more nucleotide sequences, each expressing a polypeptide of interest.
  • the polynucleotide of the disclosure e.g ., a RNA, e.g., an mRNA
  • a first nucleic acid sequence e.g ., a first ORF
  • a second nucleic acid sequence e.g ., a second ORF
  • the IL12B and/or IL12A can be fused directly or by a linker. In other embodiments, the IL12B and/or IL12A can be fused directly to by a linker to a heterologous polypeptide.
  • the linkers suitable for fusing the IL12B to IL12A or the IL12B and/or IL12A to a heterologous polypeptide can be a polypeptide (or peptide) moiety or a non-polypeptide moiety.
  • lipid nanoparticle comprising a polynucleotide encoding a human IL12 polypeptide, wherein the polynucleotide comprises an ORF encoding a human IL12B polypeptide operably linked to a human IL12A polypeptide.
  • the IL12B polypeptide is operably linked to the IL12A polypeptide by a peptide linker.
  • the IL12B polypeptide is located at the 5' terminus of the IL12A polypeptide or the peptide linker.
  • the IL12A polypeptide is located at the 5' terminus of the IL12B polypeptide or the peptide linker.
  • the linker is a peptide linker, including from one amino acid to about 200 amino acids.
  • the linker comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, or at least 40 amino acids.
  • the linker can be GS (Gly/Ser) linkers, for example, comprising (G n S) m , wherein n is an integer from 1 to 20 and m is an integer from 1 to 20.
  • the Gly/Ser linker comprises (G n S) m (SEQ ID NO: 203), wherein n is 1, 2 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20.
  • the GS linker can comprise (GGGGS) o (SEQ ID NO: 204), wherein o is an integer from 1 to 5.
  • the GS linker can comprise GGSGGGGSGG (SEQ ID NO: 205), GGSGGGGG (SEQ ID NO: 206), or GSGSGSGS (SEQ ID NO: 207).
  • the Gly/Ser linker comprises (G n S) m , wherein n is 6 and m is 1.
  • the linker suitable for the disclosure can be a Gly-rich linker, for example, comprising (Gly) p (SEQ ID NO: 208), wherein p is an integer from 1 to 40.
  • a Gly-rich linker can comprise GGGGG, GGGGGG, GGGGGGG or GGGGGGGG.
  • the linker suitable for the disclosure can comprise (EAAAK) q (SEQ ID NO: 209), wherein q is an integer from 1 to 5. In one embodiment, the linker suitable for the disclosure can comprise (EAAAK) 3 .
  • linkers include, but not limited to, GGGGSLVPRGSGGGGS (SEQ ID NO: 210), GSGSGS (SEQ ID NO: 211), GGGGSLVPRGSGGGG (SEQ ID NO: 212), GGSGGHMGSGG (SEQ ID NO: 213), GGSGGSGGSGG (SEQ ID NO: 214), GGSGG (SEQ ID NO: 215), GSGSGSGS (SEQ ID NO: 216), GGGSEGGGSEGGGSEGGG (SEQ ID NO: 217), AAGAATAA (SEQ ID NO: 218), GGSSG (SEQ ID NO: 219), GSGGGTGGGSG (SEQ ID NO: 220), GSGSGSGSGGSG (SEQ ID NO: 221), GSGGSGSGGSGGSG (SEQ ID NO: 222), and GSGGSGGSGGSGGS (SEQ ID NO: 223).
  • the nucleotides encoding the linkers can be constructed to fuse the nucleotide sequences of the present disclosure. Based on the RNA sequences provided, a person of ordinary skill in the art would understand the corresponding DNA sequence (e.g., conversion of uracil to thymine). Likewise, based on the DNA sequences provided, a person of ordinary skill in the art would understand the corresponding RNA sequence (e.g., conversion of thymine to uracil).
  • the polynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure is sequence optimized.
  • the polynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure comprises a nucleotide sequence (e.g., an ORF) encoding an IL12B and/or IL12A polypeptide, a nucleotide sequence (e.g ., an ORF) encoding another polypeptide of interest, a 5'-UTR, a 3'-UTR, a miRNA, a nucleotide sequence encoding a linker, or any combination thereof that is sequence optimized.
  • a sequence-optimized nucleotide sequence e.g ., an codon-optimized mRNA sequence encoding an IL12B and/or IL12A polypeptide, is a sequence comprising at least one synonymous nucleobase substitution with respect to a reference sequence (e.g., a wild type nucleotide sequence encoding an IL12B and/or IL12A polypeptide).
  • a sequence-optimized nucleotide sequence can be partially or completely different in sequence from the reference sequence.
  • a reference sequence encoding polyserine uniformly encoded by TCT codons can be sequence-optimized by having 100% of its nucleobases substituted (for each codon, T in position 1 replaced by A, C in position 2 replaced by G, and T in position 3 replaced by C) to yield a sequence encoding polyserine which would be uniformly encoded by AGC codons.
  • the percentage of sequence identity obtained from a global pairwise alignment between the reference polyserine nucleic acid sequence and the sequence-optimized polyserine nucleic acid sequence would be 0%.
  • the protein products from both sequences would be 100% identical.
  • sequence optimization also sometimes referred to codon optimization
  • results can include, e.g ., matching codon frequencies in certain tissue targets and/or host organisms to ensure proper folding; biasing G/C content to increase mRNA stability or reduce secondary structures; minimizing tandem repeat codons or base runs that can impair gene construction or expression; customizing transcriptional and translational control regions; inserting or removing protein trafficking sequences; removing/adding post translation modification sites in an encoded protein ( e.g ., glycosylation sites); adding, removing or shuffling protein domains; inserting or deleting restriction sites; modifying ribosome binding sites and mRNA degradation sites; adjusting translational rates to allow the various domains of the protein to fold properly; and/or reducing or eliminating problem secondary structures within the polynucleotide.
  • Sequence optimization tools, algorithms and services are known in the art, non-limiting examples include services from GeneArt (Life Technologies),
  • Codon options for each amino acid are given in Table 3. Table 3. Codon Options Amino Acid Single Letter Code Codon Options Isoleucine I ATT, ATC, ATA Leucine L CTT, CTC, CTA, CTG, TTA, TTG Valine V GTT, GTC, GTA, GTG Phenylalanine F TTT, TTC Methionine M ATG Cysteine C TGT, TGC Alanine A GCT, GCC, GCA, GCG Glycine G GGT, GGC, GGA, GGG Proline P CCT, CCC, CCA, CCG Threonine T ACT, ACC, ACA, ACG Serine S TCT, TCC, TCA, TCG, AGT, AGC Tyrosine Y TAT, TAC Tryptophan W TGG Glutamine Q CAA, CAG Asparagine N AAT, AAC Histidine H CAT, CAC Glutamic acid E GAA, GAG Aspartic acid D GAT, GAC Lysine K AAA,
  • a polynucleotide e.g ., a RNA, e.g., an mRNA
  • a sequence-optimized nucleotide sequence e.g ., an ORF
  • the IL12B and/or IL12A polypeptide, functional fragment, or a variant thereof encoded by the sequence-optimized nucleotide sequence has improved properties (e.g., compared to an IL12B and/or IL12A polypeptide, functional fragment, or a variant thereof encoded by a reference nucleotide sequence that is not sequence optimized), e.g ., improved properties related to expression efficacy after administration in vivo.
  • Such properties include, but are not limited to, improving nucleic acid stability (e.g ., mRNA stability), increasing translation efficacy in the target tissue, reducing the number of truncated proteins expressed, improving the folding or prevent misfolding of the expressed proteins, reducing toxicity of the expressed products, reducing cell death caused by the expressed products, increasing and/or decreasing protein aggregation.
  • nucleic acid stability e.g ., mRNA stability
  • increasing translation efficacy in the target tissue reducing the number of truncated proteins expressed, improving the folding or prevent misfolding of the expressed proteins, reducing toxicity of the expressed products, reducing cell death caused by the expressed products, increasing and/or decreasing protein aggregation.
  • the sequence-optimized nucleotide sequence is codon optimized for expression in human subjects, having structural and/or chemical features that avoid one or more of the problems in the art, for example, features which are useful for optimizing formulation and delivery of nucleic acid-based therapeutics while retaining structural and functional integrity; overcoming a threshold of expression; improving expression rates; half-life and/or protein concentrations; optimizing protein localization; and avoiding deleterious bio-responses such as the immune response and/or degradation pathways.
  • the polynucleotides of the disclosure comprise a nucleotide sequence (e.g., a nucleotide sequence (e.g., an ORF) encoding an IL12B and/or IL12A polypeptide, a nucleotide sequence (e.g ., an ORF) encoding an additional polypeptide of interest, a 5'-UTR, a 3'-UTR, a microRNA, a nucleic acid sequence encoding a linker, or any combination thereof) that is sequence-optimized according to a method comprising:
  • sequence-optimized nucleotide sequence e.g ., an ORF encoding an IL12B and/or IL12A polypeptide
  • the sequence optimization method is multiparametric and comprises one, two, three, four, or more methods disclosed herein and/or other optimization methods known in the art.
  • regions of the polynucleotide can be encoded by or within regions of the polynucleotide and such regions can be upstream (5') to, downstream (3') to, or within the region that encodes the IL12B and/or IL12A polypeptide. These regions can be incorporated into the polynucleotide before and/or after sequence-optimization of the protein encoding region or open reading frame (ORF). Examples of such features include, but are not limited to, untranslated regions (UTRs), microRNA sequences, Kozak sequences, oligo(dT) sequences, poly-A tail, and detectable tags and can include multiple cloning sites that may have XbaI recognition.
  • UTRs untranslated regions
  • microRNA sequences microRNA sequences
  • Kozak sequences oligo(dT) sequences
  • poly-A tail poly-A tail
  • detectable tags can include multiple cloning sites that may have XbaI recognition.
  • the polynucleotide of the disclosure comprises a 5' UTR, a 3' UTR and/or a miRNA binding site. In some embodiments, the polynucleotide comprises two or more 5' UTRs and/or 3' UTRs, which can be the same or different sequences. In some embodiments, the polynucleotide comprises two or more miRNA binding sites, which can be the same or different sequences. Any portion of the 5' UTR, 3' UTR, and/or miRNA binding site, including none, can be sequence-optimized and can independently contain one or more different structural or chemical modifications, before and/or after sequence optimization.
  • the polynucleotide is reconstituted and transformed into a vector such as, but not limited to, plasmids, viruses, cosmids, and artificial chromosomes.
  • a vector such as, but not limited to, plasmids, viruses, cosmids, and artificial chromosomes.
  • the optimized polynucleotide can be reconstituted and transformed into chemically competent E. coli, yeast, neurospora, maize, drosophila, etc. where high copy plasmid-like or chromosome structures occur by methods described herein.
  • the polynucleotide of the disclosure comprises a sequence-optimized nucleotide sequence encoding an IL12B and/or IL12A polypeptide disclosed herein. In some embodiments, the polynucleotide of the disclosure comprises an open reading frame (ORF) encoding an IL12B and/or IL12A polypeptide, wherein the ORF has been sequence optimized.
  • ORF open reading frame
  • Exemplary sequence-optimized nucleotide sequences encoding human IL12B and/or IL12A are shown in Tables 4A-4D.
  • the sequence optimized IL12B and/or IL12A sequences in Table 4A-4D, fragments, and variants thereof are used to practice the methods disclosed herein.
  • the sequence optimized IL12B and/or IL12A sequences in Table 4A-4D, fragments and variants thereof are combined with or alternatives to the wild-type sequences disclosed in Figure 1 . Based on the RNA sequences provided, a person of ordinary skill in the art would understand the corresponding DNA sequence (e.g., conversion of uracil to thymine).
  • RNA sequence e.g., conversion of thymine to uracil.
  • Table 4B Sequence Optimized Polynucleotides Comprising 5' UTR, ORF, 3' UTR hIL12AB_ 001 (SEQ ID NO: 55) hIL12AB_ 002 (SEQ ID NO: 56) hIL12AB_ 003 (SEQ ID NO: 57) hIL12AB_ 004 (SEQ ID NO: 58) hIL12AB_ 005 (SEQ ID NO: 59) hIL12AB_ 006 (SEQ ID NO: 60) hIL12AB_ 007 (SEQ ID NO: 61) hIL12AB_ 008 (SEQ ID NO: 62) hIL12AB_ 009 (SEQ ID NO: 63) hIL12AB_ 010 (SEQ ID NO: 64) hIL
  • sequence-optimized nucleotide sequences disclosed herein are distinct from the corresponding wild type nucleotide acid sequences and from other known sequence-optimized nucleotide sequences, e . g ., these sequence-optimized nucleic acids have unique compositional characteristics.
  • the percentage of uracil or thymine nucleobases in a sequence-optimized nucleotide sequence is modified ( e . g .,. reduced) with respect to the percentage of uracil or thymine nucleobases in the reference wild-type nucleotide sequence.
  • a sequence-optimized nucleotide sequence e.g., encoding an IL12B and/or IL12A polypeptide, a functional fragment, or a variant thereof
  • Such a sequence is referred to as a uracil-modified or thymine-modified sequence.
  • the percentage of uracil or thymine content in a nucleotide sequence can be determined by dividing the number of uracils or thymines in a sequence by the total number of nucleotides and multiplying by 100.
  • the sequence-optimized nucleotide sequence has a lower uracil or thymine content than the uracil or thymine content in the reference wild-type sequence.
  • the uracil or thymine content in a sequence-optimized nucleotide sequence of the disclosure is greater than the uracil or thymine content in the reference wild-type sequence and still maintain beneficial effects, e . g ., increased expression and/or reduced Toll-Like Receptor (TLR) response when compared to the reference wild-type sequence.
  • TLR Toll-Like Receptor
  • the optimized sequences of the present disclosure contain unique ranges of uracils or thymine (if DNA) in the sequence.
  • the uracil or thymine content of the optimized sequences can be expressed in various ways, e . g ., uracil or thymine content of optimized sequences relative to the theoretical minimum (%U TM or %T TM ), relative to the wild-type (%U WT or %T WT ), and relative to the total nucleotide content (%U TL or %T TL ).
  • %U TM or %T TM the theoretical minimum
  • %U WT or %T WT wild-type
  • %U TL or %T TL total nucleotide content
  • %U TM , %U WT , or %U TL with respect to RNA are equally applicable to %T TM , %T WT , or %T TL with respect to DNA.
  • Uracil- or thymine- content relative to the uracil or thymine theoretical minimum refers to a parameter determined by dividing the number of uracils or thymines in a sequence-optimized nucleotide sequence by the total number of uracils or thymines in a hypothetical nucleotide sequence in which all the codons in the hypothetical sequence are replaced with synonymous codons having the lowest possible uracil or thymine content and multiplying by 100.
  • This parameter is abbreviated herein as %U TM or %T TM
  • the %U TM of a uracil-modified sequence encoding an IL12B polypeptide of the disclosure is below 196%, below 195%, below 190%, below 185%, below 180%, below 175%, below 170%, below 165%, below 160%, below 155%, below 150%, below 145%, below 140%, below 139%, below 138%, below 137%, below 136%, below 135%, below 134%, below 133%, below 132%, below 131%, below 130%, below 129%, below 128%, below 127%, below 126%, below 125%, below 124%, below 123%, below 122%, below 121%, below 120%, below 119%, below 118%, below 117%, below 116%, or below 115%.
  • the %U TM of a uracil-modified sequence encoding an IL12B polypeptide of the disclosure is below 196% and above 100%, above 101%, above 102%, above 103%, above 104%, above 105%, above 106%, above 107%, above 108%, above 109%, above 110%, above 111%, above 112%, above 113%, above 114%, above 115%, above 116%, above 117%, above 118%, above 119%, above 120%, above 121%, above 122%, above 123%, above 124%, above 125%, above 126%, above 127%, above 128%, above 129%, or above 130%, above 135%, above 130%, above 131%, or above 132%.
  • the %U TM of a uracil-modified sequence encoding an IL12B polypeptide of the disclosure is between 132% and 150%, between 133% and 150%, between 134% and 150%, between 135% and 150%, between 136% and 150%, between 137% and 150%, between 138% and 150%, between 139% and 150%, between 140% and 150%, between 132% and 151%, between 132% and 152%, between 132% and 153%, between 132% and 154%, between 132% and 155%, between 132% and 156%, between 132% and 157%, between 132% and 158%, between 132% and 159%, between 132% and 160%, between 133% and 151%, between 134% and 152%, between 135% and 153%, between 136% and 154%, between 137% and 155%, between 138% and 156%, between 138% and 157%, between 139% and 158%, between 140% and 159%, or between 141% and 160%.
  • the %U TM of a uracil-modified sequence encoding an IL12B polypeptide of the disclosure is between about 133% and about 152%, e.g., between 132.32% and 150.51%.
  • the %U TM of a uracil-modified sequence encoding an IL12A polypeptide of the disclosure is below 198%, below 195%, below 190%, below 185%, below 180%, below 175%, below 170%, below 165%, below 160%, below 155%, below 150%, below 145%, below 140%, below 139%, below 138%, below 137%, below 136%, below 135%, below 134%, below 133%, below 132%, below 131%, below 130%, below 129%, below 128%, below 127%, below 126%, below 125%, below 124%, below 123%, below 122%, below 121%, below 120%, below 119%, below 118%, below 117%, below 116%, or below 115%.
  • the %U TM of a uracil-modified sequence encoding an IL12A polypeptide of the disclosure is below 198% and above 100%, above 101%, above 102%, above 103%, above 104%, above 105%, above 106%, above 107%, above 108%, above 109%, above 110%, above 111%, above 112%, above 113%, above 114%, above 115%, above 116%, above 117%, above 118%, above 119%, above 120%, above 121%, above 122%, above 123%, above 124%, or above 125%.
  • the %U TM of a uracil-modified sequence encoding an IL12A polypeptide of the disclosure is between 125% and 143%, between 126% and 143%, between 127% and 143%, between 128% and 143%, between 129% and 143%, between 130% and 143%, between 131% and 132%, between 133% and 134%, between 135% and 143%, between 125% and 144%, between 125% and 145%, between 125% and 146%, between 125% and 147%, between 125% and 148%, between 125% and 149%, between 125% and 150%, between 125% and 151%, between 125% and 152%, between 125% and 153%, between 125% and 154%, between 125% and 155%, between 126% and 144%, between 127% and 145%, between 128% and 146%, between 129% and 147%, between 130% and 148%, between 131% and 149%, between 132% and 150%, or between 133% and 151%.
  • the %U TM of a uracil-modified sequence encoding an IL12A polypeptide of the disclosure is between about 124% and about 145%, e.g., between 125% and 144.42%.
  • a uracil- or thymine-modified sequence encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides of the disclosure can also be described according to its uracil or thymine content relative to the uracil or thymine content in the corresponding wild-type nucleic acid sequence (%U WT or %T WT ).
  • uracil or thymine content relative to the uracil or thymine content in the wild type nucleic acid sequence refers to a parameter determined by dividing the number of uracils or thymines in a sequence-optimized nucleic acid by the total number of uracils or thymines in the corresponding wild-type nucleic acid sequence and multiplying by 100. This parameter is abbreviated herein as %U WT or %T WT .
  • the %U WT or %T WT of a uracil- or thymine-modified sequence encoding an IL12B polypeptide of the disclosure is above 50%, above 55%, above 60%, above 65%, above 70%, above 75%, above 80%, above 85%, above 90%, or above 95%.
  • the %U WT or %T WT of a uracil- or thymine modified sequence encoding an IL12B polypeptide of the disclosure is between 55% and 88%, between 56% and 87%, between 57% and 86%, between 58% and 85%, between 59% and 84%, between 60% and 83%, between 61% and 82%, between 62% and 81%, between 63% and 80%, between 64% and 79%, between 65% and 78%, or between 65% and 77%.
  • the %U WT or %T WT of a uracil- or thymine-modified sequence encoding an II,12B polypeptide of the disclosure is between 66% and 78%, between 66% and 77%, between 67% and 77%, between 67% and 76%, or between 65% and 77%.
  • the %U WT or %T WT of a uracil- or thymine-modified sequence encoding an II,12B polypeptide of the disclosure is between about 66% and about 77%, e.g ., between 67% and 76%.
  • the %U WT or %T WT of a uracil- or thymine-modified sequence encoding an IL12A polypeptide of the disclosure is above 50%, above 55%, above 60%, above 65%, above 70%, above 75%, above 80%, above 85%, above 90%, or above 95%.
  • the %U WT or %T WT of a uracil- or thymine modified sequence encoding an IL12A polypeptide of the disclosure is between 50% and 85%, between 51% and 84%, between 52% and 83%, between 53% and 82%, between 54% and 81%, between 55% and 80%, between 56% and 79%, between 57% and 78%, between 58% and 77%, between 59% and 76%, between 60% and 75%, between 61% and 74%, or between 62% and 73%.
  • the %U WT or %T WT of a uracil- or thymine-modified sequence encoding an IL12A polypeptide of the disclosure is between 61% and 74%, between 61% and 73%, between 61% and 72%, between 61% and 73%, between 62% and 73%, between 62% and 72%, between 62% and 74%, or between 63% and 72%.
  • the %U WT or %T WT of a uracil- or thymine-modified sequence encoding an IL12A polypeptide of the disclosure is between about 62% and about 73%, e . g ., between 63% and 72%.
  • the uracil or thymine content of wild-type IL12B relative to the total nucleotide content (%) is about 21%.
  • the uracil or thymine content of a uracil- or thymine- modified sequence encoding an IL12B polypeptide relative to the total nucleotide content (%) is less than 21%.
  • the %U TL or %T TL is less than 20%, less than 19%, less that 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, or less than 10%.
  • the %U TL or %T TL is not less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%.
  • the uracil or thymine content of a uracil- or thymine-modified sequence encoding an IL12B polypeptide of the disclosure relative to the total nucleotide content is between 10% and 20%, between 11% and 20%, between 11.5% and 19.5%, between 12% and 19%, between 12% and 18%, between 13% and 18%, between 13% and 17%, between 13% and 16%, between 13% and 16%, between 14% and 16%, between 14% and 17%, or between 13% and 17%.
  • the uracil or thymine content (%U TL or %T TL ) of a uracil- or thymine modified sequence encoding an IL12B polypeptide of the disclosure is between about 13% and about 17%, e.g., between 14% and 16%
  • the uracil or thymine content of wild-type IL12A relative to the total nucleotide content (%) is about 26%.
  • the uracil or thymine content of a uracil- or thymine- modified sequence encoding an IL12A polypeptide relative to the total nucleotide content (%) is less than 25%.
  • the %U TL or %T TL is less than 25%, less than 24%, less than 23%, less than 22%, less than 21%, less than 20%, less than 19%, less that 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, or less than 10%. In some embodiments, the %U TL or %T TL is not less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%.
  • the uracil or thymine content of a uracil- or thymine-modified sequence encoding an IL12A polypeptide of the disclosure relative to the total nucleotide content is between 10% and 25%, between 11% and 25%, between 12% and 25%, between 13% and 25%, between 14% and 25%, between 15% and 25%, between 16% and 25%, between 10% and 24%, between 10% and 23%, between 11% and 22%, between 11% and 21%, between 11% and 20%, between 11% and 19%, between 11% and 18%, between 12% and 24%, between 12% and 23%, between 13% and 22%, between 14% and 21%, between 13% and 20%, between 15% and 19%, between 15% and 20%, between 16% and 19%, between 16% and 18%, or between 13% and 17%.
  • the uracil or thymine content (%U TL or %T TL ) of a uracil- or thymine modified sequence encoding an IL12A polypeptide of the disclosure is between about 15% and about 19%, e . g ., between 16% and 18%
  • a uracil-modified sequence encoding an IL12B polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure has a reduced number of consecutive uracils with respect to the corresponding wild-type nucleic acid sequence.
  • two consecutive leucines can be encoded by the sequence CUUUUG, which includes a four uracil cluster.
  • Such a subsequence can be substituted, e . g ., with CUGCUC, which removes the uracil cluster.
  • Phenylalanine can be encoded by UUC or UUU. Thus, even if phenylalanines encoded by UUU are replaced by UUC, the synonymous codon still contains a uracil pair (UU). Accordingly, the number of phenylalanines in a sequence establishes a minimum number of uracil pairs (UU) that cannot be eliminated without altering the number of phenylalanines in the encoded polypeptide.
  • a uracil-modified sequence encoding an IL12B and/or IL12A polypeptide of the disclosure has a reduced number of uracil triplets (UUU) with respect to the wild-type nucleic acid sequence.
  • a uracil-modified sequence encoding an IL12B and/or IL12A polypeptide of the disclosure contains 4, 3, 2, 1 or no uracil triplets (UUU).
  • a uracil-modified sequence encoding an IL12B and/or IL12A polypeptide has a reduced number of uracil pairs (UU) with respect to the number of uracil pairs (UU) in the wild-type nucleic acid sequence.
  • a uracil-modified sequence encoding an IL12B and/or IL12A polypeptide of the disclosure has a number of uracil pairs (UU) corresponding to the minimum possible number of uracil pairs (UU) in the wild-type nucleic acid sequence.
  • a uracil-modified sequence encoding an IL12B polypeptide of the disclosure has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 uracil pairs (UU) less than the number of uracil pairs (UU) in the wild-type nucleic acid sequence. In some embodiments, a uracil-modified sequence encoding an IL12B polypeptide of the disclosure has between 7 and 13, between 8 and 14, between 9 and 15, between 10 and 16, between 11 and 7, between 12 and 18 uracil pairs (UU).
  • a uracil-modified sequence encoding an IL12B polypeptide of the disclosure has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 uracil pairs (UU) less than the number of uracil pairs (UU) in the wild-type nucleic acid sequence.
  • a uracil-modified sequence encoding an IL12A polypeptide of the disclosure has between 7 and 13, between 8 and 14, between 9 and 15, between 10 and 16, between 11 and 7, between 12 and 18 uracil pairs (UU).
  • uracil pairs (UU) relative to the uracil pairs (UU) in the wild type nucleic acid sequence refers to a parameter determined by dividing the number of uracil pairs (UU) in a sequence-optimized nucleotide sequence by the total number of uracil pairs (UU) in the corresponding wild-type nucleotide sequence and multiplying by 100. This parameter is abbreviated herein as %UU wt .
  • a uracil-modified sequence encoding an IL12A or IL12B polypeptide of the disclosure has a %UU wt less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 65%, less than 60%, less than 55%, less than 50%, less than 40%, less than 30%, or less than 20%.
  • a uracil-modified sequence encoding an IL12B polypeptide has a %UU wt between 24% and 59%.
  • a uracil-modified sequence encoding an IL12B polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure has a %UU wt between 29% and 55% .
  • a uracil-modified sequence encoding an IL12A polypeptide has a %UU wt between 14% and 57%.
  • a uracil-modified sequence encoding an IL12B polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure has a %UU wt between 19% and 52% .
  • the polynucleotide of the disclosure comprises a uracil-modified sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides disclosed herein.
  • the uracil-modified sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides comprises at least one chemically modified nucleobase, e.g., 5-methoxyuracil.
  • At least 95% of a nucleobase e.g., uracil
  • a nucleobase e.g., uracil
  • at least 95% of uracil in a uracil-modified sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is 5-methoxyuracil.
  • the polynucleotide comprising a uracil-modified sequence further comprises a miRNA binding site, e.g., a miRNA binding site that binds to miR-122.
  • the polynucleotide comprising a uracil-modified sequence is formulated with a delivery agent, e.g., a compound having Formula (I), e.g., any of Compounds 1-147 or any of Compounds 1-232.
  • the "guanine content of the sequence optimized ORF encoding IL12B and/or IL12A with respect to the theoretical maximum guanine content of a nucleotide sequence encoding the IL12B and/or IL12A polypeptide," abbreviated as %G TMX is at least 69%, at least 70%, at least 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%. In some embodiments, the %G TMX is between about 70% and about 80%, between about 71% and about 79%, between about 71% and about 78%, or between about 71% and about 77%.
  • the "cytosine content of the ORF relative to the theoretical maximum cytosine content of a nucleotide sequence encoding the IL12B and/or IL12A polypeptide," abbreviated as %C TMX , is at least 59%, at least 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%.
  • the %C TMX is between about 60% and about 80%, between about 62% and about 80%, between about 63% and about 79%, or between about 68% and about 76%.
  • the "guanine and cytosine content (G/C) of the ORF relative to the theoretical maximum G/C content in a nucleotide sequence encoding the IL12B and/or IL12A polypeptide,” abbreviated as %G/C TMX is at least about 81%, at least about 85%, at least about 90%, at least about 95%, or about 100%.
  • the %G/C TMX is between about 80% and about 100%, between about 85% and about 99%, between about 90% and about 97%, or between about 91% and about 96%.
  • the "G/C content in the ORF relative to the G/C content in the corresponding wild-type ORF," abbreviated as%G/C WT is at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 110%, at least 115%, or at least 120%.
  • the average G/C content in the 3rd codon position in the ORF is at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, or at least 30% higher than the average G/C content in the 3rd codon position in the corresponding wild-type ORF.
  • the polynucleotide of the disclosure comprises an open reading frame (ORF) encoding an IL12B and/or IL12A polypeptide, wherein the ORF has been sequence optimized, and wherein each of %U TL , %U WT , %U TM , %G TL , %G WT , %G TMX , %C TL , %C WT , %C TMX , %G/C TL , %G/C WT , or %G/C TMX , alone or in a combination thereof is in a range between (i) a maximum corresponding to the parameter's maximum value (MAX) plus about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 standard deviations (STD DEV), and (ii) a minimum corresponding to the parameter's minimum value (MIN)
  • ORF
  • a polynucleotide of the disclosure e.g., a polynucleotide comprising a nucleotide sequence, e . g ., an ORF, encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides (e.g., the wild-type sequence, functional fragment, or variant thereof)
  • a sequence optimized nucleotide sequence comprises at least one codon modification with respect to a reference sequence ( e .
  • a wild-type sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides.
  • at least one codon is different from a corresponding codon in a reference sequence (e.g., a wild-type sequence).
  • sequence optimized nucleic acids are generated by at least a step comprising substituting codons in a reference sequence with synonymous codons (i.e., codons that encode the same amino acid).
  • substitutions can be effected, for example, by applying a codon substitution map (i.e., a table providing the codons that will encode each amino acid in the codon optimized sequence), or by applying a set of rules (e . g ., if glycine is next to neutral amino acid, glycine would be encoded by a certain codon, but if it is next to a polar amino acid, it would be encoded by another codon).
  • codon substitutions i .
  • compositions and formulations comprising these sequence optimized nucleic acids (e.g., a RNA, e.g., an mRNA) can be administered to a subject in need thereof to facilitate in vivo expression of functionally active IL12.
  • sequence optimized nucleic acids e.g., a RNA, e.g., an mRNA
  • the recombinant expression of large molecules in cell cultures can be a challenging task with numerous limitations (e . g. , poor protein expression levels, stalled translation resulting in truncated expression products, protein misfolding, etc.) These limitations can be reduced or avoided by administering the polynucleotides (e . g ., a RNA, e . g ., an mRNA), which encode a functionally active IL12 or compositions or formulations comprising the same to a patient suffering from cancer, so the synthesis and delivery of the IL12 polypeptide to treat cancer takes place endogenously.
  • the polynucleotides e . g ., a RNA, e . g ., an mRNA
  • codon usage i.e., the frequency with which different organisms use codons for expressing a polypeptide sequence
  • codon usage differs among organisms (for example, recombinant production of human or humanized therapeutic antibodies frequently takes place in hamster cell cultures).
  • a reference nucleic acid sequence can be sequence optimized by applying a codon map.
  • T bases in the codon maps disclosed below are present in DNA, whereas the T bases would be replaced by U bases in corresponding RNAs.
  • a sequence optimized nucleic acid disclosed herein in DNA form e.g., a vector or an in-vitro translation (IVT) template, would have its T bases transcribed as U based in its corresponding transcribed mRNA.
  • IVTT in-vitro translation
  • a TTC codon (DNA map) would correspond to a UUC codon (RNA map), which in turn may correspond to a ⁇ C codon (RNA map in which U has been replaced with pseudouridine).
  • a reference sequence encoding IL12A, IL12B, or both IL12A and IL12B can be optimized by replacing all the codons encoding a certain amino acid with only one of the alternative codons provided in a codon map.
  • all the valines in the optimized sequence would be encoded by GTG or GTC or GTT.
  • Sequence optimized polynucleotides of the disclosure can be generated using one or more codon optimization methods, or a combination thereof. Sequence optimization methods which may be used to sequence optimize nucleic acid sequences are described in detail herein. This list of methods is not comprehensive or limiting.
  • sequence optimization methods can be, for example, dependent on the specific chemistry used to produce a synthetic polynucleotide. Such a choice can also depend on characteristics of the protein encoded by the sequence optimized nucleic acid, e.g., a full sequence, a functional fragment, or a fusion protein comprising IL12, etc. In some embodiments, such a choice can depend on the specific tissue or cell targeted by the sequence optimized nucleic acid (e.g., a therapeutic synthetic mRNA).
  • the mechanisms of combining the sequence optimization methods or design rules derived from the application and analysis of the optimization methods can be either simple or complex.
  • the combination can be:
  • each one of these approaches can result in a specific set of rules which in many cases can be summarized in a single codon table, i.e., a sorted list of codons for each amino acid in the target protein (i.e., an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides), with a specific rule or set of rules indicating how to select a specific codon for each amino acid position.
  • uridine in a nucleic acid sequence can have detrimental effects on translation, e . g ., slow or prematurely terminated translation, especially when modified uridine analogs are used in the production of synthetic mRNAs.
  • high uridine content can also reduce the in vivo half-life of synthetic mRNAs due to TLR activation.
  • a nucleic acid sequence can be sequence optimized using a method comprising at least one uridine content optimization step.
  • a step comprises, e . g ., substituting at least one codon in the reference nucleic acid with an alternative codon to generate a uridine-modified sequence, wherein the uridine-modified sequence has at least one of the following properties:
  • the sequence optimization process comprises optimizing the global uridine content, i.e., optimizing the percentage of uridine nucleobases in the sequence optimized nucleic acid with respect to the percentage of uridine nucleobases in the reference nucleic acid sequence. For example, 30% of nucleobases may be uridines in the reference sequence and 10% of nucleobases may be uridines in the sequence optimized nucleic acid.
  • the sequence optimization process comprises reducing the local uridine content in specific regions of a reference nucleic acid sequence, i.e., reducing the percentage of uridine nucleobases in a subsequence of the sequence optimized nucleic acid with respect to the percentage of uridine nucleobases in the corresponding subsequence of the reference nucleic acid sequence.
  • the reference nucleic acid sequence may have a 5'-end region ( e . g ., 30 codons) with a local uridine content of 30%, and the uridine content in that same region could be reduced to 10% in the sequence optimized nucleic acid.
  • codons can be replaced in the reference nucleic acid sequence to reduce or modify, for example, the number, size, location, or distribution of uridine clusters that could have deleterious effects on protein translation.
  • codons can be replaced in the reference nucleic acid sequence to reduce or modify, for example, the number, size, location, or distribution of uridine clusters that could have deleterious effects on protein translation.
  • it is desirable to reduce the uridine content of the reference nucleic acid sequence in certain embodiments the uridine content, and in particular the local uridine content, of some subsequences of the reference nucleic acid sequence can be increased.
  • uridine content optimization can be combined with ramp design, since using the rarest codons for most amino acids will, with a few exceptions, reduce the U content.
  • the uridine-modified sequence is designed to induce a lower Toll-Like Receptor (TLR) response when compared to the reference nucleic acid sequence.
  • TLR Toll-Like Receptor
  • ds Double-stranded
  • ss Single-stranded
  • Single-stranded (ss)RNA activates TLR7. See Diebold et al. (2004) Science 303 :1529-1531 .
  • RNA oligonucleotides for example RNA with phosphorothioate internucleotide linkages, are ligands of human TLR8. See Heil et al. (2004) Science 303:1526-1529 . DNA containing unmethylated CpG motifs, characteristic of bacterial and viral DNA, activate TLR9. See Hemmi et al. (2000) Nature, 408: 740-745 .
  • TLR response is defined as the recognition of single-stranded RNA by a TLR7 receptor, and in some embodiments encompasses the degradation of the RNA and/or physiological responses caused by the recognition of the single-stranded RNA by the receptor.
  • Methods to determine and quantitate the binding of an RNA to a TLR7 are known in the art.
  • methods to determine whether an RNA has triggered a TLR7-mediated physiological response e . g ., cytokine secretion
  • a TLR response can be mediated by TLR3, TLR8, or TLR9 instead of TLR7.
  • Human rRNA for example, has ten times more pseudouridine ( ⁇ ) and 25 times more 2'-O-methylated nucleosides than bacterial rRNA.
  • Bacterial mRNA contains no nucleoside modifications, whereas mammalian mRNAs have modified nucleosides such as 5-methylcytidine (m5C), N6-methyladenosine (m6A), inosine and many 2'-O-methylated nucleosides in addition to N7-methylguanosine (m7G).
  • m5C 5-methylcytidine
  • m6A N6-methyladenosine
  • inosine inosine
  • 2'-O-methylated nucleosides in addition to N7-methylguanosine (m7G).
  • one or more of the optimization methods disclosed herein comprises reducing the uridine content (locally and/or locally) and/or reducing or modifying uridine clustering to reduce or to suppress a TLR7-mediated response.
  • the TLR response (e.g., a response mediated by TLR7) caused by the uridine-modified sequence is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% lower than the TLR response caused by the reference nucleic acid sequence.
  • the TLR response caused by the reference nucleic acid sequence is at least about 1-fold, at least about 1. 1-fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, or at least about 10-fold higher than the TLR response caused by the uridine-modified sequence.
  • the uridine content (average global uridine content) (absolute or relative) of the uridine-modified sequence is higher than the uridine content (absolute or relative) of the reference nucleic acid sequence. Accordingly, in some embodiments, the uridine-modified sequence contains at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% more uridine that the reference nucleic acid sequence.
  • the uridine content (average global uridine content) (absolute or relative) of the uridine-modified sequence is lower than the uridine content (absolute or relative) of the reference nucleic acid sequence. Accordingly, in some embodiments, the uridine-modified sequence contains at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% less uridine that the reference nucleic acid sequence.
  • the uridine content (average global uridine content) (absolute or relative) of the uridine-modified sequence is less than 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the total nucleobases in the uridine-modified sequence.
  • the uridine content of the uridine-modified sequence is between about 10% and about 20%. In some particular embodiments, the uridine content of the uridine-modified sequence is between about 12% and about 16%.
  • the uridine content of the reference nucleic acid sequence can be measured using a sliding window.
  • the length of the sliding window is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleobases.
  • the sliding window is over 40 nucleobases in length.
  • the sliding window is 20 nucleobases in length. Based on the uridine content measured with a sliding window, it is possible to generate a histogram representing the uridine content throughout the length of the reference nucleic acid sequence and sequence optimized nucleic acids.
  • a reference nucleic acid sequence can be modified to reduce or eliminate peaks in the histogram that are above or below a certain percentage value. In some embodiments, the reference nucleic acid sequence can be modified to eliminate peaks in the sliding-window representation which are above 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30% uridine. In another embodiment, the reference nucleic acid sequence can be modified so no peaks are over 30% uridine in the sequence optimized nucleic acid, as measured using a 20 nucleobase sliding window.
  • the reference nucleic acid sequence can be modified so no more or no less than a predetermined number of peaks in the sequence optimized nucleic sequence, as measured using a 20 nucleobase sliding window, are above or below a certain threshold value.
  • the reference nucleic acid sequence can be modified so no peaks or no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 peaks in the sequence optimized nucleic acid are above 10%, 15%, 20%, 25% or 30% uridine.
  • the sequence optimized nucleic acid contains between 0 peaks and 2 peaks with uridine contents 30% of higher.
  • a reference nucleic acid sequence can be sequence optimized to reduce the incidence of consecutive uridines. For example, two consecutive leucines could be encoded by the sequence CUUUUG, which would include a four uridine cluster. Such subsequence could be substituted with CUGCUC, which would effectively remove the uridine cluster. Accordingly, a reference nucleic sequence can be sequence optimized by reducing or eliminating uridine pairs (UU), uridine triplets (UUU) or uridine quadruplets (UUUU). Higher order combinations of U are not considered combinations of lower order combinations. Thus, for example, UUUU is strictly considered a quadruplet, not two consecutive U pairs; or UUUUUU is considered a sextuplet, not three consecutive U pairs, or two consecutive U triplets, etc.
  • all uridine pairs (UU) and/or uridine triplets (UUU) and/or uridine quadruplets (UUUU) can be removed from the reference nucleic acid sequence.
  • uridine pairs (UU) and/or uridine triplets (UUU) and/or uridine quadruplets (UUUU) can be reduced below a certain threshold, e.g., no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 occurrences in the sequence optimized nucleic acid.
  • the sequence optimized nucleic acid contains less than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 uridine pairs.
  • the sequence optimized nucleic acid contains no uridine pairs and/or triplets.
  • Phenylalanine codons i.e., UUC or UUU
  • UUC or UUU comprise a uridine pair or triples and therefore sequence optimization to reduce uridine content can at most reduce the phenylalanine U triplet to a phenylalanine U pair.
  • the occurrence of uridine pairs (UU) and/or uridine triplets (UUU) refers only to non-phenylalanine U pairs or triplets.
  • non-phenylalanine uridine pairs (UU) and/or uridine triplets (UUU) can be reduced below a certain threshold, e.g., no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 occurrences in the sequence optimized nucleic acid.
  • the sequence optimized nucleic acid contains less than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 non-phenylalanine uridine pairs and/or triplets.
  • the sequence optimized nucleic acid contains no non-phenylalanine uridine pairs and/or triplets.
  • the reduction in uridine combinations (e.g., pairs, triplets, quadruplets) in the sequence optimized nucleic acid can be expressed as a percentage reduction with respect to the uridine combinations present in the reference nucleic acid sequence.
  • a sequence optimized nucleic acid can contain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or 65% of the total number of uridine pairs present in the reference nucleic acid sequence.
  • a sequence optimized nucleic acid can contain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or 65% of the total number of uridine triplets present in the reference nucleic acid sequence.
  • a sequence optimized nucleic acid can contain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or 65% of the total number of uridine quadruplets present in the reference nucleic acid sequence.
  • a sequence optimized nucleic acid can contain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or 65% of the total number of non-phenylalanine uridine pairs present in the reference nucleic acid sequence.
  • a sequence optimized nucleic acid can contain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or 65% of the total number of non-phenylalanine uridine triplets present in the reference nucleic acid sequence.
  • the uridine content in the sequence optimized sequence can be expressed with respect to the theoretical minimum uridine content in the sequence.
  • the term "theoretical minimum uridine content” is defined as the uridine content of a nucleic acid sequence as a percentage of the sequence's length after all the codons in the sequence have been replaced with synonymous codon with the lowest uridine content.
  • the uridine content of the sequence optimized nucleic acid is identical to the theoretical minimum uridine content of the reference sequence (e.g., a wild type sequence).
  • the uridine content of the sequence optimized nucleic acid is about 90%, about 95%, about 100%, about 105%, about 110%, about 115%, about 120%, about 125%, about 130%, about 135%, about 140%, about 145%, about 150%, about 155%, about 160%, about 165%, about 170%, about 175%, about 180%, about 185%, about 190%, about 195% or about 200% of the theoretical minimum uridine content of the reference sequence (e.g., a wild type sequence).
  • the reference sequence e.g., a wild type sequence
  • the uridine content of the sequence optimized nucleic acid is identical to the theoretical minimum uridine content of the reference sequence (e.g., a wild type sequence).
  • the reference nucleic acid sequence can comprise uridine clusters which due to their number, size, location, distribution or combinations thereof have negative effects on translation.
  • uridine cluster refers to a subsequence in a reference nucleic acid sequence or sequence optimized nucleic sequence with contains a uridine content (usually described as a percentage) which is above a certain threshold.
  • a subsequence comprises more than about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% or 65% uridine content, such subsequence would be considered a uridine cluster.
  • uridine clusters can be, for example, eliciting a TLR7 response.
  • the reference nucleic acid sequence comprises at least one uridine cluster, wherein said uridine cluster is a subsequence of the reference nucleic acid sequence wherein the percentage of total uridine nucleobases in said subsequence is above a predetermined threshold.
  • the length of the subsequence is at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 nucleobases.
  • the subsequence is longer than 100 nucleobases.
  • the threshold is 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or 25% uridine content. In some embodiments, the threshold is above 25%.
  • an amino acid sequence comprising A, D, G, S and R could be encoded by the nucleic acid sequence GCU, GAU, GGU, AGU, CGU. Although such sequence does not contain any uridine pairs, triplets, or quadruplets, one third of the nucleobases would be uridines. Such a uridine cluster could be removed by using alternative codons, for example, by using GCC, GAC, GGC, AGC, and CGC, which would contain no uridines.
  • the reference nucleic acid sequence comprises at least one uridine cluster, wherein said uridine cluster is a subsequence of the reference nucleic acid sequence wherein the percentage of uridine nucleobases of said subsequence as measured using a sliding window that is above a predetermined threshold.
  • the length of the sliding window is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleobases.
  • the sliding window is over 40 nucleobases in length.
  • the threshold is 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or 25% uridine content. In some embodiments, the threshold is above 25%.
  • the reference nucleic acid sequence comprises at least two uridine clusters.
  • the uridine-modified sequence contains fewer uridine-rich clusters than the reference nucleic acid sequence.
  • the uridine-modified sequence contains more uridine-rich clusters than the reference nucleic acid sequence.
  • the uridine-modified sequence contains uridine-rich clusters with are shorter in length than corresponding uridine-rich clusters in the reference nucleic acid sequence.
  • the uridine-modified sequence contains uridine-rich clusters which are longer in length than the corresponding uridine-rich cluster in the reference nucleic acid sequence.
  • a reference nucleic acid sequence can be sequence optimized using methods comprising altering the Guanine/Cytosine (G/C) content (absolute or relative) of the reference nucleic acid sequence.
  • Such optimization can comprise altering ( e . g ., increasing or decreasing) the global G/C content (absolute or relative) of the reference nucleic acid sequence; introducing local changes in G/C content in the reference nucleic acid sequence ( e . g ., increase or decrease G/C in selected regions or subsequences in the reference nucleic acid sequence); altering the frequency, size, and distribution of G/C clusters in the reference nucleic acid sequence, or combinations thereof.
  • the sequence optimized nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides comprises an overall increase in G/C content (absolute or relative) relative to the G/C content (absolute or relative) of the reference nucleic acid sequence.
  • the overall increase in G/C content is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% relative to the G/C content (absolute or relative) of the reference nucleic acid sequence.
  • the sequence optimized nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides comprises an overall decrease in G/C content (absolute or relative) relative to the G/C content of the reference nucleic acid sequence.
  • the overall decrease in G/C content is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% relative to the G/C content (absolute or relative) of the reference nucleic acid sequence.
  • the sequence optimized nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides comprises a local increase in Guanine/Cytosine (G/C) content (absolute or relative) in a subsequence ( i . e ., a G/C modified subsequence) relative to the G/C content (absolute or relative) of the corresponding subsequence in the reference nucleic acid sequence.
  • G/C Guanine/Cytosine
  • the local increase in G/C content is by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% relative to the G/C content (absolute or relative) of the corresponding subsequence in the reference nucleic acid sequence.
  • the sequence optimized nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides comprises a local decrease in Guanine/Cytosine (G/C) content (absolute or relative) in a subsequence ( i . e ., a G/C modified subsequence) relative to the G/C content (absolute or relative) of the corresponding subsequence in the reference nucleic acid sequence.
  • G/C Guanine/Cytosine
  • the local decrease in G/C content is by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% relative to the G/C content (absolute or relative) of the corresponding subsequence in the reference nucleic acid sequence.
  • the G/C content (absolute or relative) is increased or decreased in a subsequence which is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleobases in length.
  • the G/C content (absolute or relative) is increased or decreased in a subsequence which is at least about 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890
  • the G/C content (absolute or relative) is increased or decreased in a subsequence which is at least about 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8
  • G and C content can be conducted by replacing synonymous codons with low G/C content with synonymous codons having higher G/C content, or vice versa.
  • L has 6 synonymous codons: two of them have 2 G/C (CUC, CUG), 3 have a single G/C (UUG, CUU, CUA), and one has no G/C (UUA). So if the reference nucleic acid had a CUC codon in a certain position, G/C content at that position could be reduced by replacing CUC with any of the codons having a single G/C or the codon with no G/C.
  • a nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides disclosed herein can be sequence optimized using methods comprising the use of modifications in the frequency of use of one or more codons relative to other synonymous codons in the sequence optimized nucleic acid with respect to the frequency of use in the non-codon optimized sequence.
  • codon usage bias i.e., the differences in the frequency of occurrence of synonymous codons in coding DNA/RNA. It is generally acknowledged that codon preferences reflect a balance between mutational biases and natural selection for translational optimization. Optimal codons help to achieve faster translation rates and high accuracy. As a result of these factors, translational selection is expected to be stronger in highly expressed genes. In the field of bioinformatics and computational biology, many statistical methods have been proposed and used to analyze codon usage bias. See, e.g., Comeron & Aguadé (1998) J. Mol. Evol. 47: 268-74 .
  • Multivariate statistical methods such as correspondence analysis and principal component analysis, are widely used to analyze variations in codon usage among genes ( Suzuki et al. (2008) DNA Res. 15 (6): 357-65 ; Sandhu et al., In Silico Biol. 2008;8(2): 187-92 ).
  • nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides disclosed herein can be codon optimized using methods comprising substituting at least one codon in the reference nucleic acid sequence with an alternative codon having a higher or lower codon frequency in the synonymous codon set; wherein the resulting sequence optimized nucleic acid has at least one optimized property with respect to the reference nucleic acid sequence.
  • At least one codon in the reference nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is substituted with an alternative codon having a codon frequency higher than the codon frequency of the substituted codon in the synonymous codon set, and at least one codon in the reference nucleic acid sequence is substituted with an alternative codon having a codon frequency lower than the codon frequency of the substituted codon in the synonymous codon set.
  • At least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, or at least about 75% of the codons in the reference nucleic acid sequence encoding IL12 are substituted with alternative codons, each alternative codon having a codon frequency higher than the codon frequency of the substituted codon in the synonymous codon set.
  • At least one alternative codon having a higher codon frequency has the highest codon frequency in the synonymous codon set. In other embodiments, all alternative codons having a higher codon frequency have the highest codon frequency in the synonymous codon set.
  • At least one alternative codon having a lower codon frequency has the lowest codon frequency in the synonymous codon set. In some embodiments, all alternative codons having a higher codon frequency have the highest codon frequency in the synonymous codon set.
  • At least one alternative codon has the second highest, the third highest, the fourth highest, the fifth highest or the sixth highest frequency in the synonymous codon set. In some specific embodiments, at least one alternative codon has the second lowest, the third lowest, the fourth lowest, the fifth lowest, or the sixth lowest frequency in the synonymous codon set.
  • Optimization based on codon frequency can be applied globally, as described above, or locally to the reference nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides.
  • regions of the reference nucleic acid sequence when applied locally, can modified based on codon frequency, substituting all or a certain percentage of codons in a certain subsequence with codons that have higher or lower frequencies in their respective synonymous codon sets.
  • At least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the codons in a subsequence of the reference nucleic acid sequence are substituted with alternative codons, each alternative codon having a codon frequency higher than the codon frequency of the substituted codon in the synonymous codon set.
  • At least one codon in a subsequence of the reference nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is substituted with an alternative codon having a codon frequency higher than the codon frequency of the substituted codon in the synonymous codon set, and at least one codon in a subsequence of the reference nucleic acid sequence is substituted with an alternative codon having a codon frequency lower than the codon frequency of the substituted codon in the synonymous codon set.
  • At least one alternative codon substituted in a subsequence of the reference nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides and having a higher codon frequency has the highest codon frequency in the synonymous codon set.
  • all alternative codons substituted in a subsequence of the reference nucleic acid sequence and having a lower codon frequency have the lowest codon frequency in the synonymous codon set.
  • At least one alternative codon substituted in a subsequence of the reference nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides and having a lower codon frequency has the lowest codon frequency in the synonymous codon set.
  • all alternative codons substituted in a subsequence of the reference nucleic acid sequence and having a higher codon frequency have the highest codon frequency in the synonymous codon set.
  • a sequence optimized nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides can comprise a subsequence having an overall codon frequency higher or lower than the overall codon frequency in the corresponding subsequence of the reference nucleic acid sequence at a specific location, for example, at the 5' end or 3' end of the sequence optimized nucleic acid, or within a predetermined distance from those region (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 codons from the 5' end or 3' end of the sequence optimized nucleic acid).
  • an sequence optimized nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides can comprise more than one subsequence having an overall codon frequency higher or lower than the overall codon frequency in the corresponding subsequence of the reference nucleic acid sequence.
  • subsequences with overall higher or lower overall codon frequencies can be organized in innumerable patterns, depending on whether the overall codon frequency is higher or lower, the length of the subsequence, the distance between subsequences, the location of the subsequences, etc.
  • motifs that fit into the category of disadvantageous motifs.
  • Some examples include, for example, restriction enzyme motifs, which tend to be relatively short, exact sequences such as the restriction site motifs for Xba1 (TCTAGA (SEQ ID NO: 224)), EcoRI (GAATTC (SEQ ID NO: 225)), EcoRII (CCWGG (SEQ ID NO: 226), wherein W means A or T, per the IUPAC ambiguity codes), or HindIII (AAGCTT (SEQ ID NO: 227)); enzyme sites, which tend to be longer and based on consensus not exact sequence, such in the T7 RNA polymerase (GnnnnWnCRnCTCnCnnWnD (SEQ ID NO: 228), wherein n means any nucleotide, R means A or G, W means A or T, D means A or G or T but not C); structural motifs, such as GGGG (SEQ ID NO: 229) repeats ( Kim et al. (1991) Nature 351(63
  • nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides disclosed herein can be sequence optimized using methods comprising substituting at least one destabilizing motif in a reference nucleic acid sequence, and removing such disadvantageous motif or replacing it with an advantageous motif.
  • the optimization process comprises identifying advantageous and/or disadvantageous motifs in the reference nucleic sequence, wherein such motifs are, e.g., specific subsequences that can cause a loss of stability in the reference nucleic acid sequence prior or during the optimization process. For example, substitution of specific bases during optimization may generate a subsequence (motif) recognized by a restriction enzyme. Accordingly, during the optimization process the appearance of disadvantageous motifs can be monitored by comparing the sequence optimized sequence with a library of motifs known to be disadvantageous. Then, the identification of disadvantageous motifs could be used as a post-hoc filter, i.e., to determine whether a certain modification which potentially could be introduced in the reference nucleic acid sequence should be actually implemented or not.
  • motifs are, e.g., specific subsequences that can cause a loss of stability in the reference nucleic acid sequence prior or during the optimization process. For example, substitution of specific bases during optimization may generate a subsequence (motif) recognized by a restriction
  • the identification of disadvantageous motifs can be used prior to the application of the sequence optimization methods disclosed herein, i.e., the identification of motifs in the reference nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides and their replacement with alternative nucleic acid sequences can be used as a preprocessing step, for example, before uridine reduction.
  • the identification of disadvantageous motifs and their removal is used as an additional sequence optimization technique integrated in a multiparametric nucleic acid optimization method comprising two or more of the sequence optimization methods disclosed herein.
  • a disadvantageous motif identified during the optimization process would be removed, for example, by substituting the lowest possible number of nucleobases in order to preserve as closely as possible the original design principle(s) (e.g., low U, high frequency, etc.).
  • sequence optimization of a reference nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides can be conducted using a limited codon set, e.g., a codon set wherein less than the native number of codons is used to encode the 20 natural amino acids, a subset of the 20 natural amino acids, or an expanded set of amino acids including, for example, non-natural amino acids.
  • a limited codon set e.g., a codon set wherein less than the native number of codons is used to encode the 20 natural amino acids, a subset of the 20 natural amino acids, or an expanded set of amino acids including, for example, non-natural amino acids.
  • the genetic code is highly similar among all organisms and can be expressed in a simple table with 64 entries which would encode the 20 standard amino acids involved in protein translation plus start and stop codons.
  • the genetic code is degenerate, i.e., in general, more than one codon specifies each amino acid.
  • the amino acid leucine is specified by the UUA, UUG, CUU, CUC, CUA, or CUG codons
  • the amino acid serine is specified by UCA, UCG, UCC, UCU, AGU, or AGC codons (difference in the first, second, or third position).
  • Native genetic codes comprise 62 codons encoding naturally occurring amino acids.
  • optimized codon sets comprising less than 62 codons to encode 20 amino acids can comprise 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, or 20 codons.
  • the limited codon set comprises less than 20 codons.
  • an optimized codon set comprises as many codons as different types of amino acids are present in the protein encoded by the reference nucleic acid sequence.
  • the optimized codon set comprises 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or even 1 codon.
  • At least one amino acid selected from the group consisting of Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro, Ser, Thr, Tyr, and Val i.e., amino acids which are naturally encoded by more than one codon, is encoded with less codons than the naturally occurring number of synonymous codons.
  • Ala can be encoded in the sequence optimized nucleic acid by 3, 2 or 1 codons; Cys can be encoded in the sequence optimized nucleic acid by 1 codon; Asp can be encoded in the sequence optimized nucleic acid by 1 codon; Glu can be encoded in the sequence optimized nucleic acid by 1 codon; Phe can be encoded in the sequence optimized nucleic acid by 1 codon; Gly can be encoded in the sequence optimized nucleic acid by 3 codons, 2 codons or 1 codon; His can be encoded in the sequence optimized nucleic acid by 1 codon; Ile can be encoded in the sequence optimized nucleic acid by 2 codons or 1 codon; Lys can be encoded in the sequence optimized nucleic acid by 1 codon; Leu can be encoded in the sequence optimized nucleic acid by 5 codons, 4 codons, 3 codons, 2 codons or 1 codon; Asn can be encoded in the sequence optimized nucleic acid by 1 codon;
  • the sequence optimized nucleic acid is a DNA and the limited codon set consists of 20 codons, wherein each codon encodes one of 20 amino acids.
  • the sequence optimized nucleic acid is a DNA and the limited codon set comprises at least one codon selected from the group consisting of GCT, GCC, GCA, and GCG; at least a codon selected from the group consisting of CGT, CGC, CGA, CGG, AGA, and AGG; at least a codon selected from AAT or ACC; at least a codon selected from GAT or GAC; at least a codon selected from TGT or TGC; at least a codon selected from CAA or CAG; at least a codon selected from GAA or GAG; at least a codon selected from the group consisting of GGT, GGC, GGA, and GGG; at least a codon selected from CAT or CAC; at least a codon selected from the group consisting of ATT, ATC, and
  • the sequence optimized nucleic acid is an RNA (e.g., an mRNA) and the limited codon set consists of 20 codons, wherein each codon encodes one of 20 amino acids.
  • the sequence optimized nucleic acid is an RNA and the limited codon set comprises at least one codon selected from the group consisting of GCU, GCC, GCA, and GCG; at least a codon selected from the group consisting of CGU, CGC, CGA, CGG, AGA, and AGG; at least a codon selected from AAU or ACC; at least a codon selected from GAU or GAC; at least a codon selected from UGU or UGC; at least a codon selected from CAA or CAG; at least a codon selected from GAA or GAG; at least a codon selected from the group consisting of GGU, GGC, GGA, and GGG; at least a codon selected from CAU or CAC; at least a codon selected from the group consisting of GGU, GGC
  • the limited codon set has been optimized for in vivo expression of a sequence optimized nucleic acid (e.g., a synthetic mRNA) following administration to a certain tissue or cell.
  • a sequence optimized nucleic acid e.g., a synthetic mRNA
  • the optimized codon set (e.g., a 20 codon set encoding 20 amino acids) complies at least with one of the following properties:
  • At least one codon in the optimized codon set has the second highest, the third highest, the fourth highest, the fifth highest or the sixth highest frequency in the synonymous codon set. In some specific embodiments, at least one codon in the optimized codon has the second lowest, the third lowest, the fourth lowest, the fifth lowest, or the sixth lowest frequency in the synonymous codon set.
  • the term “native codon set” refers to the codon set used natively by the source organism to encode the reference nucleic acid sequence.
  • the term “original codon set” refers to the codon set used to encode the reference nucleic acid sequence before the beginning of sequence optimization, or to a codon set used to encode an optimized variant of the reference nucleic acid sequence at the beginning of a new optimization iteration when sequence optimization is applied iteratively or recursively.
  • 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of codons in the codon set are those with the highest frequency.
  • 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of codons in the codon set are those with the lowest frequency.
  • 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of codons in the codon set are those with the highest uridine content. In some embodiments, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of codons in the codon set are those with the lowest uridine content.
  • the average G/C content (absolute or relative) of the codon set is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% higher than the average G/C content (absolute or relative) of the original codon set.
  • the average G/C content (absolute or relative) of the codon set is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% lower than the average G/C content (absolute or relative) of the original codon set.
  • the uracil content (absolute or relative) of the codon set is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% higher than the average uracil content (absolute or relative) of the original codon set.
  • the uracil content (absolute or relative) of the codon set is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% lower than the average uracil content (absolute or relative) of the original codon set.
  • the polynucleotide e.g., a RNA, e.g., an mRNA
  • a sequence optimized nucleic acid e.g., an ORF
  • encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides can be can be tested to determine whether at least one nucleic acid sequence property (e . g ., stability when exposed to nucleases) or expression property has been improved with respect to the non-sequence optimized nucleic acid.
  • expression property refers to a property of a nucleic acid sequence either in vivo (e.g., translation efficacy of a synthetic mRNA after administration to a subject in need thereof) or in vitro (e.g., translation efficacy of a synthetic mRNA tested in an in vitro model system).
  • Expression properties include but are not limited to the amount of protein produced by an mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides after administration, and the amount of soluble or otherwise functional protein produced.
  • sequence optimized nucleic acids disclosed herein can be evaluated according to the viability of the cells expressing a protein encoded by a sequence optimized nucleic acid sequence (e.g., a RNA, e.g., an mRNA) encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides disclosed herein.
  • a sequence optimized nucleic acid sequence e.g., a RNA, e.g., an mRNA
  • a plurality of sequence optimized nucleic acids disclosed herein e.g., a RNA, e.g., an mRNA
  • a property of interest for example an expression property in an in vitro model system, or in vivo in a target tissue or cell.
  • the desired property of the polynucleotide is an intrinsic property of the nucleic acid sequence.
  • the nucleotide sequence e.g., a RNA, e.g., an mRNA
  • the nucleotide sequence can be sequence optimized for in vivo or in vitro stability.
  • the nucleotide sequence can be sequence optimized for expression in a particular target tissue or cell.
  • the nucleic acid sequence is sequence optimized to increase its plasma half by preventing its degradation by endo and exonucleases.
  • the nucleic acid sequence is sequence optimized to increase its resistance to hydrolysis in solution, for example, to lengthen the time that the sequence optimized nucleic acid or a pharmaceutical composition comprising the sequence optimized nucleic acid can be stored under aqueous conditions with minimal degradation.
  • sequence optimized nucleic acid can be optimized to increase its resistance to hydrolysis in dry storage conditions, for example, to lengthen the time that the sequence optimized nucleic acid can be stored after lyophilization with minimal degradation.
  • the desired property of the polynucleotide is the level of expression of an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides encoded by a sequence optimized sequence disclosed herein.
  • Protein expression levels can be measured using one or more expression systems. In some embodiments, expression can be measured in cell culture systems, e . g ., CHO cells or HEK293 cells. In some embodiments, expression can be measured using in vitro expression systems prepared from extracts of living cells, e . g ., rabbit reticulocyte lysates, or in vitro expression systems prepared by assembly of purified individual components. In other embodiments, the protein expression is measured in an in vivo system, e.g., mouse, rabbit, monkey, etc.
  • protein expression in solution form can be desirable.
  • a reference sequence can be sequence optimized to yield a sequence optimized nucleic acid sequence having optimized levels of expressed proteins in soluble form.
  • Levels of protein expression and other properties such as solubility, levels of aggregation, and the presence of truncation products (i.e., fragments due to proteolysis, hydrolysis, or defective translation) can be measured according to methods known in the art, for example, using electrophoresis (e . g ., native or SDS-PAGE) or chromatographic methods ( e . g ., HPLC, size exclusion chromatography, etc.).
  • heterologous therapeutic proteins encoded by a nucleic acid sequence can have deleterious effects in the target tissue or cell, reducing protein yield, or reducing the quality of the expressed product ( e.g., due to the presence of protein fragments or precipitation of the expressed protein in inclusion bodies), or causing toxicity.
  • sequence optimization of a nucleic acid sequence disclosed herein e.g., a nucleic acid sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides, can be used to increase the viability of target cells expressing the protein encoded by the sequence optimized nucleic acid.
  • Heterologous protein expression can also be deleterious to cells transfected with a nucleic acid sequence for autologous or heterologous transplantation. Accordingly, in some embodiments of the present disclosure the sequence optimization of a nucleic acid sequence disclosed herein can be used to increase the viability of target cells expressing the protein encoded by the sequence optimized nucleic acid sequence. Changes in cell or tissue viability, toxicity, and other physiological reaction can be measured according to methods known in the art.
  • the administration of a sequence optimized nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides or a functional fragment thereof may trigger an immune response, which could be caused by (i) the therapeutic agent (e.g., an mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides), or (ii) the expression product of such therapeutic agent (e.g., the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides encoded by the mRNA), or (iv) a combination thereof.
  • the therapeutic agent e.g., an mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides
  • nucleic acid sequence e.g ., an mRNA
  • sequence optimization of nucleic acid sequence can be used to decrease an immune or inflammatory response triggered by the administration of a nucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and II,12B fusion polypeptides or by the expression product of IL12A, IL12B, and/or IL12A and IL12B fusion encoded by such nucleic acid.
  • an inflammatory response can be measured by detecting increased levels of one or more inflammatory cytokines using methods known in the art, e.g., ELISA.
  • inflammatory cytokine refers to cytokines that are elevated in an inflammatory response.
  • inflammatory cytokines include interleukin-6 (IL-6), CXCL1 (chemokine (C-X-C motif) ligand 1; also known as GRO ⁇ , interferon- ⁇ (IPN ⁇ ), tumor necrosis factor ⁇ (TNF ⁇ ), interferon ⁇ -induced protein 10 (IP-10), or granulocyte-colony stimulating factor (G-CSF).
  • IL-6 interleukin-6
  • CXCL1 chemokine (C-X-C motif) ligand 1
  • GRO ⁇ interferon- ⁇
  • TNF ⁇ tumor necrosis factor ⁇
  • IP-10 interferon ⁇ -induced protein 10
  • G-CSF granulocyte-colony stimulating factor
  • inflammatory cytokines includes also other cytokines associated with inflammatory responses known in the art, e.g ., interleukin-1 (IL-1), interleukin-8 (IL-8), interleukin-13 (Il-13), interferon ⁇ (IFN- ⁇ ), etc.
  • IL-1 interleukin-1
  • IL-8 interleukin-8
  • Il-13 interleukin-13
  • IFN- ⁇ interferon ⁇
  • the polynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure comprises a chemically modified nucleobase, e.g ., 5-methoxyuracil.
  • the mRNA is a uracil-modified sequence comprising an ORF encoding an IL12B polypeptide, IL12A polypeptide, and/ IL12B and IL12A fusion polypeptides, wherein the mRNA comprises a chemically modified nucleobase, e.g ., 5-methoxyuracil.
  • the resulting modified nucleoside or nucleotide is referred to as 5-methoxyuridine.
  • uracil in the polynucleotide is at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least 90%, at least 95%, at least 99%, or about 100% 5-methoxyuracil.
  • uracil in the polynucleotide is at least 95% 5-methoxyuracil.
  • uracil in the polynucleotide is 100% 5-methoxyuracil.
  • uracil in the polynucleotide is at least 95% 5-methoxyuracil
  • overall uracil content can be adjusted such that an mRNA provides suitable protein expression levels while inducing little to no immune response.
  • the uracil content of the ORF (%U TM ) is between about 105% and about 145%, about 105% and about 140%, about 110% and about 140%, about 110% and about 145%, about 115% and about 135%, about 105% and about 135%, about 110% and about 135%, about 115% and about 145%, or about 115% and about 140%.
  • the uracil content of the ORF is between about 117% and about 134% or between 118% and 132% of the %U TM .
  • the %U TM is about 115%, about 120%, about 125%, about 130%, about 135%, about 140%, about 145%, or about 150%.
  • uracil can refer to 5-methoxyuracil and/or naturally occurring uracil.
  • the uracil content in the ORF of the mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure is less than about 50%, about 40%, about 30%, or about 20% of the total nucleobase content in the ORF. In some embodiments, the uracil content in the ORF is between about 15 % and about 25% of the total nucleobase content in the ORF. In other embodiments, the uracil content in the ORF is between about 20% and about 30% of the total nucleobase content in the ORF.
  • the uracil content in the ORF of the mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is less than about 20% of the total nucleobase content in the open reading frame.
  • uracil can refer to 5-methoxyuracil and/or naturally occurring uracil.
  • the ORF of the mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides having 5-methoxyuracil and adjusted uracil content has increased Cytosine (C), Guanine (G), or Guanine/Cytosine (G/C) content (absolute or relative).
  • the overall increase in C, G, or G/C content (absolute or relative) of the ORF is at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 10%, at least about 15%, at least about 20%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 100% relative to the G/C content (absolute or relative) of the wild-type ORF.
  • the G, the C, or the G/C content in the ORF is less than about 100%, less than about 90%, less than about 85%, or less than about 80% of the theoretical maximum G, C, or G/C content of the corresponding wild type nucleotide sequence encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides (%G TMX ; %C TMX , or %G/C TMX ).
  • the G, the C, or the G/C content in the ORF is between about 70% and about 80%, between about 71% and about 79%, between about 71% and about 78%, or between about 71% and about 77% of the %G TMX , %C TMX , or %G/C TMX .
  • the increases in G and/or C content (absolute or relative) described herein can be conducted by replacing synonymous codons with low G, C, or G/C content with synonymous codons having higher G, C, or G/C content.
  • the increase in G and/or C content (absolute or relative) is conducted by replacing a codon ending with U with a synonymous codon ending with G or C.
  • the ORF of the mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure comprises 5-methoxyuracil and has an adjusted uracil content containing less uracil pairs (UU) and/or uracil triplets (UUU) and/or uracil quadruplets (UUUU) than the corresponding wild-type nucleotide sequence encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides.
  • the ORF of the mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure contains no uracil pairs and/or uracil triplets and/or uracil quadruplets.
  • uracil pairs and/or uracil triplets and/or uracil quadruplets are reduced below a certain threshold, e.g., no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 occurrences in the ORF of the mRNA encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides.
  • the ORF of the mRNA encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure contains less than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 non-phenylalanine uracil pairs and/or triplets.
  • the ORF of the mRNA encoding the IL 12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides contains no non-phenylalanine uracil pairs and/or triplets.
  • the ORF of the mRNA encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure comprises 5-methoxyuracil and has an adjusted uracil content containing less uracil-rich clusters than the corresponding wild-type nucleotide sequence encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides.
  • the ORF of the mRNA encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of the disclosure contains uracil-rich clusters that are shorter in length than corresponding uracil-rich clusters in the corresponding wild-type nucleotide sequence encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides.
  • alternative lower frequency codons are employed. At least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% of the codons in the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides -encoding ORF of the 5-methoxyuracil-comprising mRNA are substituted with alternative codons, each alternative codon having a codon frequency lower than the codon frequency of the substituted codon in the synonymous codon set.
  • the ORF also has adjusted uracil content, as described above.
  • at least one codon in the ORF of the mRNA encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is substituted with an alternative codon having a codon frequency lower than the codon frequency of the substituted codon in the synonymous codon set.
  • the adjusted uracil content, IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides -encoding ORF of the 5-methoxyuracil-comprising mRNA exhibits expression levels of IL12 when administered to a mammalian cell that are higher than expression levels of IL12 from the corresponding wild-type mRNA.
  • the expression levels of IL12 when administered to a mammalian cell are increased relative to a corresponding mRNA containing at least 95% 5-methoxyuracil and having a uracil content of about 160%, about 170%, about 180%, about 190%, or about 200% of the theoretical minimum.
  • the expression levels of IL12 when administered to a mammalian cell are increased relative to a corresponding mRNA, wherein at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of uracils are 1-methylpseudouracil or pseudouracils.
  • the mammalian cell is a mouse cell, a rat cell, or a rabbit cell.
  • the mammalian cell is a monkey cell or a human cell.
  • the human cell is a HeLa cell, a BJ fibroblast cell, or a peripheral blood mononuclear cell (PBMC).
  • PBMC peripheral blood mononuclear cell
  • IL12 is expressed when the mRNA is administered to a mammalian cell in vivo.
  • the mRNA is administered to mice, rabbits, rats, monkeys, or humans.
  • mice are null mice.
  • the mRNA is administered to mice in an amount of about 0.01 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, or about 0.15 mg/kg.
  • the mRNA is administered intravenously or intramuscularly.
  • the IL12 polypeptide is expressed when the mRNA is administered to a mammalian cell in vitro.
  • the expression is increased by at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 500-fold, at least about 1500-fold, or at least about 3000-fold. In other embodiments, the expression is increased by at least about 10%, about 20%, about 30%, about 40%, about 50%, 60%, about 70%, about 80%, about 90%, or about 100%.
  • adjusted uracil content, IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides -encoding ORF of the 5-methoxyuracil-comprising mRNA exhibits increased stability.
  • the mRNA exhibits increased stability in a cell relative to the stability of a corresponding wild-type mRNA under the same conditions.
  • the mRNA exhibits increased stability including resistance to nucleases, thermal stability, and/or increased stabilization of secondary structure.
  • increased stability exhibited by the mRNA is measured by determining the half-life of the mRNA (e.g ., in a plasma, cell, or tissue sample) and/or determining the area under the curve (AUC) of the protein expression by the mRNA over time ( e.g., in vitro or in vivo ) .
  • An mRNA is identified as having increased stability if the half-life and/or the AUC is greater than the half-life and/or the AUC of a corresponding wild-type mRNA under the same conditions.
  • the mRNA of the present disclosure induces a detectably lower immune response (e.g ., innate or acquired) relative to the immune response induced by a corresponding wild-type mRNA under the same conditions.
  • the mRNA of the present disclosure induces a detectably lower immune response (e.g ., innate or acquired) relative to the immune response induced by an mRNA that encodes for an IL12B polypeptide, IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides but does not comprise 5-methoxyuracil under the same conditions, or relative to the immune response induced by an mRNA that encodes for an IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides and that comprises 5-methoxyuracil but that does not have adjusted uracil content under the same conditions.
  • the innate immune response can be manifested by increased expression of pro-inflammatory cytokines, activation of intracellular PRRs (RIG-I, MDA5, etc), cell death, and/or termination or reduction in protein translation.
  • a reduction in the innate immune response can be measured by expression or activity level of Type 1 interferons (e.g ., IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , and IFN- ⁇ ) or the expression of interferon-regulated genes such as the toll-like receptors (e.g ., TLR7 and TLR8), and/or by decreased cell death following one or more administrations of the mRNA of the disclosure into a cell.
  • Type 1 interferons e.g ., IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , and IFN- ⁇
  • interferon-regulated genes e.g ., TLR7 and TLR
  • the expression of Type-1 interferons by a mammalian cell in response to the mRNA of the present disclosure is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, or greater than 99.9% relative to a corresponding wild-type mRNA, to an mRNA that encodes an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides but does not comprise 5-methoxyuracil, or to an mRNA that encodes an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides and that comprises 5-methoxyuracil but that does not have adjusted uracil content.
  • the interferon is IFN- ⁇ .
  • cell death frequency caused by administration of mRNA of the present disclosure to a mammalian cell is 10%, 25%, 50%, 75%, 85%, 90%, 95%, or over 95% less than the cell death frequency observed with a corresponding wild-type mRNA, an mRNA that encodes for an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides but does not comprise 5-methoxyuracil, or an mRNA that encodes for an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides and that comprises 5-methoxyuracil but that does not have adjusted uracil content.
  • the mammalian cell is a BJ fibroblast cell. In other embodiments, the mammalian cell is a splenocyte. In some embodiments, the mammalian cell is that of a mouse or a rat. In other embodiments, the mammalian cell is that of a human. In one embodiment, the mRNA of the present disclosure does not substantially induce an innate immune response of a mammalian cell into which the mRNA is introduced.
  • the polynucleotide is an mRNA that comprises an ORF that encodes an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides, wherein uracil in the mRNA is at least about 95% 5-methoxyuracil, wherein the uracil content of the ORF is between about 115% and about 135% of the theoretical minimum uracil content in the corresponding wild-type ORF, and wherein the uracil content in the ORF encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is less than about 30% of the total nucleobase content in the ORF.
  • the ORF that encodes the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is further modified to increase G/C content of the ORF (absolute or relative) by at least about 40%, as compared to the corresponding wild-type ORF.
  • the ORF encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides contains less than 20 non-phenylalanine uracil pairs and/or triplets.
  • At least one codon in the ORF of the mRNA encoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is further substituted with an alternative codon having a codon frequency lower than the codon frequency of the substituted codon in the synonymous codon set.
  • the mRNA comprises an open ORF wherein uracil in the mRNA is at least about 95% 5-methoxyuracil, and wherein the uracil content of the ORF is between about 115% and about 135% of the theoretical minimum uracil content in the corresponding wild-type ORF, and wherein the mRNA does not substantially induce an innate immune response of a mammalian cell into which the mRNA is introduced.
  • the disclosure includes modified polynucleotides comprising a polynucleotide described herein (e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides).
  • the modified polynucleotides can be chemically modified and/or structurally modified.
  • the polynucleotides of the present disclosure are chemically and/or structurally modified the polynucleotides can be referred to as "modified polynucleotides.”
  • nucleosides and nucleotides of a polynucleotide e.g ., RNA polynucleotides, such as mRNA polynucleotides
  • a "nucleoside” refers to a compound containing a sugar molecule (e.g ., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g ., a purine or pyrimidine) or a derivative thereof (also referred to herein as "nucleobase”).
  • nucleotide refers to a nucleoside including a phosphate group.
  • Modified nucleotides may by synthesized by any useful method, such as, for example, chemically, enzymatically, or recombinantly, to include one or more modified or non-natural nucleosides.
  • Polynucleotides may comprise a region or regions of linked nucleosides. Such regions may have variable backbone linkages. The linkages may be standard phosphodiester linkages, in which case the polynucleotides would comprise regions of nucleotides.
  • modified polynucleotides disclosed herein can comprise various distinct modifications.
  • the modified polynucleotides contain one, two, or more (optionally different) nucleoside or nucleotide modifications.
  • a modified polynucleotide, introduced to a cell may exhibit one or more desirable properties, e.g ., improved protein expression, reduced immunogenicity, or reduced degradation in the cell, as compared to an unmodified polynucleotide.
  • a polynucleotide of the present disclosure e.g ., a polynucleotide comprising a nucleotide sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides
  • a "structural" modification is one in which two or more linked nucleosides are inserted, deleted, duplicated, inverted or randomized in a polynucleotide without significant chemical modification to the nucleotides themselves. Because chemical bonds will necessarily be broken and reformed to effect a structural modification, structural modifications are of a chemical nature and hence are chemical modifications.
  • the polynucleotide "ATCG (SEQ ID NO: 230)” can be chemically modified to "AT-5meC-G".
  • the same polynucleotide can be structurally modified from “ATCG (SEQ ID NO: 230)” to "ATCCCG (SEQ ID NO: 231)".
  • the dinucleotide "CC” has been inserted, resulting in a structural modification to the polynucleotide.
  • the polynucleotides of the present disclosure e.g ., a polynucleotide comprising a nucleotide sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides
  • a polynucleotide comprising a nucleotide sequence encoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides are chemically modified.
  • the terms "chemical modification” or, as appropriate, “chemically modified” refer to modification with respect to adenosine (A), guanosine (G), uridine (U), thymidine (T) or cytidine (C) ribo- or deoxyribonucleosides in one or more of their position, pattern, percent or population, including, but not limited to, its nucleobase, sugar, backbone, or any combination thereof. Generally, herein, these terms are not intended to refer to the ribonucleotide modifications in naturally occurring 5'-terminal mRNA cap moieties.
  • the polynucleotides of the disclosure can have a uniform chemical modification of all or any of the same nucleoside type or a population of modifications produced by downward titration of the same starting modification in all or any of the same nucleoside type, or a measured percent of a chemical modification of all any of the same nucleoside type but with random incorporation, such as where all uridines are replaced by a uridine analog, e.g., 5-methoxyuridine.
  • the polynucleotides can have a uniform chemical modification of two, three, or four of the same nucleoside type throughout the entire polynucleotide (such as all uridines and/or all cytidines, etc. are modified in the same way).
  • Modified nucleotide base pairing encompasses not only the standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and/or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures.
  • non-standard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil. Any combination of base/sugar or linker may be incorporated into polynucleotides of the present disclosure.
  • RNA polynucleotides such as mRNA polynucleotides
  • Modifications of polynucleotides include, but are not limited to the following: 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine; 2-methylthio-N6-methyladenosine; 2-methylthio-N6-threonyl carbamoyladenosine; N6-glycinylcarbamoyladenosine; N6-isopentenyladenosine; N6-methyladenosine; N6-threonylcarbamoyladenosine; 1,2'-O-dimethyladenosine; 1-methyladenosine; 2'-O-methyladenosine; 2'-O-ribosyladenosine (phosphate); 2-methyladenosine; 2-methylthio-N6 isopentenyladen
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide includes a combination of at least two ( e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.
  • the mRNA comprises at least one chemically modified nucleoside.
  • the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine ( ⁇ ), N1-methylpseudouridine (m1 ⁇ ), 2-thiouridine (s2U), 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, 2'
  • the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and a combination thereof.
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the at least one chemically modified nucleoside is N1-methylpseudouridine.
  • the chemical modification is at nucleobases in the polynucleotides (e.g ., RNA polynucleotide, such as mRNA polynucleotide).
  • a polynucleotide as disclosed herein comprises at least one chemically modified nucleobase.
  • the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil ( ⁇ ), N1-methylpseudouracil (m1 ⁇ ), 2-thiouracil (s2U), 4'-thiouracil, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouracil, 2-thio-1-methyl-pseudouracil, 2-thio-5-aza-uracil, 2-thio-dihydropseudouracil, 2-thio-dihydrouracil, 2-thio-pseudouracil, 4-methoxy-2-thio-pseudouracil, 4-methoxy-pseudouracil, 4-thio-1-methyl-pseudouracil, 4-thio-pseudouracil, 5-aza-uracil, dihydropseudouracil, 5-methyluracil, 5-methoxyuracil, 2'-O-
  • the nucleobases in a polynucleotide as disclosed herein are chemically modified by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least 95%, at least 99%, or 100%.
  • the chemically modified nucleobases are selected from the group consisting of uracil, adenine, cytosine, guanine, and any combination thereof.
  • the uracils in a polynucleotide disclosed herein are chemically modified by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least 95%, at least 99%, or 100%.
  • the adenines in a polynucleotide disclosed herein are chemically modified by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least 95%, at least 99%, or 100%.
  • the cytosines in a polynucleotide disclosed herein are chemically modified by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least 95%, at least 99%, or 100%.
  • the guanines in a polynucleotide disclosed herein are chemically modified by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least 95%, at least 99%, or 100%.
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide includes a combination of at least two (e.g., 2, 3, 4 or more) of modified nucleobases.
  • modified nucleobases in the polynucleotide are selected from the group consisting of 1-methyl-pseudouridine (m1 ⁇ ), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), pseudouridine ( ⁇ ), ⁇ -thio-guanosine and ⁇ -thio-adenosine.
  • the polynucleotide includes a combination of at least two ( e.g ., 2, 3, 4 or more) of the aforementioned modified nucleobases.
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide comprises pseudouridine ( ⁇ ) and 5-methyl-cytidine (m5C).
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide (e.g ., RNA polynucleotide, such as mRNA polynucleotide) comprises 1-methyl-pseudouridine (m1 ⁇ ) and 5-methyl-cytidine (m5C).
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide (e.g ., RNA polynucleotide, such as mRNA polynucleotide) comprises 2-thiouridine and 5-methyl-cytidine (m5C).
  • the polynucleotide (e.g ., RNA polynucleotide, such as mRNA polynucleotide) comprises methoxy-uridine (mo5U). In some embodiments, the polynucleotide (e.g ., RNA polynucleotide, such as mRNA polynucleotide) comprises 5-methoxy-uridine (mo5U) and 5-methyl-cytidine (m5C). In some embodiments, the polynucleotide (e.g ., RNA polynucleotide, such as mRNA polynucleotide) comprises 2'-O-methyl uridine.
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide comprises 2'-O-methyl uridine and 5-methyl-cytidine (m5C).
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • RNA polynucleotide comprises N6-methyl-adenosine (m6A) and 5-methyl-cytidine (m5C).
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • RNA polynucleotide is uniformly modified (e.g ., fully modified, modified throughout the entire sequence) for a particular modification.
  • a polynucleotide can be uniformly modified with 5-methyl-cytidine (m5C), meaning that all cytosine residues in the mRNA sequence are replaced with 5-methyl-cytidine (m5C).
  • m5C 5-methyl-cytidine
  • a polynucleotide can be uniformly modified for any type of nucleoside residue present in the sequence by replacement with a modified residue such as any of those set forth above.
  • the chemically modified nucleosides in the open reading frame are selected from the group consisting of uridine, adenine, cytosine, guanine, and any combination thereof.
  • the modified nucleobase is a modified cytosine.
  • nucleobases and nucleosides having a modified cytosine include N4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g ., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio-5-methyl-cytidine.
  • a modified nucleobase is a modified uridine.
  • Example nucleobases and nucleosides having a modified uridine include 5-cyano uridine or 4'-thio uridine.
  • a modified nucleobase is a modified adenine.
  • Example nucleobases and nucleosides having a modified adenine include 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenine (m6A), and 2,6-Diaminopurine.
  • a modified nucleobase is a modified guanine.
  • Example nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQO), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine.
  • the nucleobase modified nucleotides in the polynucleotide are 5-methoxyuridine.
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide includes a combination of at least two (e.g., 2, 3, 4 or more) of modified nucleobases.
  • At least 95% of a type of nucleobases e.g ., uracil
  • a polynucleotide of the disclosure e.g ., an mRNA polynucleotide encoding an II,12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides
  • a polynucleotide of the disclosure e.g ., an mRNA polynucleotide encoding an II,12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides
  • At least 95% of uracil in a polynucleotide of the present disclosure is 5-methoxyuracil.
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • the polynucleotide comprises 5-methoxyuridine (5mo5U) and 5-methyl-cytidine (m5C).
  • the polynucleotide e.g ., RNA polynucleotide, such as mRNA polynucleotide
  • RNA polynucleotide is uniformly modified (e.g ., fully modified, modified throughout the entire sequence) for a particular modification.
  • a polynucleotide can be uniformly modified with 5-methoxyuridine, meaning that substantially all uridine residues in the mRNA sequence are replaced with 5-methoxyuridine.
  • a polynucleotide can be uniformly modified for any type of nucleoside residue present in the sequence by replacement with a modified residue such as any of those set forth above.
  • the modified nucleobase is a modified cytosine.
  • a modified nucleobase is a modified uracil.
  • Example nucleobases and nucleosides having a modified uracil include 5-methoxyuracil.
  • a modified nucleobase is a modified adenine.
  • a modified nucleobase is a modified guanine.
  • the nucleobases, sugar, backbone, or any combination thereof in the open reading frame encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides are chemically modified by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100%.
  • the uridine nucleosides in the open reading frame encoding IL12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides are chemically modified by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100%.
  • the adenosine nucleosides in the open reading frame encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides are chemically modified by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100%.
  • the cytidine nucleosides in the open reading frame encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides are chemically modified by at least at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100%.
  • the guanosine nucleosides in the open reading frame encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusion polypeptides are chemically modified by at least at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100%.
  • the polynucleotides can include any useful linker between the nucleosides, including subunit and heterologous polypeptide linkers as disclosed elsewhere herein.
  • linkers including backbone modifications, that are useful in the composition of the present disclosure include, but are not limited to the following: 3'-alkylene phosphonates, 3'-amino phosphoramidate, alkene containing backbones, aminoalkylphosphoramidates, aminoalkylphosphotriesters, boranophosphates, -CH 2 -O-N(CH 3 )-CH 2 -, -CH 2 -N(CH 3 )-N(CH 3 )-CH 2 -, -CH 2 -NH-CH 2 -, chiral phosphonates, chiral phosphorothioates, formacetyl and thioformacetyl backbones, methylene (methylimino), methylene formacetyl and thioformacetyl backbones,
  • modified nucleosides and nucleotides e.g ., building block molecules
  • a polynucleotide e.g ., RNA or mRNA, as described herein
  • a polynucleotide e.g ., RNA or mRNA, as described herein
  • the 2' hydroxyl group can be modified or replaced with a number of different substituents.
  • substitutions at the 2'-position include, but are not limited to, H, halo, optionally substituted C 1-6 alkyl; optionally substituted C 1-6 alkoxy; optionally substituted C 6-10 aryloxy; optionally substituted C 3-8 cycloalkyl; optionally substituted C 3-8 cycloalkoxy; optionally substituted C 6-10 aryloxy; optionally substituted C 6-10 aryl-C 1-6 alkoxy, optionally substituted C 1-12 (heterocyclyl)oxy; a sugar ( e.g ., ribose, pentose, or any described herein); a polyethyleneglycol (PEG), -O(CH 2 CH 2 O) n CH 2 CH 2 OR, where R is H or optionally substituted alkyl, and n is an integer from 0 to 20 ( e.g ., from 0 to 4, from 0 to 8, from 0 to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from
  • RNA includes the sugar group ribose, which is a 5-membered ring having an oxygen.
  • modified nucleotides include replacement of the oxygen in ribose (e.g ., with S, Se, or alkylene, such as methylene or ethylene); addition of a double bond ( e.g ., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose ( e.g ., to form a 4-membered ring of cyclobutane or oxetane); ring expansion of ribose ( e.g ., to form a 6- or 7-membered ring having an additional carbon or heteroatom, such as for anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino that also has a phosphoramidate backbone
  • the sugar group can also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose.
  • a polynucleotide molecule can include nucleotides containing, e.g ., arabinose, as the sugar.
  • Such sugar modifications are taught International Patent Publication Nos. WO2013052523 and WO2014093924 , the contents of each of which are incorporated herein by reference in their entireties.
  • polynucleotides of the disclosure can include a combination of modifications to the sugar, the nucleobase, and/or the internucleoside linkage. These combinations can include any one or more modifications described herein.
  • modified nucleotides and modified nucleotide combinations are provided below in Table 5 .
  • Combinations of modified nucleotides can be used to form the polynucleotides of the disclosure.
  • the modified nucleotides can be completely substituted for the natural nucleotides of the polynucleotides of the disclosure.
  • the natural nucleotide uridine can be substituted with a modified nucleoside described herein.
  • the natural nucleotide uridine can be partially substituted or replaced ( e.g ., about 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99.9%) with at least one of the modified nucleoside disclosed herein.
  • Any combination of base/sugar or linker can be incorporated into the polynucleotides of the disclosure and such modifications are taught in International Patent Publications WO2013052523 and WO2014093924 , and U.S. Publ. Nos.
  • Untranslated regions are nucleic acid sections of a polynucleotide before a start codon (5'UTR) and after a stop codon (3'UTR) that are not translated.
  • a polynucleotide e.g., a ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)
  • RNA e.g., a messenger RNA (mRNA)
  • mRNA messenger RNA
  • ORF open reading frame
  • UTR e.g., a 5'UTR or functional fragment thereof, a 3'UTR or functional fragment thereof, or a combination thereof.
  • a UTR can be homologous or heterologous to the coding region in a polynucleotide.
  • the UTR is homologous to the ORF encoding the IL12 polypeptide.
  • the UTR is heterologous to the ORF encoding the IL12 polypeptide.
  • the polynucleotide comprises two or more 5 UTRs or functional fragments thereof, each of which have the same or different nucleotide sequences.
  • the polynucleotide comprises two or more 3'UTRs or functional fragments thereof, each of which have the same or different nucleotide sequences.
  • the 5'UTR or functional fragment thereof, 3' UTR or functional fragment thereof, or any combination thereof is sequence optimized.
  • the 5'UTR or functional fragment thereof, 3' UTR or functional fragment thereof, or any combination thereof comprises at least one chemically modified nucleobase, e.g., 5-methoxyuracil.
  • UTRs can have features that provide a regulatory role, e.g., increased or decreased stability, localization and/or translation efficiency.
  • a polynucleotide comprising a UTR can be administered to a cell, tissue, or organism, and one or more regulatory features can be measured using routine methods.
  • a functional fragment of a 5'UTR or 3'UTR comprises one or more regulatory features of a full length 5' or 3' UTR, respectively.
  • Natural 5 UTRs bear features that play roles in translation initiation. They harbor signatures like Kozak sequences that are commonly known to be involved in the process by which the ribosome initiates translation of many genes. Kozak sequences have the consensus CCR(A/G)CCAUGG (SEQ ID NO: 232), where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), which is followed by another 'G'. 5'UTRs also have been known to form secondary structures that are involved in elongation factor binding.
  • liver-expressed mRNA such as albumin, serum amyloid A, Apolipoprotein A/B/E, transferrin, alpha fetoprotein, erythropoietin, or Factor VIII, can enhance expression of polynucleotides in hepatic cell lines or liver.
  • 5'UTR from other tissue-specific mRNA to improve expression in that tissue is possible for muscle (e.g., MyoD, Myosin, Myoglobin, Myogenin, Herculin), for endothelial cells (e.g., Tie-1, CD36), for myeloid cells (e.g., C/EBP, AML1, G-CSF, GM-CSF, CD11b, MSR, Fr-1, i-NOS), for leukocytes ( e.g ., CD45, CD18), for adipose tissue ( e.g ., CD36, GLUT4, ACRP30, adiponectin) and for lung epithelial cells (e.g., SP-A/B/C/D).
  • muscle e.g., MyoD, Myosin, Myoglobin, Myogenin, Herculin
  • endothelial cells e.g., Tie-1, CD36
  • myeloid cells e.g.
  • UTRs are selected from a family of transcripts whose proteins share a common function, structure, feature or property.
  • an encoded polypeptide can belong to a family of proteins (i.e ., that share at least one function, structure, feature, localization, origin, or expression pattern), which are expressed in a particular cell, tissue or at some time during development.
  • the UTRs from any of the genes or mRNA can be swapped for any other UTR of the same or different family of proteins to create a new polynucleotide.
  • the 5'UTR and the 3'UTR can be heterologous. In some embodiments, the 5'UTR can be derived from a different species than the 3'UTR. In some embodiments, the 3'UTR can be derived from a different species than the 5'UTR.
  • Exemplary UTRs of the application include, but are not limited to, one or more 5'UTR and/or 3'UTR derived from the nucleic acid sequence of: a globin, such as an ⁇ - or ⁇ -globin (e.g., a Xenopus, mouse, rabbit, or human globin); a strong Kozak translational initiation signal; a CYBA (e.g ., human cytochrome b-245 ⁇ polypeptide); an albumin ( e.g ., human albumin7); a HSD17B4 (hydroxysteroid (17- ⁇ ) dehydrogenase); a virus (e.g., a tobacco etch virus (TEV), a Venezuelan equine encephalitis virus (VEEV), a Dengue virus, a cytomegalovirus (CMV) (e.g., CMV immediate early 1 (IE1)), a hepatitis virus (e.g ., hepatitis B
  • exemplary 5' and 3' UTRs include, but are not limited to, those described in Karikó et al., Mol. Ther. 2008 16(11):1833-1840 ; Karikó et al., Mol. Ther. 2012 20(5):948-953 ; Karikó et al., Nucleic Acids Res. 2011 39(21):e142 ; Strong et al., Gene Therapy 1997 4:624-627 ; Hansson et al., J. Biol. Chem. 2015 290(9):5661-5672 ; Yu et al., Vaccine 2007 25(10):1701-1711 ; Cafri et al., Mol. Ther.
  • the 5'UTR is selected from the group consisting of a ⁇ -globin 5'UTR; a 5'UTR containing a strong Kozak translational initiation signal; a cytochrome b-245 ⁇ polypeptide (CYBA) 5'UTR; a hydroxysteroid (17- ⁇ ) dehydrogenase (HSD17B4) 5'UTR; a Tobacco etch virus (TEV) 5'UTR; a Vietnamese etch virus (TEV) 5'UTR; a decielen equine encephalitis virus (TEEV) 5'UTR; a 5' proximal open reading frame of rubella virus (RV) RNA encoding nonstructural proteins; a Dengue virus (DEN) 5'UTR; a heat shock protein 70 (Hsp70) 5'UTR; a eIF4G 5'UTR; a GLUT1 5'UTR; functional fragments thereof and any combination thereof.
  • CYBA cytochrome b-2
  • the 3'UTR is selected from the group consisting of a ⁇ -globin 3'UTR; a CYBA 3'UTR; an albumin 3'UTR; a growth hormone (GH) 3'UTR; a VEEV 3'UTR; a hepatitis B virus (HBV) 3'UTR; ⁇ -globin 3'UTR; a DEN 3'UTR; a PAV barley yellow dwarf virus (BYDV-PAV) 3'UTR; an elongation factor 1 ⁇ 1 (EEF1A1) 3'UTR; a manganese superoxide dismutase (MnSOD) 3'UTR; a ⁇ subunit of mitochondrial H(+)-ATP synthase ( ⁇ -mRNA) 3'UTR; a GLUT1 3'UTR; a MEF2A 3'UTR; a ⁇ -F1-ATPase 3'UTR; functional fragments thereof and combinations thereof.
  • UTRs include, but are not limited to, one or more of the UTRs, including any combination of UTRs, disclosed in WO2014/164253 , the contents of which are incorporated herein by reference in their entirety. Shown in Table 21 of U.S. Provisional Application No. 61/775,509 and in Table 22 of U.S. Provisional Application No. 61/829,372 , the contents of each are incorporated herein by reference in their entirety, is a listing start and stop sites for 5'UTRs and 3'UTRs.
  • each 5'UTR (5'-UTR-005 to 5'-UTR 68511) is identified by its start and stop site relative to its native or wild-type (homologous) transcript (ENST; the identifier used in the ENSEMBL database).
  • ENST wild-type (homologous) transcript
  • Wild-type UTRs derived from any gene or mRNA can be incorporated into the polynucleotides of the disclosure.
  • a UTR can be altered relative to a wild type or native UTR to produce a variant UTR, e.g., by changing the orientation or location of the UTR relative to the ORF; or by inclusion of additional nucleotides, deletion of nucleotides, swapping or transposition of nucleotides.
  • variants of 5' or 3' UTRs can be utilized, for example, mutants of wild type UTRs, or variants wherein one or more nucleotides are added to or removed from a terminus of the UTR.
  • one or more synthetic UTRs can be used in combination with one or more non-synthetic UTRs. See, e.g., Mandal and Rossi, Nat. Protoc. 2013 8(3):568-82 , the contents of which are incorporated herein by reference in their entirety, and sequences available at www.addgene.org/Derrick_Rossi/ , last accessed April 16, 2016. UTRs or portions thereof can be placed in the same orientation as in the transcript from which they were selected or can be altered in orientation or location. Hence, a 5' and/or 3' UTR can be inverted, shortened, lengthened, or combined with one or more other 5' UTRs or 3' UTRs.
  • the polynucleotide comprises multiple UTRs, e.g., a double, a triple or a quadruple 5'UTR or 3'UTR.
  • a double UTR comprises two copies of the same UTR either in series or substantially in series.
  • a double beta-globin 3'UTR can be used (see US2010/0129877 , the contents of which are incorporated herein by reference in its entirety).
  • the polynucleotides of the disclosure comprise a 5'UTR and/or a 3'UTR selected from any of the UTRs disclosed herein.
  • the 5'UTR comprises:
  • the 3'UTR comprises:
  • the 5'UTR and/or 3'UTR sequence of the disclosure comprises a nucleotide sequence at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a sequence selected from the group consisting of 5'UTR sequences comprising any of the 5'UTR sequences disclosed herein and/or 3'UTR sequences comprises any of the 3'UTR sequences disclosed herein, and any combination thereof.
  • the 3' UTR sequence comprises one or more miRNA binding sites, e.g., miR-122 binding sites, or any other heterologous nucleotide sequences therein, without disrupting the function of the 3' UTR.
  • miRNA binding sites e.g., miR-122 binding sites, or any other heterologous nucleotide sequences therein, without disrupting the function of the 3' UTR.
  • Some examples of 3' UTR sequences comprising a miRNA binding site are listed in TABLE 6.
  • the 3' UTR sequence comprises a nucleotide sequence at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a sequence selected from the group consisting of SEQ ID NOs: 238-240.
  • the 3' UTR sequence comprises a nucleotide sequence at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 238.
  • the 3' UTR sequence comprises a nucleotide sequence at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 239.
  • the 3' UTR sequence comprises a nucleotide sequence at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 240.
  • Table 6 Exemplary 3' UTR with miRNA Binding Sites 3'UTR Identifier/ miRNA BS Name/ Description Sequence SEQ ID NO.
  • the polynucleotides of the disclosure can comprise combinations of features.
  • the ORF can be flanked by a 5'UTR that comprises a strong Kozak translational initiation signal and/or a 3 UTR comprising an oligo(dT) sequence for templated addition of a poly-A tail.
  • a 5 UTR can comprise a first polynucleotide fragment and a second polynucleotide fragment from the same and/or different UTRs (see, e.g., US2010/0293625 , herein incorporated by reference in its entirety).
  • patterned UTRs include a repeating or alternating pattern, such as ABABAB or AABBAABBAABB or ABCABCABC or variants thereof repeated once, twice, or more than 3 times. In these patterns, each letter, A, B, or C represent a different UTR nucleic acid sequence.
  • non-UTR sequences can be used as regions or subregions within the polynucleotides of the disclosure.
  • introns or portions of intron sequences can be incorporated into the polynucleotides of the disclosure. Incorporation of intronic sequences can increase protein production as well as polynucleotide expression levels.
  • the polynucleotide of the disclosure comprises an internal ribosome entry site (IRES) instead of or in addition to a UTR (see, e.g. , Yakubov et al., Biochem. Biophys. Res. Commun. 2010 394(1):189-193 , the contents of which are incorporated herein by reference in their entirety).
  • ITR internal ribosome entry site
  • the polynucleotide of the disclosure comprises 5' and/or 3' sequence associated with the 5' and/or 3' ends of rubella virus (RV) genomic RNA, respectively, or deletion derivatives thereof, including the 5' proximal open reading frame of RV RNA encoding nonstructural proteins (e.g ., see Pogue et al., J. Virol. 67(12):7106-7117 , the contents of which are incorporated herein by reference in their entirety).
  • RV rubella virus
  • Viral capsid sequences can also be used as a translational enhancer, e.g., the 5' portion of a capsid sequence, (e.g., semliki forest virus and Sindbis virus capsid RNAs as described in Sjöberg et al., Biotechnology (NY) 1994 12(11):1127-1131 , and Frolov and Schlesinger J. Virol. 1996 70(2): 1182-1190 , the contents of each of which are incorporated herein by reference in their entirety).
  • the polynucleotide comprises an IRES instead of a 5'UTR sequence.
  • the polynucleotide comprises an ORF and a viral capsid sequence.
  • the polynucleotide comprises a synthetic 5'UTR in combination with a non-synthetic 3'UTR.
  • the UTR can also include at least one translation enhancer polynucleotide, translation enhancer element, or translational enhancer elements (collectively, "TEE," which refers to nucleic acid sequences that increase the amount of polypeptide or protein produced from a polynucleotide.
  • TEE translation enhancer polynucleotide, translation enhancer element, or translational enhancer elements
  • the TEE can include those described in US2009/0226470 , incorporated herein by reference in its entirety, and others known in the art.
  • the TEE can be located between the transcription promoter and the start codon.
  • the 5'UTR comprises a TEE.
  • a TEE is a conserved element in a UTR that can promote translational activity of a nucleic acid such as, but not limited to, cap-dependent or cap-independent translation.
  • a nucleic acid such as, but not limited to, cap-dependent or cap-independent translation.
  • the conservation of these sequences has been shown across 14 species including humans. See, e.g., Panek et al., "An evolutionary conserved pattern of 18S rRNA sequence complementarity to mRNA 5'UTRs and its implications for eukaryotic gene translation regulation," Nucleic Acids Research 2013, doi:10.1093/nar/gkt548 , incorporated herein by reference in its entirety.
  • the TEE comprises the TEE sequence in the 5'-leader of the Gtx homeodomain protein. See Chappell et al., PNAS 2004 101:9590-9594 , incorporated herein by reference in its entirety.
  • the TEE comprises a TEE having one or more of the sequences of SEQ ID NOs: 1-35 in US2009/0226470 , US2013/0177581 , and WO2009/075886 ; SEQ ID NOs: 1-5 and 7-645 in WO2012/009644 ; and SEQ ID NO: 1 WO1999/024595 , US6310197 , and US6849405 ; the contents of each of which are incorporated herein by reference in their entirety.
  • the TEE is an internal ribosome entry site (IRES), HCV-IRES, or an IRES element such as, but not limited to, those described in: US7468275 , US2007/0048776 , US2011/0124100 , WO2007/025008 , and WO2001/055369 ; the contents of each of which re incorporated herein by reference in their entirety.
  • IRES internal ribosome entry site
  • HCV-IRES HCV-IRES
  • IRES element such as, but not limited to, those described in: US7468275 , US2007/0048776 , US2011/0124100 , WO2007/025008 , and WO2001/055369 ; the contents of each of which re incorporated herein by reference in their entirety.
  • the IRES elements can include, but are not limited to, the Gtx sequences (e.g., Gtx9-nt, Gtx8-nt, Gtx7-nt) as described by Chappell et al., PNAS 2004 101:9590-9594 , Zhou et al., PNAS 2005 102:6273-6278 , US2007/0048776 , US2011/0124100 , and WO2007/025008 ; the contents of each of which are incorporated herein by reference in their entirety.
  • Gtx sequences e.g., Gtx9-nt, Gtx8-nt, Gtx7-nt
  • Translational enhancer polynucleotide or “translation enhancer polynucleotide sequence” refer to a polynucleotide that includes one or more of the TEE provided herein and/or known in the art (see. e.g., US6310197 , US6849405 , US7456273 , US7183395 , US2009/0226470 , US2007/0048776 , US2011/0124100 , US2009/0093049 , US2013/0177581 , WO2009/075886 , WO2007/025008 , WO2012/009644 , WO2001/055371 , WO1999/024595 , EP2610341A1 , and EP2610340A1 ; the contents of each of which are incorporated herein by reference in their entirety), or their variants, homologs, or functional derivatives.
  • the polynucleotide of the disclosure comprises one or multiple copies of a TEE.
  • the TEE in a translational enhancer polynucleotide can be organized in one or more sequence segments.
  • a sequence segment can harbor one or more of the TEEs provided herein, with each TEE being present in one or more copies.
  • multiple sequence segments are present in a translational enhancer polynucleotide, they can be homogenous or heterogeneous.
  • the multiple sequence segments in a translational enhancer polynucleotide can harbor identical or different types of the TEE provided herein, identical or different number of copies of each of the TEE, and/or identical or different organization of the TEE within each sequence segment.
  • the polynucleotide of the disclosure comprises a translational enhancer polynucleotide sequence.
  • a 5'UTR and/or 3'UTR of a polynucleotide of the disclosure comprises at least one TEE or portion thereof that is disclosed in: WO1999/024595 , WO2012/009644 , WO2009/075886 , WO2007/025008 , WO1999/024595 , WO2001/055371 , EP2610341A1 , EP2610340A1 , US6310197 , US6849405 , US7456273 , US7183395 , US2009/0226470 , US2011/0124100 , US2007/0048776 , US2009/0093049 , or US2013/0177581 , the contents of each are incorporated herein by reference in their entirety.
  • a 5'UTR and/or 3'UTR of a polynucleotide of the disclosure comprises a TEE that is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a TEE disclosed in: US2009/0226470 , US2007/0048776 , US2013/0177581 , US2011/0124100 , WO1999/024595 , WO2012/009644 , WO2009/075886 , WO2007/025008 , EP2610341A1 , EP2610340A1 , US6310197 , US6849405 , US
  • a 5'UTR and/or 3'UTR of a polynucleotide of the disclosure comprises a TEE which is selected from a 5-30 nucleotide fragment, a 5-25 nucleotide fragment, a 5-20 nucleotide fragment, a 5-15 nucleotide fragment, or a 5-10 nucleotide fragment (including a fragment of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides) of a TEE sequence disclosed in: US2009/0226470 , US2007/0048776 , US2013/0177581 , US2011/0124100 , WO1999/024595 , WO2012/009644 , WO2009/075886 , WO2007/025008 , EP2610341A1 , EP2610340A1 , US6310197 , US6849405 , US7456273 , US7183395
  • a 5'UTR and/or 3'UTR of a polynucleotide of the disclosure comprises a TEE which is a transcription regulatory element described in any of US7456273 , US7183395 , US2009/0093049 , and WO2001/055371 , the contents of each of which are incorporated herein by reference in their entirety.
  • the transcription regulatory elements can be identified by methods known in the art, such as, but not limited to, the methods described in US7456273 , US7183395 , US2009/0093049 , and WO2001/055371 .
  • a 5'UTR and/or 3'UTR comprising at least one TEE described herein can be incorporated in a monocistronic sequence such as, but not limited to, a vector system or a nucleic acid vector.
  • a monocistronic sequence such as, but not limited to, a vector system or a nucleic acid vector.
  • the vector systems and nucleic acid vectors can include those described in US7456273 , US7183395 , US2007/0048776 , US2009/0093049 , US2011/0124100 , WO2007/025008 , and WO2001/055371 .
  • a 5'UTR and/or 3'UTR of a polynucleotide of the disclosure comprises a TEE or portion thereof described herein.
  • the TEEs in the 3'UTR can be the same and/or different from the TEE located in the 5'UTR.
  • a 5'UTR and/or 3'UTR of a polynucleotide of the disclosure can include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55 or more than 60 TEE sequences.
  • the 5'UTR of a polynucleotide of the disclosure can include 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 TEE sequences.
  • the TEE sequences in the 5'UTR of the polynucleotide of the disclosure can be the same or different TEE sequences.
  • a combination of different TEE sequences in the 5'UTR of the polynucleotide of the disclosure can include combinations in which more than one copy of any of the different TEE sequences are incorporated.
  • the TEE sequences can be in a pattern such as ABABAB or AABBAABBAABB or ABCABCABC or variants thereof repeated one, two, three, or more than three times.
  • each letter, A, B, or C represent a different TEE nucleotide sequence.
  • the TEE can be identified by the methods described in US2007/0048776 , US2011/0124100 , WO2007/025008 , WO2012/009644 , the contents of each of which are incorporated herein by reference in their entirety.
  • the 5'UTR and/or 3'UTR comprises a spacer to separate two TEE sequences.
  • the spacer can be a 15 nucleotide spacer and/or other spacers known in the art.
  • the 5'UTR and/or 3'UTR comprises a TEE sequence-spacer module repeated at least once, at least twice, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, or more than 10 times in the 5'UTR and/or 3'UTR, respectively.
  • the 5'UTR and/or 3'UTR comprises a TEE sequence-spacer module repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times.
  • the spacer separating two TEE sequences can include other sequences known in the art that can regulate the translation of the polynucleotide of the disclosure, e.g., miR sequences described herein (e.g., miR binding sites and miR seeds).
  • miR sequences described herein e.g., miR binding sites and miR seeds.
  • each spacer used to separate two TEE sequences can include a different miR sequence or component of a miR sequence (e.g ., miR seed sequence).
  • a polynucleotide of the disclosure comprises a miR and/or TEE sequence.
  • the incorporation of a miR sequence and/or a TEE sequence into a polynucleotide of the disclosure can change the shape of the stem loop region, which can increase and/or decrease translation. See e.g., Kedde et al., Nature Cell Biology 2010 12(10): 1014-20 , herein incorporated by reference in its entirety).
  • Sensor sequences include, for example, microRNA (miRNA) binding sites, transcription factor binding sites, structured mRNA sequences and/or motifs, artificial binding sites engineered to act as pseudo-receptors for endogenous nucleic acid binding molecules, and combinations thereof.
  • miRNA microRNA
  • Non-limiting examples of sensor sequences are described in U.S. Publication 2014/0200261 , the contents of which are incorporated herein by reference in their entirety.
  • a polynucleotide e.g., a ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)
  • RNA ribonucleic acid
  • mRNA messenger RNA
  • ORF open reading frame
  • the sensor sequence is a miRNA binding site.
  • a miRNA is a 19-25 nucleotide long noncoding RNA that binds to a polynucleotide and down-regulates gene expression either by reducing stability or by inhibiting translation of the polynucleotide.
  • a miRNA sequence comprises a "seed" region, i.e., a sequence in the region of positions 2-8 of the mature miRNA.
  • a miRNA seed can comprise positions 2-8 or 2-7 of the mature miRNA.
  • a miRNA seed can comprise 7 nucleotides (e.g., nucleotides 2-8 of the mature miRNA), wherein the seed-complementary site in the corresponding miRNA binding site is flanked by an adenosine (A) opposed to miRNA position 1.
  • A adenosine
  • a miRNA seed can comprise 6 nucleotides (e.g ., nucleotides 2-7 of the mature miRNA), wherein the seed-complementary site in the corresponding miRNA binding site is flanked by an adenosine (A) opposed to miRNA position 1.
  • A adenosine
  • miRNA profiling of the target cells or tissues can be conducted to determine the presence or absence of miRNA in the cells or tissues.
  • a polynucleotide e.g ., a ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)
  • RNA ribonucleic acid
  • mRNA messenger RNA
  • microRNA binding site refers to a sequence within a polynucleotide, e.g ., within a DNA or within an RNA transcript, including in the 5'UTR and/or 3'UTR, that has sufficient complementarity to all or a region of a miRNA to interact with, associate with or bind to the miRNA.
  • a polynucleotide of the disclosure comprising an ORF encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides further comprises a miRNA binding site.
  • a 5'UTR and/or 3'UTR of the polynucleotide e.g., a ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)
  • RNA ribonucleic acid
  • mRNA messenger RNA
  • a miRNA binding site having sufficient complementarity to a miRNA refers to a degree of complementarity sufficient to facilitate miRNA-mediated regulation of a polynucleotide, e.g ., miRNA-mediated translational repression or degradation of the polynucleotide.
  • a miRNA binding site having sufficient complementarity to the miRNA refers to a degree of complementarity sufficient to facilitate miRNA-mediated degradation of the polynucleotide, e.g ., miRNA-guided RNA-induced silencing complex (RISC)-mediated cleavage of mRNA.
  • miRNA-guided RNA-induced silencing complex RISC
  • the miRNA binding site can have complementarity to, for example, a 19-25 nucleotide miRNA sequence, to a 19-23 nucleotide miRNA sequence, or to a 22 nucleotide miRNA sequence.
  • a miRNA binding site can be complementary to only a portion of a miRNA, e.g., to a portion less than 1, 2, 3, or 4 nucleotides of the full length of a naturally-occurring miRNA sequence.
  • Full or complete complementarity e.g ., full complementarity or complete complementarity over all or a significant portion of the length of a naturally-occurring miRNA is preferred when the desired regulation is mRNA degradation.
  • a miRNA binding site includes a sequence that has complementarity (e.g ., partial or complete complementarity) with an miRNA seed sequence. In some embodiments, the miRNA binding site includes a sequence that has complete complementarity with a miRNA seed sequence. In some embodiments, a miRNA binding site includes a sequence that has complementarity ( e.g ., partial or complete complementarity) with an miRNA sequence. In some embodiments, the miRNA binding site includes a sequence that has complete complementarity with a miRNA sequence. In some embodiments, a miRNA binding site has complete complementarity with a miRNA sequence but for 1, 2, or 3 nucleotide substitutions, terminal additions, and/or truncations.
  • the miRNA binding site is the same length as the corresponding miRNA. In other embodiments, the miRNA binding site is one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve nucleotide(s) shorter than the corresponding miRNA at the 5' terminus, the 3' terminus, or both. In still other embodiments, the microRNA binding site is two nucleotides shorter than the corresponding microRNA at the 5' terminus, the 3' terminus, or both. The miRNA binding sites that are shorter than the corresponding miRNAs are still capable of degrading the mRNA incorporating one or more of the miRNA binding sites or preventing the mRNA from translation.
  • the miRNA binding site binds to the corresponding mature miRNA that is part of an active RISC containing Dicer. In another embodiment, binding of the miRNA binding site to the corresponding miRNA in RISC degrades the mRNA containing the miRNA binding site or prevents the mRNA from being translated. In some embodiments, the miRNA binding site has sufficient complementarity to miRNA so that a RISC complex comprising the miRNA cleaves the polynucleotide comprising the miRNA binding site. In other embodiments, the miRNA binding site has imperfect complementarity so that a RISC complex comprising the miRNA induces instability in the polynucleotide comprising the miRNA binding site. In another embodiment, the miRNA binding site has imperfect complementarity so that a RISC complex comprising the miRNA represses transcription of the polynucleotide comprising the miRNA binding site.
  • the miRNA binding site has one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve mismatch(es) from the corresponding miRNA.
  • the miRNA binding site has at least about ten, at least about eleven, at least about twelve, at least about thirteen, at least about fourteen, at least about fifteen, at least about sixteen, at least about seventeen, at least about eighteen, at least about nineteen, at least about twenty, or at least about twenty-one contiguous nucleotides complementary to at least about ten, at least about eleven, at least about twelve, at least about thirteen, at least about fourteen, at least about fifteen, at least about sixteen, at least about seventeen, at least about eighteen, at least about nineteen, at least about twenty, or at least about twenty-one, respectively, contiguous nucleotides of the corresponding miRNA.
  • the polynucleotide By engineering one or more miRNA binding sites into a polynucleotide of the disclosure, the polynucleotide can be targeted for degradation or reduced translation, provided the miRNA in question is available. This can reduce off-target effects upon delivery of the polynucleotide. For example, if a polynucleotide of the disclosure is not intended to be delivered to a tissue or cell but ends up there, then a miRNA abundant in the tissue or cell can inhibit the expression of the gene of interest if one or multiple binding sites of the miRNA are engineered into the 5'UTR and/or 3'UTR of the polynucleotide.
  • miRNA binding sites can be removed from polynucleotide sequences in which they naturally occur in order to increase protein expression in specific tissues.
  • a binding site for a specific miRNA can be removed from a polynucleotide to improve protein expression in tissues or cells containing the miRNA.
  • a polynucleotide of the disclosure can include at least one miRNA-binding site in the 5'UTR and/or 3'UTR in order to direct cytotoxic or cytoprotective mRNA therapeutics to specific cells such as, but not limited to, normal and/or cancerous cells.
  • a polynucleotide of the disclosure can include two, three, four, five, six, seven, eight, nine, ten, or more miRNA-binding sites in the 5'-UTR and/or 3'-UTR in order to direct cytotoxic or cytoprotective mRNA therapeutics to specific cells such as, but not limited to, normal and/or cancerous cells.
  • Regulation of expression in multiple tissues can be accomplished through introduction or removal of one or more miRNA binding sites.
  • the decision whether to remove or insert a miRNA binding site can be made based on miRNA expression patterns and/or their profilings in diseases. Identification of miRNAs, miRNA binding sites, and their expression patterns and role in biology have been reported ( e.g ., Bonauer et al., Curr Drug Targets 2010 11:943-949 ; Anand and Cheresh Curr Opin Hematol 2011 18:171-176 ; Contreras and Rao Leukemia 2012 26:404-413 (2011 Dec 20.
  • miRNAs and miRNA binding sites can correspond to any known sequence, including non-limiting examples described in U.S. Publication Nos. 2014/0200261 , 2005/0261218 , and 2005/0059005 , each of which are incorporated herein by reference in their entirety.
  • tissues where miRNA are known to regulate mRNA, and thereby protein expression include, but are not limited to, liver (miR-122), muscle (miR-133, miR-206, miR-208), endothelial cells (miR-17-92, miR-126), myeloid cells (miR-142-3p, miR-142-5p, miR-16, miR-21, miR-223, miR-24, miR-27), adipose tissue (let-7, miR-30c), heart (miR-1d, miR-149), kidney (miR-192, miR-194, miR-204), and lung epithelial cells (let-7, miR-133, miR-126).
  • liver miR-122
  • muscle miR-133, miR-206, miR-208
  • endothelial cells miR-17-92, miR-126
  • myeloid cells miR-142-3p, miR-142-5p, miR-16, miR-21, miR-223, miR
  • microRNAs e.g ., miR-122
  • Some microRNAs are abundant in normal tissue but are present in much lower levels in cancer or tumor tissue.
  • engineering microRNA target sequences i.e., microRNA binding site
  • into the polynucleotides encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides e.g ., in a 3'UTR like region or other region
  • This provides a tumor-targeting approach for the methods and compositions of the disclosure.
  • miRNA binding sites include immune cell specific miRNAs including, but not limited to, hsa-let-7a-2-3p, hsa-let-7a-3p, hsa-7a-5p, hsa-let-7c, hsa-let-7e-3p, hsa-let-7e-5p, hsa-let-7g-3p, hsa-let-7g-5p, hsa-let-7i-3p, hsa-let-7i-5p, miR-10a-3p, miR-10a-5p, miR-1184, hsa-let-7f-1-3p, hsa-let-7f-2--5p, hsa-let-7f-5p, miR-125b-1-3p, miR-125b-2-3p, miR-125b-5p, miR-1279, miR-130a-3p, miR-130a-5p, miR-132-3p, miR-132-5p, miR
  • novel miRNAs can be identified in immune cell through micro-array hybridization and microtome analysis (e.g ., Jima DD et al, Blood, 2010, 116:e118-e127 ; Vaz C et al., BMC Genomics, 2010, 11,288 , the content of each of which is incorporated herein by reference in its entirety.)
  • MiRNAs that are known to be expressed in the liver include, but are not limited to, miR-107, miR-122-3p, miR-122-5p, miR-1228-3p, miR-1228-5p, miR-1249, miR-129-5p, miR-1303, miR-151a-3p, miR-151a-5p, miR-152, miR-194-3p, miR-194-5p, miR-199a-3p, miR-199a-5p, miR-199b-3p, miR-199b-5p, miR-296-5p, miR-557, miR-581, miR-939-3p, and miR-939-5p.
  • MiRNA binding sites from any liver specific miRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the liver.
  • Liver specific miRNA binding sites can be engineered alone or further in combination with immune cell (e.g., APC) miRNA binding sites in a polynucleotide of the disclosure.
  • MiRNAs that are known to be expressed in the lung include, but are not limited to, let-7a-2-3p, let-7a-3p, let-7a-5p, miR-126-3p, miR-126-5p, miR-127-3p, miR-127-5p, miR-130a-3p, miR-130a-5p, miR-130b-3p, miR-130b-5p, miR-133a, miR-133b, miR-134, miR-18a-3p, miR-18a-5p, miR-18b-3p, miR-18b-5p, miR-24-1-5p, miR-24-2-5p, miR-24-3p, miR-296-3p, miR-296-5p, miR-32-3p, miR-337-3p, miR-337-5p, miR-381-3p, and miR-381-5p.
  • MiRNA binding sites from any lung specific miRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the lung.
  • Lung specific miRNA binding sites can be engineered alone or further in combination with immune cell (e.g., APC) miRNA binding sites in a polynucleotide of the disclosure.
  • MiRNAs that are known to be expressed in the heart include, but are not limited to, miR-1, miR-133a, miR-133b, miR-149-3p, miR-149-5p, miR-186-3p, miR-186-5p, miR-208a, miR-208b, miR-210, miR-296-3p, miR-320, miR-451a, miR-451b, miR-499a-3p, miR-499a-5p, miR-499b-3p, miR-499b-5p, miR-744-3p, miR-744-5p, miR-92b-3p, and miR-92b-5p.
  • MiRNA binding sites from any heart specific microRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the heart.
  • Heart specific miRNA binding sites can be engineered alone or further in combination with immune cell (e.g., APC) miRNA binding sites in a polynucleotide of the disclosure.
  • MiRNAs that are known to be expressed in the nervous system include, but are not limited to, miR-124-5p, miR-125a-3p, miR-125a-5p, miR-125b-1-3p, miR-125b-2-3p, miR-125b-5p,miR-1271-3p, miR-1271-5p, miR-128, miR-132-5p, miR-135a-3p, miR-135a-5p, miR-135b-3p, miR-135b-5p, miR-137, miR-139-5p, miR-139-3p, miR-149-3p, miR-149-5p, miR-153, miR-181c-3p, miR-181c-5p, miR-183-3p, miR-183-5p, miR-190a, miR-190b, miR-212-3p, miR-212-5p, miR-219-1-3p, miR-219-2-3p, miR-23a-3p, miR-23a-5p,mi
  • MiRNAs enriched in the nervous system further include those specifically expressed in neurons, including, but not limited to, miR-132-3p, miR-132-3p, miR-148b-3p, miR-148b-5p, miR-151a-3p, miR-151a-5p, miR-212-3p, miR-212-5p, miR-320b, miR-320e, miR-323a-3p, miR-323a-5p, miR-324-5p, miR-325, miR-326, miR-328, miR-922 and those specifically expressed in glial cells, including, but not limited to, miR-1250, miR-219-1-3p, miR-219-2-3p, miR-219-5p, miR-23a-3p, miR-23a-5p, miR-3065-3p, miR-3065-5p, miR-30e-3p, miR-30e-5p, miR-32-5p, miR-338-5p, and miR-657.
  • MiRNA binding sites from any CNS specific miRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the nervous system.
  • Nervous system specific miRNA binding sites can be engineered alone or further in combination with immune cell (e.g ., APC) miRNA binding sites in a polynucleotide of the disclosure.
  • MiRNAs that are known to be expressed in the pancreas include, but are not limited to, miR-105-3p, miR-105-5p, miR-184, miR-195-3p, miR-195-5p, miR-196a-3p, miR-196a-5p, miR-214-3p, miR-214-5p, miR-216a-3p, miR-216a-5p, miR-30a-3p, miR-33a-3p, miR-33a-5p, miR-375, miR-7-1-3p, miR-7-2-3p, miR-493-3p, miR-493-5p, and miR-944.
  • MiRNA binding sites from any pancreas specific miRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the pancreas.
  • Pancreas specific miRNA binding sites can be engineered alone or further in combination with immune cell (e.g . APC) miRNA binding sites in a polynucleotide of the disclosure.
  • MiRNAs that are known to be expressed in the kidney include, but are not limited to, miR-122-3p, miR-145-5p, miR-17-5p, miR-192-3p, miR-192-5p, miR-194-3p, miR-194-5p, miR-20a-3p, miR-20a-5p, miR-204-3p, miR-204-5p, miR-210, miR-216a-3p, miR-216a-5p, miR-296-3p, miR-30a-3p, miR-30a-5p, miR-30b-3p, miR-30b-5p, miR-30c-1-3p, miR-30c-2-3p, miR30c-5p, miR-324-3p, miR-335-3p, miR-335-5p, miR-363-3p, miR-363-5p, and miR-562.
  • MiRNA binding sites from any kidney specific miRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the kidney.
  • Kidney specific miRNA binding sites can be engineered alone or further in combination with immune cell (e.g., APC) miRNA binding sites in a polynucleotide of the disclosure.
  • MiRNAs that are known to be expressed in the muscle include, but are not limited to, let-7g-3p, let-7g-5p, miR-1, miR-1286, miR-133a, miR-133b, miR-140-3p, miR-143-3p, miR-143-5p, miR-145-3p, miR-145-5p, miR-188-3p, miR-188-5p, miR-206, miR-208a, miR-208b, miR-25-3p, and miR-25-5p.
  • MiRNA binding sites from any muscle specific miRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the muscle.
  • Muscle specific miRNA binding sites can be engineered alone or further in combination with immune cell (e.g., APC) miRNA binding sites in a polynucleotide of the disclosure .
  • MiRNAs are also differentially expressed in different types of cells, such as, but not limited to, endothelial cells, epithelial cells, and adipocytes.
  • MiRNAs that are known to be expressed in endothelial cells include, but are not limited to, let-7b-3p, let-7b-5p, miR-100-3p, miR-100-5p, miR-101-3p, miR-101-5p, miR-126-3p, miR-126-5p, miR-1236-3p, miR-1236-5p, miR-130a-3p, miR-130a-5p, miR-17-5p, miR-17-3p, miR-18a-3p, miR-18a-5p, miR-19a-3p, miR-19a-5p, miR-19b-1-5p, miR-19b-2-5p, miR-19b-3p, miR-20a-3p, miR-20a-5p, miR-217, miR-210, miR-21-3p, miR-21-5p, miR-221-3p, miR-221-5p, miR-222-3p, miR-222-5p, miR-23a-3p, miR-23a-5p, miR-296-5p
  • MiRNA binding sites from any endothelial cell specific miRNA can be introduced to or removed from a polynucleotide of the disclosure to regulate expression of the polynucleotide in the endothelial cells.
  • MiRNAs that are known to be expressed in epithelial cells include, but are not limited to, let-7b-3p, let-7b-5p, miR-1246, miR-200a-3p, miR-200a-5p, miR-200b-3p, miR-200b-5p, miR-200c-3p, miR-200c-5p, miR-338-3p, miR-429, miR-451a, miR-451b, miR-494, miR-802 and miR-34a, miR-34b-5p, miR-34c-5p, miR-449a, miR-449b-3p, miR-449b-5p specific in respiratory ciliated epithelial cells, let-7 family, miR-133a, miR-133b, miR-126 specific in lung epithelial cells, miR-382-3p, miR-382-5p specific in renal epithelial cells, and miR-762 specific in corneal epithelial cells. MiRNA binding sites from any epithelial cell
  • a large group of miRNAs are enriched in embryonic stem cells, controlling stem cell self-renewal as well as the development and/or differentiation of various cell lineages, such as neural cells, cardiac, hematopoietic cells, skin cells, osteogenic cells and muscle cells ( e.g ., Kuppusamy KT et al., Curr. Mol Med, 2013, 13(5), 757-764 ; Vidigal JA and Ventura A, Semin Cancer Biol.
  • MiRNAs abundant in embryonic stem cells include, but are not limited to, let-7a-2-3p, let-a-3p, let-7a-5p, let7d-3p, let-7d-5p, miR-103a-2-3p, miR-103a-5p, miR-106b-3p, miR-106b-5p, miR-1246, miR-1275, miR-138-1-3p, miR-138-2-3p, miR-138-5p, miR-154-3p, miR-154-5p, miR-200c-3p, miR-200c-5p, miR-290, miR-301a-3p, miR-301a-5p, miR-302a-3p, miR-302a-5p, miR-302b-3p, miR-302b-5p, miR-302c-3p, miR-302c-5p, miR-302d-3p, miR-302d-5p, miR-302e, miR-367-3p, miR-367-5p, miR-369-3p
  • the binding sites of embryonic stem cell specific miRNAs can be included in or removed from the 3'UTR of a polynucleotide of the disclosure to modulate the development and/or differentiation of embryonic stem cells, to inhibit the senescence of stem cells in a degenerative condition (e.g. degenerative diseases), or to stimulate the senescence and apoptosis of stem cells in a disease condition (e.g. cancer stem cells).
  • a degenerative condition e.g. degenerative diseases
  • apoptosis of stem cells e.g. cancer stem cells
  • miRNAs are differentially expressed in cancer cells ( WO2008/154098 , US2013/0059015 , US2013/0042333 , WO2011/157294 ); cancer stem cells ( US2012/0053224 ); pancreatic cancers and diseases ( US2009/0131348 , US2011/0171646 , US2010/0286232 , US8389210 ); asthma and inflammation ( US8415096 ); prostate cancer ( US2013/0053264 ); hepatocellular carcinoma ( WO2012/151212 , US2012/0329672 , WO2008/054828 , US8252538 ); lung cancer cells ( WO2011/076143 , WO2013/033640 , WO2009/070653 , US2010/0323357 ); cutaneous T cell lymph
  • miRNA binding sites for miRNAs that are over-expressed in certain cancer and/or tumor cells can be removed from the 3'UTR of a polynucleotide of the disclosure, restoring the expression suppressed by the over-expressed miRNAs in cancer cells, thus ameliorating the corresponsive biological function, for instance, transcription stimulation and/or repression, cell cycle arrest, apoptosis and cell death.
  • normal cells and tissues, wherein miRNAs expression is not up-regulated, will remain unaffected.
  • MiRNA can also regulate complex biological processes such as angiogenesis (e.g ., miR-132) ( Anand and Cheresh Curr Opin Hematol 2011 18:171-176 ).
  • angiogenesis e.g ., miR-132
  • miRNA binding sites that are involved in such processes can be removed or introduced, in order to tailor the expression of the polynucleotides to biologically relevant cell types or relevant biological processes.
  • the polynucleotides of the disclosure are defined as auxotrophic polynucleotides.
  • the microRNA binding site (e.g ., miR-122 binding site) is fully complementary to miRNA (e.g ., miR-122), thereby degrading the mRNA fused to the miRNA binding site.
  • the miRNA binding site is not fully complementary to the corresponding miRNA.
  • the miRNA binding site (e.g ., miR-122 binding site) is the same length as the corresponding miRNA ( e.g ., miR-122).
  • the microRNA binding site (e.g ., miR-122 binding site) is one nucleotide shorter than the corresponding microRNA (e.g ., miR-122, which has 22 nts) at the 5' terminus, the 3' terminus, or both.
  • the microRNA binding site (e.g ., miR-122 binding site) is two nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus, the 3' terminus, or both.
  • the microRNA binding site (e.g ., miR-122 binding site) is three nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus, the 3' terminus, or both. In some embodiments, the microRNA binding site (e.g ., miR-122 binding site) is four nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus, the 3' terminus, or both.
  • the microRNA binding site (e.g ., miR-122 binding site) is five nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus, the 3' terminus, or both. In some embodiments, the microRNA binding site ( e.g ., miR-122 binding site) is six nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus, the 3' terminus, or both.
  • the microRNA binding site (e.g ., miR-122 binding site) is seven nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus or the 3' terminus. In other embodiments, the microRNA binding site ( e.g ., miR-122 binding site) is eight nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus or the 3' terminus. In other embodiments, the microRNA binding site ( e.g ., miR-122 binding site) is nine nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus or the 3' terminus.
  • the microRNA binding site (e.g ., miR-122 binding site) is ten nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus or the 3' terminus. In other embodiments, the microRNA binding site (e.g ., miR-122 binding site) is eleven nucleotides shorter than the corresponding microRNA ( e.g ., miR-122) at the 5' terminus or the 3' terminus.
  • the microRNA binding site (e.g ., miR-122 binding site) is twelve nucleotides shorter than the corresponding microRNA (e.g ., miR-122) at the 5' terminus or the 3' terminus.
  • the miRNA binding sites that are shorter than the corresponding miRNAs are still capable of degrading the mRNA incorporating one or more of the miRNA binding sites or preventing the mRNA from translation.
  • the microRNA binding site (e.g ., miR-122 binding site) has sufficient complementarity to miRNA (e.g ., miR-122) so that a RISC complex comprising the miRNA ( e.g ., miR-122) cleaves the polynucleotide comprising the microRNA binding site.
  • the microRNA binding site (e.g ., miR-122 binding site) has imperfect complementarity so that a RISC complex comprising the miRNA ( e.g ., miR-122) induces instability in the polynucleotide comprising the microRNA binding site.
  • the microRNA binding site (e.g ., miR-122 binding site) has imperfect complementarity so that a RISC complex comprising the miRNA (e.g ., miR-122) represses transcription of the polynucleotide comprising the microRNA binding site.
  • the miRNA binding site (e.g ., miR-122 binding site) has one mismatch from the corresponding miRNA( e.g ., miR-122).
  • the miRNA binding site has two mismatches from the corresponding miRNA.
  • the miRNA binding site has three mismatches from the corresponding miRNA.
  • the miRNA binding site has four mismatches from the corresponding miRNA.
  • the miRNA binding site has five mismatches from the corresponding miRNA. In other embodiments, the miRNA binding site has six mismatches from the corresponding miRNA. In certain embodiments, the miRNA binding site has seven mismatches from the corresponding miRNA. In other embodiments, the miRNA binding site has eight mismatches from the corresponding miRNA. In other embodiments, the miRNA binding site has nine mismatches from the corresponding miRNA. In other embodiments, the miRNA binding site has ten mismatches from the corresponding miRNA. In other embodiments, the miRNA binding site has eleven mismatches from the corresponding miRNA. In other embodiments, the miRNA binding site has twelve mismatches from the corresponding miRNA.
  • the miRNA binding site (e.g ., miR-122 binding site) has at least about ten contiguous nucleotides complementary to at least about ten contiguous nucleotides of the corresponding miRNA (e.g ., miR-122), at least about eleven contiguous nucleotides complementary to at least about eleven contiguous nucleotides of the corresponding miRNA, at least about twelve contiguous nucleotides complementary to at least about twelve contiguous nucleotides of the corresponding miRNA, at least about thirteen contiguous nucleotides complementary to at least about thirteen contiguous nucleotides of the corresponding miRNA, or at least about fourteen contiguous nucleotides complementary to at least about fourteen contiguous nucleotides of the corresponding miRNA.
  • the miRNA binding sites have at least about fifteen contiguous nucleotides complementary to at least about fifteen contiguous nucleotides of the corresponding miRNA, at least about sixteen contiguous nucleotides complementary to at least about sixteen contiguous nucleotides of the corresponding miRNA, at least about seventeen contiguous nucleotides complementary to at least about seventeen contiguous nucleotides of the corresponding miRNA, at least about eighteen contiguous nucleotides complementary to at least about eighteen contiguous nucleotides of the corresponding miRNA, at least about nineteen contiguous nucleotides complementary to at least about nineteen contiguous nucleotides of the corresponding miRNA, at least about twenty contiguous nucleotides complementary to at least about twenty contiguous nucleotides of the corresponding miRNA, or at least about twenty one contiguous nucleotides complementary to at least about twenty one contiguous nucleotides of the corresponding miRNA.
  • the polynucleotides comprise an mRNA encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides and at least one miR-122 binding site, at least two miR-122 binding sites, at least three miR-122 binding sites, at least four miR-122 binding sites, or at least five miR-122 binding sites.
  • the miRNA binding site binds miR-122 or is complementary to miR-122. In another aspect, the miRNA binding site binds to miR-122-3p or miR-122-5p.
  • the miRNA binding site comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 52 or 54, wherein the miRNA binding site binds to miR-122.
  • the miRNA binding site comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 54, wherein the miRNA binding site binds to miR-122.
  • a miRNA binding site (e.g., miR-122 binding site) is inserted in the polynucleotide of the disclosure in any position of the polynucleotide ( e.g ., 3' UTR); the insertion site in the polynucleotide can be anywhere in the polynucleotide as long as the insertion of the miRNA binding site in the polynucleotide does not interfere with the translation of the functional IL12B polypeptide, IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides in the absence of the corresponding miRNA ( e.g ., miR-122); and in the presence of the miRNA ( e.g ., miR-122), the insertion of the miRNA binding site in the polynucleotide and the binding of the miRNA binding site to the corresponding miRNA are capable of degrading the polynucleotide or preventing the translation of the polynucle
  • a miRNA binding site is inserted in at least about 30 nucleotides downstream from the stop codon of the an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides-encoding mRNA.
  • a miRNA binding site is inserted in at least about 10 nucleotides, at least about 15 nucleotides, at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at least about 35 nucleotides, at least about 40 nucleotides, at least about 45 nucleotides, at least about 50 nucleotides, at least about 55 nucleotides, at least about 60 nucleotides, at least about 65 nucleotides, at least about 70 nucleotides, at least about 75 nucleotides, at least about 80 nucleotides, at least about 85 nucleotides, at least about 90 nucleotides, at least about 95 nucleotides, or at least about 100 nucleotides downstream from the stop codon of the polynucleotide, e.g ., the IL12B polypeptide, IL12A polypeptide, and/or IL12B and IL
  • a miRNA binding site is inserted in about 10 nucleotides to about 100 nucleotides, about 20 nucleotides to about 90 nucleotides, about 30 nucleotides to about 80 nucleotides, about 40 nucleotides to about 70 nucleotides, about 50 nucleotides to about 60 nucleotides, about 45 nucleotides to about 65 nucleotides downstream from the stop codon of the polynucleotide, e.g ., the IL12B polypeptide, IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides-encoding mRNA.
  • the miRNA binding site is inserted downstream of the stop codon in the nucleic acid sequence encoding an IL12 polypeptide as disclosed herein. In some embodiments, the miRNA binding site is inserted downstream of the stop codon in the nucleic acid sequence encoding membrane domain as disclosed herein. In some embodiments, the miRNA binding site is inserted downstream of the stop codon in the nucleic acid sequence encoding heterologous polypeptide as disclosed herein.
  • a miRNA binding site is inserted in the polynucleotide of the disclosure in any position of the polynucleotide (e.g ., the 5'UTR and/or 3'UTR).
  • the 5'UTR comprises a miRNA binding site.
  • the 3'UTR comprises a miRNA binding site.
  • the 5'UTR and the 3'UTR comprise a miRNA binding site.
  • the insertion site in the polynucleotide can be anywhere in the polynucleotide as long as the insertion of the miRNA binding site in the polynucleotide does not interfere with the translation of a functional polypeptide in the absence of the corresponding miRNA; and in the presence of the miRNA, the insertion of the miRNA binding site in the polynucleotide and the binding of the miRNA binding site to the corresponding miRNA are capable of degrading the polynucleotide or preventing the translation of the polynucleotide.
  • a miRNA binding site is inserted in at least about 30 nucleotides downstream from the stop codon of an ORF in a polynucleotide of the disclosure comprising the ORF. In some embodiments, a miRNA binding site is inserted in at least about 10 nucleotides, at least about 15 nucleotides, at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at least about 35 nucleotides, at least about 40 nucleotides, at least about 45 nucleotides, at least about 50 nucleotides, at least about 55 nucleotides, at least about 60 nucleotides, at least about 65 nucleotides, at least about 70 nucleotides, at least about 75 nucleotides, at least about 80 nucleotides, at least about 85 nucleotides, at least about 90 nucleotides, at least about 95 nucleotides, or at least about 100 nucle
  • a miRNA binding site is inserted in about 10 nucleotides to about 100 nucleotides, about 20 nucleotides to about 90 nucleotides, about 30 nucleotides to about 80 nucleotides, about 40 nucleotides to about 70 nucleotides, about 50 nucleotides to about 60 nucleotides, about 45 nucleotides to about 65 nucleotides downstream from the stop codon of an ORF in a polynucleotide of the disclosure.
  • MiRNA gene regulation can be influenced by the sequence surrounding the miRNA such as, but not limited to, the species of the surrounding sequence, the type of sequence (e.g ., heterologous, homologous, exogenous, endogenous, or artificial), regulatory elements in the surrounding sequence and/or structural elements in the surrounding sequence.
  • the miRNA can be influenced by the 5'UTR and/or 3'UTR.
  • a non-human 3'UTR can increase the regulatory effect of the miRNA sequence on the expression of a polypeptide of interest compared to a human 3'UTR of the same sequence type.
  • other regulatory elements and/or structural elements of the 5'UTR can influence miRNA mediated gene regulation.
  • a regulatory element and/or structural element is a structured IRES (Internal Ribosome Entry Site) in the 5'UTR, which is necessary for the binding of translational elongation factors to initiate protein translation. EIF4A2 binding to this secondarily structured element in the 5'-UTR is necessary for miRNA mediated gene expression ( Meijer HA et al., Science, 2013, 340, 82-85 , herein incorporated by reference in its entirety).
  • the polynucleotides of the disclosure can further include this structured 5'UTR in order to enhance microRNA mediated gene regulation.
  • At least one miRNA binding site can be engineered into the 3'UTR of a polynucleotide of the disclosure.
  • at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more miRNA binding sites can be engineered into a 3'UTR of a polynucleotide of the disclosure.
  • 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 2, or 1 miRNA binding sites can be engineered into the 3'UTR of a polynucleotide of the disclosure.
  • miRNA binding sites incorporated into a polynucleotide of the disclosure can be the same or can be different miRNA sites.
  • a combination of different miRNA binding sites incorporated into a polynucleotide of the disclosure can include combinations in which more than one copy of any of the different miRNA sites are incorporated.
  • miRNA binding sites incorporated into a polynucleotide of the disclosure can target the same or different tissues in the body.
  • tissue-, cell-type-, or disease-specific miRNA binding sites in the 3'-UTR of a polynucleotide of the disclosure can be reduced.
  • specific cell types e.g ., hepatocytes, myeloid cells, endothelial cells, cancer cells, etc.
  • a miRNA binding site can be engineered near the 5' terminus of the 3'UTR, about halfway between the 5' terminus and 3' terminus of the 3'UTR and/or near the 3' terminus of the 3'UTR in a polynucleotide of the disclosure.
  • a miRNA binding site can be engineered near the 5' terminus of the 3'UTR and about halfway between the 5' terminus and 3' terminus of the 3'UTR.
  • a miRNA binding site can be engineered near the 3' terminus of the 3'UTR and about halfway between the 5' terminus and 3' terminus of the 3'UTR.
  • a miRNA binding site can be engineered near the 5' terminus of the 3'UTR and near the 3' terminus of the 3 UTR.
  • a 3'UTR can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 miRNA binding sites.
  • the miRNA binding sites can be complementary to a miRNA, miRNA seed sequence, and/or miRNA sequences flanking the seed sequence.
  • a polynucleotide of the disclosure can be engineered to include more than one miRNA site expressed in different tissues or different cell types of a subject.
  • a polynucleotide of the disclosure can be engineered to include miR-192 and miR-122 to regulate expression of the polynucleotide in the liver and kidneys of a subject.
  • a polynucleotide of the disclosure can be engineered to include more than one miRNA site for the same tissue.
  • the therapeutic window and or differential expression associated with the polypeptide encoded by a polynucleotide of the disclosure can be altered with a miRNA binding site.
  • a polynucleotide encoding a polypeptide that provides a death signal can be designed to be more highly expressed in cancer cells by virtue of the miRNA signature of those cells.
  • the polynucleotide encoding the binding site for that miRNA (or miRNAs) would be more highly expressed.
  • the polypeptide that provides a death signal triggers or induces cell death in the cancer cell.
  • Neighboring noncancer cells harboring a higher expression of the same miRNA would be less affected by the encoded death signal as the polynucleotide would be expressed at a lower level due to the effects of the miRNA binding to the binding site or "sensor" encoded in the 3'UTR.
  • cell survival or cytoprotective signals can be delivered to tissues containing cancer and non-cancerous cells where a miRNA has a higher expression in the cancer cells-the result being a lower survival signal to the cancer cell and a larger survival signal to the normal cell.
  • Multiple polynucleotides can be designed and administered having different signals based on the use of miRNA binding sites as described herein.
  • the expression of a polynucleotide of the disclosure can be controlled by incorporating at least one sensor sequence in the polynucleotide and formulating the polynucleotide for administration.
  • a polynucleotide of the disclosure can be targeted to a tissue or cell by incorporating a miRNA binding site and formulating the polynucleotide in a lipid nanoparticle comprising a cationic lipid, including any of the lipids described herein.
  • a polynucleotide of the disclosure can be engineered for more targeted expression in specific tissues, cell types, or biological conditions based on the expression patterns of miRNAs in the different tissues, cell types, or biological conditions. Through introduction of tissue-specific miRNA binding sites, a polynucleotide of the disclosure can be designed for optimal protein expression in a tissue or cell, or in the context of a biological condition.
  • a polynucleotide of the disclosure can be designed to incorporate miRNA binding sites that either have 100% identity to known miRNA seed sequences or have less than 100% identity to miRNA seed sequences.
  • a polynucleotide of the disclosure can be designed to incorporate miRNA binding sites that have at least: 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to known miRNA seed sequences.
  • the miRNA seed sequence can be partially mutated to decrease miRNA binding affinity and as such result in reduced downmodulation of the polynucleotide.
  • the degree of match or mis-match between the miRNA binding site and the miRNA seed can act as a rheostat to more finely tune the ability of the miRNA to modulate protein expression.
  • mutation in the non-seed region of a miRNA binding site can also impact the ability of a miRNA to modulate protein expression.
  • a miRNA sequence can be incorporated into the loop of a stem loop.
  • a miRNA seed sequence can be incorporated in the loop of a stem loop and a miRNA binding site can be incorporated into the 5' or 3' stem of the stem loop.
  • a translation enhancer element can be incorporated on the 5'end of the stem of a stem loop and a miRNA seed can be incorporated into the stem of the stem loop.
  • a TEE can be incorporated on the 5' end of the stem of a stem loop, a miRNA seed can be incorporated into the stem of the stem loop and a miRNA binding site can be incorporated into the 3' end of the stem or the sequence after the stem loop.
  • the miRNA seed and the miRNA binding site can be for the same and/or different miRNA sequences.
  • the incorporation of a miRNA sequence and/or a TEE sequence changes the shape of the stem loop region which can increase and/or decrease translation.
  • a miRNA sequence and/or a TEE sequence changes the shape of the stem loop region which can increase and/or decrease translation.
  • the 5'-UTR of a polynucleotide of the disclosure can comprise at least one miRNA sequence.
  • the miRNA sequence can be, but is not limited to, a 19 or 22 nucleotide sequence and/or a miRNA sequence without the seed.
  • the miRNA sequence in the 5'UTR can be used to stabilize a polynucleotide of the disclosure described herein.
  • a miRNA sequence in the 5'UTR of a polynucleotide of the disclosure can be used to decrease the accessibility of the site of translation initiation such as, but not limited to a start codon. See, e.g ., Matsuda et al., PLoS One. 2010 11(5):e15057 ; incorporated herein by reference in its entirety, which used antisense locked nucleic acid (LNA) oligonucleotides and exon-junction complexes (EJCs) around a start codon (-4 to +37 where the A of the AUG codons is +1) in order to decrease the accessibility to the first start codon (AUG).
  • LNA antisense locked nucleic acid
  • EJCs exon-junction complexes
  • a polynucleotide of the disclosure can comprise a miRNA sequence, instead of the LNA or EJC sequence described by Matsuda et al, near the site of translation initiation in order to decrease the accessibility to the site of translation initiation.
  • the site of translation initiation can be prior to, after or within the miRNA sequence.
  • the site of translation initiation can be located within a miRNA sequence such as a seed sequence or binding site.
  • the site of translation initiation may be located within a miR-122 sequence such as the seed sequence or the mir-122 binding site.
  • a polynucleotide of the disclosure can include at least one miRNA in order to dampen expression of the encoded polypeptide in a tissue or cell of interest.
  • a polynucleotide of the disclosure can include at least one miR-122 binding site in order to dampen expression of an encoded polypeptide of interest in the liver.
  • a polynucleotide of the disclosure can include at least one miR-142-3p binding site, miR-142-3p seed sequence, miR-142-3p binding site without the seed, miR-142-5p binding site, miR-142-5p seed sequence, miR-142-5p binding site without the seed, miR-146 binding site, miR-146 seed sequence and/or miR-146 binding site without the seed sequence.
  • a polynucleotide of the disclosure can comprise at least one miRNA binding site in the 3'UTR in order to selectively degrade mRNA therapeutics in the immune cells to subdue unwanted immunogenic reactions caused by therapeutic delivery.
  • the miRNA binding site can make a polynucleotide of the disclosure more unstable in antigen presenting cells.
  • these miRNAs include mir-122-5p or mir-122-3p.
  • a polynucleotide of the disclosure comprises at least one miRNA sequence in a region of the polynucleotide that can interact with a RNA binding protein.
  • the polynucleotide of the disclosure e.g ., a RNA, e.g., an mRNA
  • a RNA e.g., an mRNA
  • a sequence-optimized nucleotide sequence e.g ., an ORF
  • an IL12B polypeptide e.g ., an IL12A polypeptide
  • IL12B and IL12A fusion polypeptides e.g ., the wild-type sequence, functional fragment, or variant thereof
  • a miRNA binding site e.g., a miRNA binding site that binds to miR-122.
  • the polynucleotide of the disclosure comprises a uracil-modified sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides disclosed herein and a miRNA binding site disclosed herein, e.g., a miRNA binding site that binds to miR-122.
  • the uracil-modified sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides comprises at least one chemically modified nucleobase, e.g ., 5-methoxyuracil.
  • At least 95% of a type of nucleobase (e.g ., uracil) in a uracil-modified sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides of the disclosure are modified nucleobases.
  • at least 95% of uracil in a uracil-modified sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides is 5-methoxyuridine.
  • the polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides disclosed herein and a miRNA binding site is formulated with a delivery agent, e.g., a compound having the Formula (I) , e.g., any of Compounds 1-147 or any of Compounds 1-232.
  • a delivery agent e.g., a compound having the Formula (I) , e.g., any of Compounds 1-147 or any of Compounds 1-232.
  • a polynucleotide of the present disclosure e.g ., a polynucleotide comprising a nucleotide sequence (e.g ., an ORF) encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides of the disclosure
  • a polynucleotide of the present disclosure further comprises a 3' UTR.
  • the 3'-UTR is the section of mRNA that immediately follows the translation termination codon and often contains regulatory regions that post-transcriptionally influence gene expression. Regulatory regions within the 3'-UTR can influence polyadenylation, translation efficiency, localization, and stability of the mRNA.
  • the 3'-UTR useful for the disclosure comprises a binding site for regulatory proteins or microRNAs.
  • the 3'-UTR has a silencer region, which binds to repressor proteins and inhibits the expression of the mRNA.
  • the 3'-UTR comprises an AU-rich element. Proteins bind AREs to affect the stability or decay rate of transcripts in a localized manner or affect translation initiation.
  • the 3'-UTR comprises the sequence AAUAAA that directs addition of several hundred adenine residues called the poly(A) tail to the end of the mRNA transcript.
  • AU rich elements can be separated into three classes (Chen et al, 1995): Class I AREs contain several dispersed copies of an AUUUA motif within U-rich regions. C-Myc and MyoD contain class I AREs. Class II AREs possess two or more overlapping UUAUUUA(U/A)(U/A) nonamers. Molecules containing this type of AREs include GM-CSF and TNF-a. Class III ARES are less well defined.
  • AREs 3' UTR AU rich elements
  • one or more copies of an ARE can be introduced to make polynucleotides of the disclosure less stable and thereby curtail translation and decrease production of the resultant protein.
  • AREs can be identified and removed or mutated to increase the intracellular stability and thus increase translation and production of the resultant protein.
  • Transfection experiments can be conducted in relevant cell lines, using polynucleotides of the disclosure and protein production can be assayed at various time points post-transfection. For example, cells can be transfected with different ARE-engineering molecules and by using an ELISA kit to the relevant protein and assaying protein produced at 6 hour, 12 hour, 24 hour, 48 hour, and 7 days post-transfection.
  • the 3' UTR useful for the polynucleotides of the disclosure comprises a 3'UTR selected from those shown in this application.
  • the 3' UTR sequence useful for the disclosure comprises a nucleotide sequence at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a sequence selected from the group consisting of 3'UTR sequences listed herein and any combination thereof.
  • the disclosure also includes a polynucleotide that comprises both a 5' Cap and a polynucleotide of the present disclosure (e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides).
  • a polynucleotide that comprises both a 5' Cap and a polynucleotide of the present disclosure (e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides).
  • the 5' cap structure of a natural mRNA is involved in nuclear export, increasing mRNA stability and binds the mRNA Cap Binding Protein (CBP), which is responsible for mRNA stability in the cell and translation competency through the association of CBP with poly(A) binding protein to form the mature cyclic mRNA species.
  • CBP mRNA Cap Binding Protein
  • the cap further assists the removal of 5' proximal introns during mRNA splicing.
  • Endogenous mRNA molecules can be 5'-end capped generating a 5'-ppp-5'-triphosphate linkage between a terminal guanosine cap residue and the 5'-terminal transcribed sense nucleotide of the mRNA molecule.
  • This 5'-guanylate cap can then be methylated to generate an N7-methyl-guanylate residue.
  • the ribose sugars of the terminal and/or anteterminal transcribed nucleotides of the 5' end of the mRNA can optionally also be 2'-O-methylated.
  • 5'-decapping through hydrolysis and cleavage of the guanylate cap structure can target a nucleic acid molecule, such as an mRNA molecule, for degradation.
  • the polynucleotides of the present disclosure incorporate a cap moiety.
  • polynucleotides of the present disclosure e.g ., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides
  • a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides comprise a non-hydrolyzable cap structure preventing decapping and thus increasing mRNA half-life. Because cap structure hydrolysis requires cleavage of 5'-ppp-5' phosphorodiester linkages, modified nucleotides can be used during the capping reaction.
  • Vaccinia Capping Enzyme from New England Biolabs (Ipswich, MA) can be used with ⁇ -thio-guanosine nucleotides according to the manufacturer's instructions to create a phosphorothioate linkage in the 5'-ppp-5' cap.
  • Additional modified guanosine nucleotides can be used such as ⁇ -methyl-phosphonate and seleno-phosphate nucleotides.
  • Additional modifications include, but are not limited to, 2'-O-methylation of the ribose sugars of 5'-terminal and/or 5'-anteterminal nucleotides of the polynucleotide (as mentioned above) on the 2'-hydroxyl group of the sugar ring.
  • Multiple distinct 5'-cap structures can be used to generate the 5'-cap of a nucleic acid molecule, such as a polynucleotide that functions as an mRNA molecule.
  • Cap analogs which herein are also referred to as synthetic cap analogs, chemical caps, chemical cap analogs, or structural or functional cap analogs, differ from natural (i.e ., endogenous, wild-type or physiological) 5'-caps in their chemical structure, while retaining cap function.
  • Cap analogs can be chemically ( i.e ., non-enzymatically) or enzymatically synthesized and/or linked to the polynucleotides of the disclosure.
  • the Anti-Reverse Cap Analog (ARCA) cap contains two guanines linked by a 5'-5'-triphosphate group, wherein one guanine contains an N7 methyl group as well as a 3'-O-methyl group (i.e ., N7,3'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine (m 7 G-3'mppp-G; which may equivalently be designated 3' O-Mem7G(5')ppp(5')G).
  • the 3'-O atom of the other, unmodified, guanine becomes linked to the 5'-terminal nucleotide of the capped polynucleotide.
  • the N7- and 3'-O-methlyated guanine provides the terminal moiety of the capped polynucleotide.
  • mCAP which is similar to ARCA but has a 2'-O-methyl group on guanosine (i.e ., N7,2'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine, m 7 Gm-ppp-G).
  • the cap is a dinucleotide cap analog.
  • the dinucleotide cap analog can be modified at different phosphate positions with a boranophosphate group or a phophoroselenoate group such as the dinucleotide cap analogs described in U.S. Patent No. US 8,519,110 , the contents of which are herein incorporated by reference in its entirety.
  • the cap is a cap analog is a N7-(4-chlorophenoxyethyl) substituted dinucleotide form of a cap analog known in the art and/or described herein.
  • Non-limiting examples of a N7-(4-chlorophenoxyethyl) substituted dinucleotide form of a cap analog include a N7-(4-chlorophenoxyethyl)-G(5')ppp(5')G and a N7-(4-chlorophenoxyethyl)-m 3'-O G(5')ppp(5')G cap analog ( See, e.g., the various cap analogs and the methods of synthesizing cap analogs described in Kore et al.
  • a cap analog of the present disclosure is a 4-chloro/bromophenoxyethyl analog.
  • cap analogs allow for the concomitant capping of a polynucleotide or a region thereof, in an in vitro transcription reaction, up to 20% of transcripts can remain uncapped. This, as well as the structural differences of a cap analog from an endogenous 5'-cap structures of nucleic acids produced by the endogenous, cellular transcription machinery, can lead to reduced translational competency and reduced cellular stability.
  • Polynucleotides of the disclosure can also be capped post-manufacture (whether IVT or chemical synthesis), using enzymes, in order to generate more authentic 5'-cap structures.
  • the phrase "more authentic” refers to a feature that closely mirrors or mimics, either structurally or functionally, an endogenous or wild type feature.
  • a "more authentic" feature is better representative of an endogenous, wild-type, natural or physiological cellular function and/or structure as compared to synthetic features or analogs, etc., of the prior art, or which outperforms the corresponding endogenous, wild-type, natural or physiological feature in one or more respects.
  • Non-limiting examples of more authentic 5'cap structures of the present disclosure are those that, among other things, have enhanced binding of cap binding proteins, increased half-life, reduced susceptibility to 5' endonucleases and/or reduced 5'decapping, as compared to synthetic 5'cap structures known in the art (or to a wild-type, natural or physiological 5'cap structure).
  • recombinant Vaccinia Virus Capping Enzyme and recombinant 2'-O-methyltransferase enzyme can create a canonical 5'-5'-triphosphate linkage between the 5'-terminal nucleotide of a polynucleotide and a guanine cap nucleotide wherein the cap guanine contains an N7 methylation and the 5'-terminal nucleotide of the mRNA contains a 2'-O-methyl.
  • Cap1 structure Such a structure is termed the Cap1 structure.
  • Cap structures include, but are not limited to, 7mG(5')ppp(5')N,pN2p (cap 0), 7mG(5')ppp(5')NlmpNp (cap 1), and 7mG(5')-ppp(5')NlmpN2mp (cap 2).
  • capping chimeric polynucleotides post-manufacture can be more efficient as nearly 100% of the chimeric polynucleotides can be capped. This is in contrast to ⁇ 80% when a cap analog is linked to a chimeric polynucleotide in the course of an in vitro transcription reaction.
  • 5' terminal caps can include endogenous caps or cap analogs.
  • a 5' terminal cap can comprise a guanine analog.
  • Useful guanine analogs include, but are not limited to, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.
  • the 5' terminal cap structure is a Cap0, Cap1, ARC A, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, 5' methylG cap, or an analog thereof.
  • the polynucleotides of the present disclosure e.g ., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides
  • a poly-A tail In further embodiments, terminal groups on the poly-A tail can be incorporated for stabilization.
  • a poly-A tail comprises des-3' hydroxyl tails.
  • a long chain of adenine nucleotides can be added to a polynucleotide such as an mRNA molecule in order to increase stability.
  • a polynucleotide such as an mRNA molecule
  • the 3' end of the transcript can be cleaved to free a 3' hydroxyl.
  • poly-A polymerase adds a chain of adenine nucleotides to the RNA.
  • polyadenylation adds a poly-A tail that can be between, for example, approximately 80 to approximately 250 residues long, including approximately 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 residues long.
  • PolyA tails can also be added after the construct is exported from the nucleus.
  • terminal groups on the poly A tail can be incorporated for stabilization.
  • Polynucleotides of the present disclosure can include des-3' hydroxyl tails. They can also include structural moieties or 2'-Omethyl modifications as taught by Junjie Li, et al. (Current Biology, Vol. 15, 1501-1507, August 23, 2005 , the contents of which are incorporated herein by reference in its entirety).
  • the polynucleotides of the present disclosure can be designed to encode transcripts with alternative polyA tail structures including histone mRNA. According to Norbury, "Terminal uridylation has also been detected on human replication-dependent histone mRNAs. The turnover of these mRNAs is thought to be important for the prevention of potentially toxic histone accumulation following the completion or inhibition of chromosomal DNA replication.
  • mRNAs are distinguished by their lack of a 3' poly(A) tail, the function of which is instead assumed by a stable stem-loop structure and its cognate stem-loop binding protein (SLBP); the latter carries out the same functions as those of PABP on polyadenylated mRNAs" ( Norbury, "Cytoplasmic RNA: a case of the tail wagging the dog," Nature Reviews Molecular Cell Biology; AOP, published online 29 August 2013; doi:10.1038/nrm3645 ) the contents of which are incorporated herein by reference in its entirety.
  • SLBP stem-loop binding protein
  • the length of a poly-A tail when present, is greater than 30 nucleotides in length. In another embodiment, the poly-A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, and 3,000 nucleotides).
  • the poly-A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600,
  • the polynucleotide or region thereof includes from about 30 to about 3,000 nucleotides (e.g ., from 30 to 50, from 30 to 100, from 30 to 250, from 30 to 500, from 30 to 750, from 30 to 1,000, from 30 to 1,500, from 30 to 2,000, from 30 to 2,500, from 50 to 100, from 50 to 250, from 50 to 500, from 50 to 750, from 50 to 1,000, from 50 to 1,500, from 50 to 2,000, from 50 to 2,500, from 50 to 3,000, from 100 to 500, from 100 to 750, from 100 to 1,000, from 100 to 1,500, from 100 to 2,000, from 100 to 2,500, from 100 to 3,000, from 500 to 750, from 500 to 1,000, from 500 to 1,500, from 500 to 2,000, from 500 to 2,500, from 500 to 3,000, from 1,000 to 1,500, from 1,000 to 2,000, from 1,000 to 2,500, from 1,000 to 3,000, from 1,500 to 2,000, from 1,500 to 2,500, from 1,500 to 3,000, from 1,500 to
  • the poly-A tail is designed relative to the length of the overall polynucleotide or the length of a particular region of the polynucleotide. This design can be based on the length of a coding region, the length of a particular feature or region or based on the length of the ultimate product expressed from the polynucleotides.
  • the poly-A tail can be 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% greater in length than the polynucleotide or feature thereof.
  • the poly-A tail can also be designed as a fraction of the polynucleotides to which it belongs.
  • the poly-A tail can be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the construct, a construct region or the total length of the construct minus the poly-A tail.
  • engineered binding sites and conjugation of polynucleotides for Poly-A binding protein can enhance expression.
  • multiple distinct polynucleotides can be linked together via the PABP (Poly-A binding protein) through the 3'-end using modified nucleotides at the 3'-terminus of the poly-A tail.
  • Transfection experiments can be conducted in relevant cell lines at and protein production can be assayed by ELISA at 12hr, 24hr, 48hr, 72hr and day 7 post-transfection.
  • the polynucleotides of the present disclosure are designed to include a polyA-G quartet region.
  • the G-quartet is a cyclic hydrogen bonded array of four guanine nucleotides that can be formed by G-rich sequences in both DNA and RNA.
  • the G-quartet is incorporated at the end of the poly-A tail.
  • the resultant polynucleotide is assayed for stability, protein production and other parameters including half-life at various time points. It has been discovered that the polyA-G quartet results in protein production from an mRNA equivalent to at least 75% of that seen using a poly-A tail of 120 nucleotides alone.
  • the disclosure also includes a polynucleotide that comprises both a start codon region and the polynucleotide described herein (e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides).
  • the polynucleotides of the present disclosure can have regions that are analogous to or function like a start codon region.
  • the translation of a polynucleotide can initiate on a codon that is not the start codon AUG.
  • Translation of the polynucleotide can initiate on an alternative start codon such as, but not limited to, ACG, AGG, AAG, CTG/CUG, GTG/GUG, ATA/AUA, ATT/AUU, TTG/LTLTG (see Touriol et al. Biology of the Cell 95 (2003) 169-178 and Matsuda and Mauro PLoS ONE, 2010 5:11 ; the contents of each of which are herein incorporated by reference in its entirety).
  • the translation of a polynucleotide begins on the alternative start codon ACG.
  • polynucleotide translation begins on the alternative start codon CTG or CUG.
  • the translation of a polynucleotide begins on the alternative start codon GTG or GUG.
  • Nucleotides flanking a codon that initiates translation such as, but not limited to, a start codon or an alternative start codon, are known to affect the translation efficiency, the length and/or the structure of the polynucleotide. ( See, e.g., Matsuda and Mauro PLoS ONE, 2010 5:11 ; the contents of which are herein incorporated by reference in its entirety). Masking any of the nucleotides flanking a codon that initiates translation can be used to alter the position of translation initiation, translation efficiency, length and/or structure of a polynucleotide.
  • a masking agent can be used near the start codon or alternative start codon in order to mask or hide the codon to reduce the probability of translation initiation at the masked start codon or alternative start codon.
  • masking agents include antisense locked nucleic acids (LNA) polynucleotides and exon-junction complexes (EJCs) ( See, e.g., Matsuda and Mauro describing masking agents LNA polynucleotides and EJCs ( PLoS ONE, 2010 5:11 ); the contents of which are herein incorporated by reference in its entirety).
  • a masking agent can be used to mask a start codon of a polynucleotide in order to increase the likelihood that translation will initiate on an alternative start codon.
  • a masking agent can be used to mask a first start codon or alternative start codon in order to increase the chance that translation will initiate on a start codon or alternative start codon downstream to the masked start codon or alternative start codon.
  • a start codon or alternative start codon can be located within a perfect complement for a miR binding site.
  • the perfect complement of a miR binding site can help control the translation, length and/or structure of the polynucleotide similar to a masking agent.
  • the start codon or alternative start codon can be located in the middle of a perfect complement for a miRNA binding site.
  • the start codon or alternative start codon can be located after the first nucleotide, second nucleotide, third nucleotide, fourth nucleotide, fifth nucleotide, sixth nucleotide, seventh nucleotide, eighth nucleotide, ninth nucleotide, tenth nucleotide, eleventh nucleotide, twelfth nucleotide, thirteenth nucleotide, fourteenth nucleotide, fifteenth nucleotide, sixteenth nucleotide, seventeenth nucleotide, eighteenth nucleotide, nineteenth nucleotide, twentieth nucleotide or twenty-first nucleotide.
  • the start codon of a polynucleotide can be removed from the polynucleotide sequence in order to have the translation of the polynucleotide begin on a codon that is not the start codon.
  • Translation of the polynucleotide can begin on the codon following the removed start codon or on a downstream start codon or an alternative start codon.
  • the start codon ATG or AUG is removed as the first 3 nucleotides of the polynucleotide sequence in order to have translation initiate on a downstream start codon or alternative start codon.
  • the polynucleotide sequence where the start codon was removed can further comprise at least one masking agent for the downstream start codon and/or alternative start codons in order to control or attempt to control the initiation of translation, the length of the polynucleotide and/or the structure of the polynucleotide.
  • the disclosure also includes a polynucleotide that comprises both a stop codon region and the polynucleotide described herein (e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides).
  • the polynucleotides of the present disclosure can include at least two stop codons before the 3' untranslated region (UTR).
  • the stop codon can be selected from TGA, TAA and TAG in the case of DNA, or from UGA, UAA and UAG in the case of RNA.
  • the polynucleotides of the present disclosure include the stop codon TGA in the case or DNA, or the stop codon UGA in the case of RNA, and one additional stop codon.
  • the addition stop codon can be TAA or UAA.
  • the polynucleotides of the present disclosure include three consecutive stop codons, four stop codons, or more.
  • the disclosure also includes a polynucleotide of the present disclosure that further comprises insertions and/or substitutions.
  • the 5'UTR of the polynucleotide can be replaced by the insertion of at least one region and/or string of nucleosides of the same base.
  • the region and/or string of nucleotides can include, but is not limited to, at least 3, at least 4, at least 5, at least 6, at least 7 or at least 8 nucleotides and the nucleotides can be natural and/or unnatural.
  • the group of nucleotides can include 5-8 adenine, cytosine, thymine, a string of any of the other nucleotides disclosed herein and/or combinations thereof.
  • the 5'UTR of the polynucleotide can be replaced by the insertion of at least two regions and/or strings of nucleotides of two different bases such as, but not limited to, adenine, cytosine, thymine, any of the other nucleotides disclosed herein and/or combinations thereof.
  • the 5'UTR can be replaced by inserting 5-8 adenine bases followed by the insertion of 5-8 cytosine bases.
  • the 5'UTR can be replaced by inserting 5-8 cytosine bases followed by the insertion of 5-8 adenine bases.
  • the polynucleotide can include at least one substitution and/or insertion downstream of the transcription start site that can be recognized by an RNA polymerase.
  • at least one substitution and/or insertion can occur downstream of the transcription start site by substituting at least one nucleic acid in the region just downstream of the transcription start site (such as, but not limited to, +1 to +6).
  • NTP nucleotide triphosphate
  • the polynucleotide can include the substitution of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12 or at least 13 guanine bases downstream of the transcription start site.
  • the polynucleotide can include the substitution of at least 1, at least 2, at least 3, at least 4, at least 5 or at least 6 guanine bases in the region just downstream of the transcription start site.
  • the guanine bases can be substituted by at least 1, at least 2, at least 3 or at least 4 adenine nucleotides (SEQ ID NO: 233).
  • the guanine bases can be substituted by at least 1, at least 2, at least 3 or at least 4 cytosine bases (SEQ ID NO: 234).
  • the guanine bases in the region are GGGAGA
  • the guanine bases can be substituted by at least 1, at least 2, at least 3 or at least 4 thymine, and/or any of the nucleotides described herein (SEQ ID NO: 235).
  • the polynucleotide can include at least one substitution and/or insertion upstream of the start codon.
  • the start codon is the first codon of the protein coding region whereas the transcription start site is the site where transcription begins.
  • the polynucleotide can include, but is not limited to, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 or at least 8 substitutions and/or insertions of nucleotide bases.
  • the nucleotide bases can be inserted or substituted at 1, at least 1, at least 2, at least 3, at least 4 or at least 5 locations upstream of the start codon.
  • the nucleotides inserted and/or substituted can be the same base (e.g ., all A or all C or all T or all G), two different bases (e.g., A and C, A and T, or C and T), three different bases ( e.g., A, C and T or A, C and T) or at least four different bases.
  • the guanine base upstream of the coding region in the polynucleotide can be substituted with adenine, cytosine, thymine, or any of the nucleotides described herein.
  • the substitution of guanine bases in the polynucleotide can be designed so as to leave one guanine base in the region downstream of the transcription start site and before the start codon (see Esvelt et al. Nature (2011) 472(7344):499-503 ; the contents of which is herein incorporated by reference in its entirety).
  • at least 5 nucleotides can be inserted at 1 location downstream of the transcription start site but upstream of the start codon and the at least 5 nucleotides can be the same base type.
  • a polynucleotide of the present disclosure for example a polynucleotide comprising an mRNA nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides, comprises from 5' to 3' end:
  • the polynucleotide further comprises a miRNA binding site, e.g., a miRNA binding site that binds to miRNA-142.
  • the 5'UTR comprises the miRNA binding site.
  • a polynucleotide of the present disclosure comprises a nucleotide sequence encoding a polypeptide sequence at least 70%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96% , at least 97%, at least 98%, at least 99%, or 100% identical to the protein sequence of a wild type IL12 (e.g ., isoform 1, 2, 3, or 4).
  • a wild type IL12 e.g ., isoform 1, 2, 3, or 4
  • the present disclosure also provides methods for making a polynucleotide of the disclosure (e.g ., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides) or a complement thereof.
  • a polynucleotide of the disclosure e.g ., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides
  • a polynucleotide e.g., a RNA, e.g., an mRNA
  • encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides can be constructed using in vitro transcription.
  • a polynucleotide e.g., a RNA, e.g., an mRNA
  • a polynucleotide e.g., a RNA, e.g., an mRNA
  • encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides can be constructed by chemical synthesis using an oligonucleotide synthesizer.
  • a polynucleotide e.g., a RNA, e.g., an mRNA
  • encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides is made by using a host cell.
  • a polynucleotide e.g ., a RNA, e.g., an mRNA
  • encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides is made by one or more combination of the IVT, chemical synthesis, host cell expression, or any other methods known in the art.
  • a host cell is a eukaryotic cell, e.g., in vitro mammalian cells.
  • Naturally occurring nucleosides, non-naturally occurring nucleosides, or combinations thereof, can totally or partially naturally replace occurring nucleosides present in the candidate nucleotide sequence and can be incorporated into a sequence-optimized nucleotide sequence (e.g., a RNA, e.g., an mRNA) encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides.
  • the resultant polynucleotides, e.g ., mRNAs can then be examined for their ability to produce protein and/or produce a therapeutic outcome.
  • polynucleotides of the present disclosure disclosed herein can be transcribed using an in vitro transcription (IVT) system.
  • IVT in vitro transcription
  • the system typically comprises a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor and a polymerase.
  • NTPs can be selected from, but are not limited to, those described herein including natural and unnatural (modified) NTPs.
  • the polymerase can be selected from, but is not limited to, T7 RNA polymerase, T3 RNA polymerase and mutant polymerases such as, but not limited to, polymerases able to incorporate polynucleotides disclosed herein. See U.S. Publ. No. US20130259923 , which is herein incorporated by reference in its entirety.
  • RNA polymerases can be modified by inserting or deleting amino acids of the RNA polymerase sequence.
  • the RNA polymerase can be modified to exhibit an increased ability to incorporate a 2'-modified nucleotide triphosphate compared to an unmodified RNA polymerase (see International Publication WO2008078180 and U.S. Patent 8,101,385 ; herein incorporated by reference in their entireties).
  • Variants can be obtained by evolving an RNA polymerase, optimizing the RNA polymerase amino acid and/or nucleic acid sequence and/or by using other methods known in the art.
  • T7 RNA polymerase variants can be evolved using the continuous directed evolution system set out by Esvelt et al.
  • T7 RNA polymerase can encode at least one mutation such as, but not limited to, lysine at position 93 substituted for threonine (K93T), I4M, A7T, E63V, V64D, A65E, D66Y, T76N, C125R, S128R, A136T, N165S, G175R, H176L, Y178H, F182L, L196F, G198V, D208Y, E222K, S228A, Q239R, T243N, G259D, M267I, G280C, H300R, D351A, A354S, E356D, L360P, A383V, Y385C, D388Y, S397R, M401T, N410S, K450R, P451T, G452V, E484A, H523L
  • T7 RNA polymerase variants can encode at least mutation as described in U.S. Pub. Nos. 20100120024 and 20070117112 ; herein incorporated by reference in their entireties.
  • Variants of RNA polymerase can also include, but are not limited to, substitutional variants, conservative amino acid substitution, insertional variants, deletional variants and/or covalent derivatives.
  • the polynucleotide can be designed to be recognized by the wild type or variant RNA polymerases. In doing so, the polynucleotide can be modified to contain sites or regions of sequence changes from the wild type or parent chimeric polynucleotide.
  • Polynucleotide or nucleic acid synthesis reactions can be carried out by enzymatic methods utilizing polymerases.
  • Polymerases catalyze the creation of phosphodiester bonds between nucleotides in a polynucleotide or nucleic acid chain.
  • DNA polymerases can be divided into different families based on amino acid sequence comparison and crystal structure analysis.
  • DNA polymerase I poly I
  • a polymerase family including the Klenow fragments of E. coli, Bacillus DNA polymerase I, Thermus aquaticus (Taq) DNA polymerases, and the T7 RNA and DNA polymerases, is among the best studied of these families.
  • DNA polymerase ⁇ (pol ⁇ ) or B polymerase family, including all eukaryotic replicating DNA polymerases and polymerases from phages T4 and RB69. Although they employ similar catalytic mechanism, these families of polymerases differ in substrate specificity, substrate analog-incorporating efficiency, degree and rate for primer extension, mode of DNA synthesis, exonuclease activity, and sensitivity against inhibitors.
  • DNA polymerases are also selected based on the optimum reaction conditions they require, such as reaction temperature, pH, and template and primer concentrations. Sometimes a combination of more than one DNA polymerases is employed to achieve the desired DNA fragment size and synthesis efficiency. For example, Cheng et al. increase pH, add glycerol and dimethyl sulfoxide, decrease denaturation times, increase extension times, and utilize a secondary thermostable DNA polymerase that possesses a 3' to 5' exonuclease activity to effectively amplify long targets from cloned inserts and human genomic DNA. ( Cheng et al., PNAS 91:5695-5699 (1994 ), the contents of which are incorporated herein by reference in their entirety).
  • RNA polymerases from bacteriophage T3, T7, and SP6 have been widely used to prepare RNAs for biochemical and biophysical studies.
  • RNA polymerases, capping enzymes, and poly-A polymerases are disclosed in the co-pending International Publication No. WO2014028429 , the contents of which are incorporated herein by reference in their entirety.
  • the RNA polymerase which can be used in the synthesis of the polynucleotides of the present disclosure is a Syn5 RNA polymerase.
  • the Syn5 RNA polymerase was recently characterized from marine cyanophage Syn5 by Zhu et al. where they also identified the promoter sequence (see Zhu et al. Nucleic Acids Research 2013 , the contents of which is herein incorporated by reference in its entirety). Zhu et al.
  • Syn5 RNA polymerase catalyzed RNA synthesis over a wider range of temperatures and salinity as compared to T7 RNA polymerase. Additionally, the requirement for the initiating nucleotide at the promoter was found to be less stringent for Syn5 RNA polymerase as compared to the T7 RNA polymerase making Syn5 RNA polymerase promising for RNA synthesis.
  • a Syn5 RNA polymerase can be used in the synthesis of the polynucleotides described herein.
  • a Syn5 RNA polymerase can be used in the synthesis of the polynucleotide requiring a precise 3'-terminus.
  • a Syn5 promoter can be used in the synthesis of the polynucleotides.
  • the Syn5 promoter can be 5'-ATTGGGCACCCGTAAGGG-3' (SEQ ID NO: 47) as described by Zhu et al. (Nucleic Acids Research 2013 ).
  • a Syn5 RNA polymerase can be used in the synthesis of polynucleotides comprising at least one chemical modification described herein and/or known in the art (see e.g., the incorporation of pseudo-UTP and SMe-CTP described in Zhu et al. Nucleic Acids Research 2013 ).
  • the polynucleotides described herein can be synthesized using a Syn5 RNA polymerase which has been purified using modified and improved purification procedure described by Zhu et al. (Nucleic Acids Research 2013 ).
  • PCR Polymerase chain reaction
  • the key components for synthesizing DNA comprise target DNA molecules as a template, primers complementary to the ends of target DNA strands, deoxynucleoside triphosphates (dNTPs) as building blocks, and a DNA polymerase.
  • dNTPs deoxynucleoside triphosphates
  • PCR As PCR progresses through denaturation, annealing and extension steps, the newly produced DNA molecules can act as a template for the next circle of replication, achieving exponentially amplification of the target DNA.
  • PCR requires a cycle of heating and cooling for denaturation and annealing.
  • Variations of the basic PCR include asymmetric PCR ( Innis et al., PNAS 85: 9436-9440 (1988 )), inverse PCR ( Ochman et al., Genetics 120(3): 621-623, (1988 )), reverse transcription PCR (RT-PCR) ( Freeman et al., BioTechniques 26(1): 112-22, 124-5 (1999 ), the contents of which are incorporated herein by reference in their entirety and so on).
  • RT-PCR a single stranded RNA is the desired target and is converted to a double stranded DNA first by reverse transcriptase.
  • strand displacement amplification is based on the ability of a restriction enzyme to form a nick ( Walker et al., PNAS 89: 392-396 (1992 ), which is incorporated herein by reference in its entirety)).
  • a restriction enzyme recognition sequence is inserted into an annealed primer sequence.
  • Primers are extended by a DNA polymerase and dNTPs to form a duplex. Only one strand of the duplex is cleaved by the restriction enzyme. Each single strand chain is then available as a template for subsequent synthesis.
  • SDA does not require the complicated temperature control cycle of PCR.
  • Nucleic acid sequence-based amplification also called transcription mediated amplification (TMA) is also an isothermal amplification method that utilizes a combination of DNA polymerase, reverse transcriptase, RNAse H, and T7 RNA polymerase.
  • a target RNA is used as a template and a reverse transcriptase synthesizes its complementary DNA strand.
  • RNAse H hydrolyzes the RNA template, making space for a DNA polymerase to synthesize a DNA strand complementary to the first DNA strand which is complementary to the RNA target, forming a DNA duplex.
  • T7 RNA polymerase continuously generates complementary RNA strands of this DNA duplex. These RNA strands act as templates for new cycles of DNA synthesis, resulting in amplification of the target gene.
  • Rolling-circle amplification amplifies a single stranded circular polynucleotide and involves numerous rounds of isothermal enzymatic synthesis where ⁇ 29 DNA polymerase extends a primer by continuously progressing around the polynucleotide circle to replicate its sequence over and over again. Therefore, a linear copy of the circular template is achieved. A primer can then be annealed to this linear copy and its complementary chain can be synthesized. See Lizardi et al., Nature Genetics 19:225-232 (1998 ), the contents of which are incorporated herein by reference in their entirety. A single stranded circular DNA can also serve as a template for RNA synthesis in the presence of an RNA polymerase.
  • LCR Ligase chain reaction
  • LCR can be combined with various amplification techniques to increase sensitivity of detection or to increase the amount of products if it is used in synthesizing polynucleotides and nucleic acids.
  • DNA fragments can be placed in a NEBNEXT ® ULTRATM DNA Library Prep Kit by NEWENGLAND BIOLABS ® for end preparation, ligation, size selection, clean-up, PCR amplification and final clean-up.
  • U.S. Pat. No. 7,550,264 to Getts et al. teaches multiple round of synthesis of sense RNA molecules are performed by attaching oligodeoxynucleotides tails onto the 3' end of cDNA molecules and initiating RNA transcription using RNA polymerase, the contents of which are incorporated herein by reference in their entirety.
  • U.S. Pat. Pub. No. 2013/0183718 to Rohayem teaches RNA synthesis by RNA-dependent RNA polymerases (RdRp) displaying an RNA polymerase activity on single-stranded DNA templates, the contents of which are incorporated herein by reference in their entirety.
  • RdRp RNA-dependent RNA polymerases
  • Oligonucleotides with non-standard nucleotides can be synthesized with enzymatic polymerization by contacting a template comprising non-standard nucleotides with a mixture of nucleotides that are complementary to the nucleotides of the template as disclosed in U.S. Pat. No. 6,617,106 to Benner , the contents of which are incorporated herein by reference in their entirety.
  • Standard methods can be applied to synthesize an isolated polynucleotide sequence encoding an isolated polypeptide of interest, such as a polynucleotide of the disclosure (e.g ., a polynucleotide comprising a nucleotide sequence encoding an II,12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides).
  • a single DNA or RNA oligomer containing a codon-optimized nucleotide sequence coding for the particular isolated polypeptide can be synthesized.
  • several small oligonucleotides coding for portions of the desired polypeptide can be synthesized and then ligated.
  • the individual oligonucleotides typically contain 5' or 3' overhangs for complementary assembly.
  • a polynucleotide disclosed herein e.g., a RNA, e.g., an mRNA
  • a RNA e.g., an mRNA
  • Purification of the polynucleotides described herein can include, but is not limited to, polynucleotide clean-up, quality assurance and quality control.
  • Clean-up can be performed by methods known in the arts such as, but not limited to, AGENCOURT ® beads (Beckman Coulter Genomics, Danvers, MA), poly-T beads, LNA TM oligo-T capture probes (EXIQON ® Inc., Vedbaek, Denmark) or HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC).
  • AGENCOURT ® beads Beckman Coulter Genomics, Danvers, MA
  • poly-T beads poly-T beads
  • LNA TM oligo-T capture probes EXIQON ® Inc., Vedbaek, Denmark
  • HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC).
  • purified when used in relation to a polynucleotide such as a “purified polynucleotide” refers to one that is separated from at least one contaminant.
  • a "contaminant” is any substance that makes another unfit, impure or inferior.
  • a purified polynucleotide e.g., DNA and RNA
  • purification of a polynucleotide of the disclosure removes impurities that can reduce or remove an unwanted immune response, e.g., reducing cytokine activity.
  • the polynucleotide of the disclosure e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides
  • column chromatography e.g., strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC), or (LCMS)
  • the polynucleotide of the disclosure e.g., a polynucleotide comprising a nucleotide sequence an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides
  • column chromatography e. g ., strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC, hydrophobic interaction HPLC (HIC-HPLC), or (LCMS)
  • RP-HPLC reverse phase HPLC
  • HIC-HPLC hydrophobic interaction HPLC
  • LCMS hydrophobic interaction HPLC
  • a column chromatography e.g., strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), hydrophobic interaction HPLC (HIC-HPLC), or (LCMS)
  • purified polynucleotide comprises a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides comprising one or more of the point mutations known in the art.
  • the use of RP-HPLC purified polynucleotide increases IL12 protein expression levels in cells when introduced into those cells, e.g., by 10-100%, i.e., at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, or at least about 100% with respect to the expression levels of IL12 protein in the cells before the RP-HPLC purified polynucleotide was introduced in the cells, or after a non-RP-HPLC purified polynucleotide was introduced in the cells.
  • the use of RP-HPLC purified polynucleotide increases functional IL12 protein expression levels in cells when introduced into those cells, e.g., by 10-100%, i.e., at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, or at least about 100% with respect to the functional expression levels of IL12 protein in the cells before the RP-HPLC purified polynucleotide was introduced in the cells, or after a non-RP-HPLC purified polynucleotide was introduced in the cells.
  • the use of RP-HPLC purified polynucleotide increases detectable IL12 activity in cells when introduced into those cells, e.g., by 10-100%, i.e., at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, or at least about 100% with respect to the activity levels of functional IL12 in the cells before the RP-HPLC purified polynucleotide was introduced in the cells, or after a non-RP-HPLC purified polynucleotide was introduced in the cells.
  • the purified polynucleotide is at least about 80% pure, at least about 85% pure, at least about 90% pure, at least about 95% pure, at least about 96% pure, at least about 97% pure, at least about 98% pure, at least about 99% pure, or about 100% pure.
  • a quality assurance and/or quality control check can be conducted using methods such as, but not limited to, gel electrophoresis, UV absorbance, or analytical HPLC.
  • the polynucleotide can be sequenced by methods including, but not limited to reverse-transcriptase-PCR.
  • the polynucleotides of the present disclosure e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides
  • their expression products, as well as degradation products and metabolites can be quantified according to methods known in the art.
  • the polynucleotides of the present disclosure can be quantified in exosomes or when derived from one or more bodily fluid.
  • bodily fluids include peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, and umbilical cord blood.
  • exosomes can be retrieved from an organ selected from the group consisting of lung, heart, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colon, breast, prostate, brain, esophagus, liver, and placenta.
  • the exosome quantification method a sample of not more than 2mL is obtained from the subject and the exosomes isolated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.
  • the level or concentration of a polynucleotide can be an expression level, presence, absence, truncation or alteration of the administered construct. It is advantageous to correlate the level with one or more clinical phenotypes or with an assay for a human disease biomarker.
  • the assay can be performed using construct specific probes, cytometry, qRT-PCR, real-time PCR, PCR, flow cytometry, electrophoresis, mass spectrometry, or combinations thereof while the exosomes can be isolated using immunohistochemical methods such as enzyme linked immunosorbent assay (ELISA) methods. Exosomes may also be isolated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.
  • immunohistochemical methods such as enzyme linked immunosorbent assay (ELISA) methods.
  • Exosomes may also be isolated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.
  • the polynucleotide can be quantified using methods such as, but not limited to, ultraviolet visible spectroscopy (UV/Vis).
  • UV/Vis ultraviolet visible spectroscopy
  • a non-limiting example of a UV/Vis spectrometer is a NANODROP ® spectrometer (ThermoFisher, Waltham, MA).
  • NANODROP ® spectrometer ThermoFisher, Waltham, MA.
  • Degradation of the polynucleotide can be checked by methods such as, but not limited to, agarose gel electrophoresis, HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC), liquid chromatography-mass spectrometry (LCMS), capillary electrophoresis (CE) and capillary gel electrophoresis (CGE).
  • HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC), liquid chromatography-mass spectrometry (LCMS), capillary electrophoresis (CE) and capillary gel electrophoresis (CGE).
  • compositions and formulations that comprise any of the polynucleotides described above.
  • the composition or formulation further comprises a delivery agent.
  • the composition or formulation can contain a polynucleotide comprising a sequence optimized nucleic acid sequence disclosed herein which encodes an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides.
  • the composition or formulation can contain a polynucleotide (e.g., a RNA, e.g., an mRNA) comprising a polynucleotide (e.g., an ORF) having significant sequence identity to a sequence optimized nucleic acid sequence disclosed herein which encodes an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides.
  • the polynucleotide further comprises a miRNA binding site, e.g., a miRNA binding site that binds miR-122.
  • compositions or formulation can optionally comprise one or more additional active substances, e.g., therapeutically and/or prophylactically active substances.
  • Pharmaceutical compositions or formulation of the present disclosure can be sterile and/or pyrogen-free. General considerations in the formulation and/or manufacture of pharmaceutical agents can be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).
  • compositions are administered to humans, human patients or subjects.
  • the phrase "active ingredient" generally refers to polynucleotides to be delivered as described herein.
  • Formulations and pharmaceutical compositions described herein can be prepared by any method known or hereafter developed in the art of pharmacology.
  • such preparatory methods include the step of associating the active ingredient with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.
  • a pharmaceutical composition or formulation in accordance with the present disclosure can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
  • a "unit dose" refers to a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
  • Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered.
  • the composition can comprise between 0.1% and 99% (w/w) of the active ingredient.
  • the composition can comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1 and 30%, between 5 and 80%, or at least 80% (w/w) active ingredient.
  • the compositions and formulations described herein can contain at least one polynucleotide of the disclosure.
  • the composition or formulation can contain 1, 2, 3, 4 or 5 polynucleotides of the disclosure.
  • the compositions or formulations described herein can comprise more than one type of polynucleotide.
  • the composition or formulation can comprise a polynucleotide in linear and circular form.
  • the composition or formulation can comprise a circular polynucleotide and an IVT polynucleotide.
  • the composition or formulation can comprise an IVT polynucleotide, a chimeric polynucleotide and a circular polynucleotide.
  • compositions and formulations are principally directed to pharmaceutical compositions and formulations that are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to any other animal, e.g., to non-human animals, e.g. non-human mammals. Modification of pharmaceutical compositions or formulations suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation.
  • Subjects to which administration of the pharmaceutical compositions or formulation is contemplated include, but are not limited to, humans and/or other primates; mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice, and/or rats; and/or birds, including commercially relevant birds such as poultry, chickens, ducks, geese, and/or turkeys.
  • the present disclosure provides pharmaceutical formulations that comprise a polynucleotide described herein (e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides).
  • a polynucleotide described herein e.g., a polynucleotide comprising a nucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides.
  • the polynucleotides described herein can be formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection; (3) permit the sustained or delayed release (e.g., from a depot formulation of the polynucleotide); (4) alter the biodistribution (e.g., target the polynucleotide to specific tissues or cell types); (5) increase the translation of encoded protein in vivo; and/or (6) alter the release profile of encoded protein in vivo.
  • the pharmaceutical formulation further comprises a delivery agent, (e.g., a compound having the Formula (I), e.g., any of Compounds 1-147 or any of Compounds 1-232).
  • a pharmaceutically acceptable excipient includes, but are not limited to, any and all solvents, dispersion media, or other liquid vehicles, dispersion or suspension aids, diluents, granulating and/or dispersing agents, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, binders, lubricants or oil, coloring, sweetening or flavoring agents, stabilizers, antioxidants, antimicrobial or antifungal agents, osmolality adjusting agents, pH adjusting agents, buffers, chelants, cyoprotectants, and/or bulking agents, as suited to the particular dosage form desired.
  • Exemplary diluents include, but are not limited to, calcium or sodium carbonate, calcium phosphate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, etc., and/or combinations thereof.
  • Exemplary granulating and/or dispersing agents include, but are not limited to, starches, pregelatinized starches, or microcrystalline starch, alginic acid, guar gum, agar, poly(vinyl-pyrrolidone), (providone), cross-linked poly(vinyl-pyrrolidone) (crospovidone), cellulose, methylcellulose, carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), magnesium aluminum silicate (VEEGUM ® ), sodium lauryl sulfate, etc., and/or combinations thereof.
  • Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), sorbitan fatty acid esters ( e .
  • natural emulsifiers e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin
  • sorbitan fatty acid esters e.
  • polyoxyethylene sorbitan monooleate [TWEEN ® 80], sorbitan monopalmitate [SPAN ® 40], glyceryl monooleate, polyoxyethylene esters, polyethylene glycol fatty acid esters ( e.g., CREMOPHOR ® ), polyoxyethylene ethers ( e.g., polyoxyethylene lauryl ether [BRIJ ® 30]), PLUORINC ® F 68, POLOXAMER ® 188, etc. and/or combinations thereof.
  • Exemplary binding agents include, but are not limited to, starch, gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol), amino acids (e.g., glycine), natural and synthetic gums (e.g., acacia, sodium alginate), ethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, etc., and combinations thereof.
  • sugars e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol
  • amino acids e.g., glycine
  • natural and synthetic gums e.g., acacia, sodium alginate
  • ethylcellulose hydroxyethylcellulose, hydroxypropyl methylcellulose, etc., and combinations thereof.
  • Oxidation is a potential degradation pathway for mRNA, especially for liquid mRNA formulations.
  • antioxidants can be added to the formulations.
  • Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, benzyl alcohol, butylated hydroxyanisole, m-cresol, methionine, butylated hydroxytoluene, monothioglycerol, sodium or potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, etc., and combinations thereof.
  • Exemplary chelating agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, trisodium edetate, etc., and combinations thereof.
  • EDTA ethylenediaminetetraacetic acid
  • citric acid monohydrate disodium edetate
  • fumaric acid malic acid
  • phosphoric acid sodium edetate
  • tartaric acid trisodium edetate, etc.
  • antimicrobial or antifungal agents include, but are not limited to, benzalkonium chloride, benzethonium chloride, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid, hydroxybenzoic acid, potassium or sodium benzoate, potassium or sodium sorbate, sodium propionate, sorbic acid, etc., and combinations thereof.
  • Exemplary preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, ascorbic acid, butylated hydroxyanisol, ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), etc., and combinations thereof.
  • the pH of polynucleotide solutions are maintained between pH 5 and pH 8 to improve stability.
  • exemplary buffers to control pH can include, but are not limited to sodium phosphate, sodium citrate, sodium succinate, histidine (or histidine-HCl), sodium malate, sodium carbonate, etc., and/or combinations thereof.
  • Exemplary lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium or magnesium lauryl sulfate, etc., and combinations thereof.
  • the pharmaceutical composition or formulation described here may contain a cyroprotectant to stabilize a polynucleotide described herein during freezing.
  • exemplary cryoprotectants include, but are not limited to mannitol, sucrose, trehalose, lactose, glycerol, dextrose, etc., and combinations thereof.
  • the pharmaceutical composition or formulation described here may contain a bulking agent in lyophilized polynucleotide formulations to yield a "pharmaceutically elegant" cake, stabilize the lyophilized polynucleotides during long term (e.g., 36 month) storage.
  • exemplary bulking agents of the present disclosure can include, but are not limited to sucrose, trehalose, mannitol, glycine, lactose, raffinose, and combinations thereof.
  • the pharmaceutical composition or formulation further comprises a delivery agent.
  • the delivery agent of the present disclosure can include, without limitation, liposomes, lipid nanoparticles, lipidoids, polymers, lipoplexes, microvesicles, exosomes, peptides, proteins, cells transfected with polynucleotides, hyaluronidase, nanoparticle mimics, nanotubes, conjugates, and combinations thereof.
  • compositions with advantageous properties.
  • present application provides pharmaceutical compositions comprising:
  • the delivery agent for the present disclosure comprises any one or more compounds disclosed in International Application No. PCT/US2016/052352, filed on September 16, 2016 , and published as WO 2017/ 049245 , which is incorporated herein by reference in its entirety.
  • the delivery agent comprises a compound having the formula (I) wherein
  • a subset of compounds of Formula (I) includes those in which
  • a subset of compounds of Formula (I) includes those in which when R 4 is -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, or -CQ(R) 2 , then (i) Q is not -N(R) 2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.
  • another subset of compounds of Formula (I) includes those in which
  • another subset of compounds of Formula (I) includes those in which
  • another subset of compounds of Formula (I) includes those in which
  • another subset of compounds of Formula (I) includes those in which
  • Another subset of compounds of Formula (I) includes those in which
  • Another subset of compounds of Formula (I) includes those in which
  • another subset of compounds of Formula (I) includes those in which
  • another subset of compounds of Formula (I) includes those in which
  • Another subset of compounds of Formula (I) includes those in which
  • Another subset of compounds of Formula (I) includes those in which
  • a subset of compounds of Formula (I) includes those of Formula (IA), or a salt or stereoisomer thereof, wherein
  • a subset of compounds of Formula (I) includes those of Formula (II), or a salt or stereoisomer thereof, wherein
  • the compound of formula (I) is of the formula (IIa), or a salt thereof, wherein R 4 is as described above.
  • the compound of formula (I) is of the formula (IIb), or a salt thereof, wherein R 4 is as described above.
  • the compound of formula (I) is of the formula (IIc), or a salt thereof, wherein R 4 is as described above.
  • the compound of formula (I) is of the formula (IIe): or a salt thereof, wherein R 4 is as described above.
  • the compound of formula (IIa), (IIb), (IIc), or (IIe) comprises an R 4 which is selected from -(CH 2 ) n Q and -(CH 2 ) n CHQR, wherein Q, R and n are as defined above.
  • Q is selected from the group consisting of -OR, -OH, -O(CH 2 ) n N(R) 2 , -OC(O)R, -CX 3 , -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O) 2 R, -N(H)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(H)C(O)N(R) 2 , -N(H)C(O)N(H)(R), -N(R)C(S)N(R) 2 , -N(H)C(S)N(R) 2 , -N(H)C(S)N(H)(R), and a heterocycle, wherein R is as defined above.
  • n is 1 or 2.
  • Q is OH, -NHC(S)N(R)
  • the compound of formula (I) is of the formula (IId), or a salt thereof, wherein R 2 and R 3 are independently selected from the group consisting of C 5-14 alkyl and C 5-14 alkenyl, n is selected from 2, 3, and 4, and R', R", R 5 , R 6 and m are as defined above.
  • R 2 is C 8 alkyl. In some aspects of the compound of formula (IId), R 3 is C 5 -C 9 alkyl. In some aspects of the compound of formula (IId), m is 5, 7, or 9. In some aspects of the compound of formula (IId), each R 5 is H. In some aspects of the compound of formula (IId), each R 6 is H.
  • a lipid composition e.g., a lipid nanoparticle (LNP)
  • a lipid nanoparticle comprising: (1) a compound having the formula (I); (2) optionally a helper lipid (e.g. a phospholipid); (3) optionally a structural lipid (e.g. a sterol); (4) optionally a lipid conjugate (e.g. a PEG-lipid); and (5) optionally a quaternary amine compound.
  • the lipid composition (e.g., LNP) further comprises a polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides, e.g., a polynucleotide encapsulated therein.
  • alkyl or “alkyl group” means a linear or branched, saturated hydrocarbon including one or more carbon atoms (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms).
  • C 1-14 alkyl means a linear or branched, saturated hydrocarbon including 1-14 carbon atoms. An alkyl group may be optionally substituted.
  • alkenyl or “alkenyl group” means a linear or branched hydrocarbon including two or more carbon atoms ( e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms) and at least one double bond.
  • C 2-14 alkenyl means a linear or branched hydrocarbon including 2-14 carbon atoms and at least one double bond.
  • An alkenyl group may include one, two, three, four, or more double bonds.
  • C 18 alkenyl may include one or more double bonds.
  • a C 18 alkenyl group including two double bonds may be a linoleyl group.
  • An alkenyl group may be optionally substituted.
  • the term "carbocycle” or “carbocyclic group” means a mono- or multi-cyclic system including one or more rings of carbon atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen membered rings.
  • C 3-6 carbocycle means a carbocycle including a single ring having 3-6 carbon atoms.
  • Carbocycles may include one or more double bonds and may be aromatic (e.g., aryl groups). Examples of carbocycles include cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and 1,2-dihydronaphthyl groups. Carbocycles may be optionally substituted.
  • heterocycle or “heterocyclic group” means a mono- or multi-cyclic system including one or more rings, where at least one ring includes at least one heteroatom.
  • Heteroatoms may be, for example, nitrogen, oxygen, or sulfur atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, or twelve membered rings.
  • Heterocycles may include one or more double bonds and may be aromatic ( e.g., heteroaryl groups).
  • heterocycles include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and isoquinolyl groups. Heterocycles may be optionally substituted.
  • a “biodegradable group” is a group that may facilitate faster metabolism of a lipid in a subject.
  • a biodegradable group may be, but is not limited to, -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O) 2 -, an aryl group, and a heteroaryl group.
  • aryl group is a carbocyclic group including one or more aromatic rings.
  • aryl groups include phenyl and naphthyl groups.
  • heteroaryl group is a heterocyclic group including one or more aromatic rings.
  • heteroaryl groups include pyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, and thiazolyl. Both aryl and heteroaryl groups may be optionally substituted.
  • M and M' can be selected from the non-limiting group consisting of optionally substituted phenyl, oxazole, and thiazole. In the formulas herein, M and M' can be independently selected from the list of biodegradable groups above.
  • Alkyl, alkenyl, and cyclyl (e.g., carbocyclyl and heterocyclyl) groups may be optionally substituted unless otherwise specified.
  • R is an alkyl or alkenyl group, as defined herein.
  • the substituent groups themselves may be further substituted with, for example, one, two, three, four, five, or six substituents as defined herein.
  • a C 1-6 alkyl group may be further substituted with one, two, three, four, five, or six substituents as described herein.
  • the compounds of any one of formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId), and (IIe) include one or more of the following features when applicable.
  • R 4 is selected from the group consisting of a C 3-6 carbocycle, -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, 5- to 14- membered aromatic or non-aromatic heterocycle having one or more heteroatoms selected from N, O, S, and P, -OR, -O(CH 2 ) n N(R) 2 , -C(O)OR, -OC(O)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -N(R) 2 , -C(O)N(R) 2 , -N(R)C(O)R, -N(R)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)C(S)N(R) 2 , -
  • R 4 is selected from the group consisting of a C 3-6 carbocycle, -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -O(CH 2 ) n N(R) 2 , -C(O)OR, -OC(O)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -C(O)N(R) 2 , -N(R)C(O)R, -N(R)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)C(S)N(R) 2 , -C(R)N(R) 2 C(O
  • R 4 is selected from the group consisting of a C 3-6 carbocycle, -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, -OR, -O(CH 2 ) n N(R) 2 , -C(O)OR, -OC(O)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -C(O)N(R) 2 , -N(R)C(O)R, -N(R)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)C(S)N(R) 2 , -C(R)N(R) 2 C(O)
  • R 4 is selected from the group consisting of a C 3-6 carbocycle, -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -O(CH 2 ) n N(R) 2 , -C(O)OR, -OC(O)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -C(O)N(R) 2 , -N(R)C(O)R, -N(R)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)C(S)N(R) 2 , -C(R)N(R) 2 C(O
  • R 4 is unsubstituted C 1-4 alkyl, e.g., unsubstituted methyl.
  • the disclosure provides a compound having the Formula (I), wherein R 4 is -(CH 2 ) n Q or -(CH 2 ) n CHQR, where Q is -N(R) 2 , and n is selected from 3, 4, and 5.
  • the disclosure provides a compound having the Formula (I), wherein R 4 is selected from the group consisting of -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, and -CQ(R) 2 , where Q is -N(R) 2 , and n is selected from 1, 2, 3, 4, and 5.
  • the disclosure provides a compound having the Formula (I), wherein R 2 and R 3 are independently selected from the group consisting of C 2-14 alkyl, C 2-14 alkenyl, -R*YR", -YR", and -R*OR", or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle, and R 4 is -(CH 2 ) n Q or -(CH 2 ) n CHQR, where Q is -N(R) 2 , and n is selected from 3, 4, and 5.
  • R 2 and R 3 are independently selected from the group consisting of C 2-14 alkyl, C 2-14 alkenyl, -R*YR", -YR", and -R*OR", or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle.
  • R 1 is selected from the group consisting of C 5-20 alkyl and C 5-20 alkenyl.
  • R 1 is selected from the group consisting of -R*YR", -YR", and -R"M'R'.
  • R 4 is selected from -R*YR" and -YR".
  • Y is a cyclopropyl group.
  • R* is C 8 alkyl or C 8 alkenyl.
  • R" is C 3-12 alkyl.
  • R" may be C 3 alkyl.
  • R" may be C 4-8 alkyl (e.g., C 4 , C 5 , C 6 , C 7 , or C 8 alkyl).
  • R 1 is C 5-20 alkyl. In some embodiments, R 1 is C 6 alkyl. In some embodiments, R 1 is C 8 alkyl. In other embodiments, R 1 is C 9 alkyl. In certain embodiments, R 1 is C 14 alkyl. In other embodiments, R 1 is C 18 alkyl.
  • R 1 is C 5-20 alkenyl. In certain embodiments, R 1 is C 18 alkenyl. In some embodiments, R 1 is linoleyl.
  • R 1 is branched ( e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadeca-9-yl).
  • R 1 is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadeca-9-yl).
  • R 1 is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl
  • R 1 is unsubstituted C 5-20 alkyl or C 5-20 alkenyl.
  • R' is substituted C 5-20 alkyl or C 5-20 alkenyl ( e.g., substituted with a C 3-6 carbocycle such as 1-cyclopropylnonyl).
  • R 1 is -R"M'R'.
  • R' is selected from -R*YR" and -YR".
  • Y is C 3-8 cycloalkyl.
  • Y is C 6-10 aryl.
  • Y is a cyclopropyl group.
  • Y is a cyclohexyl group.
  • R* is C 1 alkyl.
  • R" is selected from the group consisting of C 3-12 alkyl and C 3-12 alkenyl.
  • R" adjacent to Y is C 1 alkyl.
  • R" adjacent to Y is C 4-9 alkyl (e.g., C 4 , C 5 , C 6 , C 7 or C 8 or C 9 alkyl).
  • R' is selected from C 4 alkyl and C 4 alkenyl. In certain embodiments, R' is selected from C 5 alkyl and C 5 alkenyl. In some embodiments, R' is selected from C 6 alkyl and C 6 alkenyl. In some embodiments, R' is selected from C 7 alkyl and C 7 alkenyl. In some embodiments, R' is selected from C 9 alkyl and C 9 alkenyl.
  • R' is selected from C 11 alkyl and C 11 alkenyl. In other embodiments, R' is selected from C 12 alkyl, C 12 alkenyl, C 13 alkyl, C 13 alkenyl, C 14 alkyl, C 14 alkenyl, C 15 alkyl, C 15 alkenyl, C 16 alkyl, C 16 alkenyl, C 17 alkyl, C 17 alkenyl, C 18 alkyl, and C 18 alkenyl.
  • R' is branched ( e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl or heptadeca-9-yl).
  • R' is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl or heptadeca-9-yl).
  • R' is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl,
  • R' is unsubstituted C 1-18 alkyl. In certain embodiments, R' is substituted C 1-18 alkyl (e.g., C 1-15 alkyl substituted with a C 3-6 carbocycle such as 1-cyclopropylnonyl).
  • R" is selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl. In some embodiments, R" is C 3 alkyl, C 4 alkyl, C 5 alkyl, C 6 alkyl, C 7 alkyl, or C 8 alkyl. In some embodiments, R" is C 9 alkyl, C 10 alkyl, C 11 alkyl, C 12 alkyl, C 13 alkyl, or C 14 alkyl.
  • M' is -C(O)O-. In some embodiments, M' is -OC(O)-.
  • M' is an aryl group or heteroaryl group.
  • M' may be selected from the group consisting of phenyl, oxazole, and thiazole.
  • M is -C(O)O- In some embodiments, M is -OC(O)-. In some embodiments, M is -C(O)N(R')-. In some embodiments, M is -P(O)(OR')O-.
  • M is an aryl group or heteroaryl group.
  • M may be selected from the group consisting of phenyl, oxazole, and thiazole.
  • M is the same as M'. In other embodiments, M is different from M'.
  • each R 5 is H. In certain such embodiments, each R 6 is also H.
  • R 7 is H. In other embodiments, R 7 is C 1-3 alkyl ( e.g., methyl, ethyl, propyl, or i-propyl).
  • R 2 and R 3 are independently C 5-14 alkyl or C 5-14 alkenyl.
  • R 2 and R 3 are the same. In some embodiments, R 2 and R 3 are Cg alkyl. In certain embodiments, R 2 and R 3 are C 2 alkyl. In other embodiments, R 2 and R 3 are C 3 alkyl. In some embodiments, R 2 and R 3 are C 4 alkyl. In certain embodiments, R 2 and R 3 are C 5 alkyl. In other embodiments, R 2 and R 3 are C 6 alkyl. In some embodiments, R 2 and R 3 are C 7 alkyl.
  • R 2 and R 3 are different.
  • R 2 is C 8 alkyl.
  • R 3 is C 1-7 ( e.g., C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , or C 7 alkyl) or C 9 alkyl.
  • R 7 and R 3 are H.
  • R 2 is H.
  • m is 5, 7, or 9.
  • R 4 is selected from -(CH 2 ) n Q and -(CH 2 ) n CHQR.
  • Q is selected from the group consisting of -OR, -OH, -O(CH 2 ) n N(R) 2 , -OC(O)R, -CX 3 , -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O) 2 R, -N(H)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(H)C(O)N(R) 2 , -N(H)C(O)N(H)(R), -N(R)C(S)N(R) 2 , -N(H)C(S)N(R) 2 , -N(H)C(S)N(H)(R), -C(R)N(R) 2 C(O)OR, a carbocycle, and a heterocycle.
  • Q is -OH.
  • Q is a substituted or unsubstituted 5- to 10- membered heteroaryl, e.g., Q is an imidazole, a pyrimidine, a purine, 2-amino-1,9-dihydro-6 H -purin-6-one-9-yl (or guanin-9-yl), adenin-9-yl, cytosin-1-yl, or uracil-1-yl.
  • Q is 4-methylpiperazinyl, 4-(4-methoxybenzyl)piperazinyl, or isoindolin-2-yl-1,3-dione.
  • Q is an unsubstituted or substituted C 6-10 aryl (such as phenyl) or C 3-6 cycloalkyl.
  • n is 1. In other embodiments, n is 2. In further embodiments, n is 3. In certain other embodiments, n is 4.
  • R 4 may be -(CH 2 ) 2 OH.
  • R 4 may be -(CH 2 ) 3 OH.
  • R 4 may be -(CH 2 ) 4 OH.
  • R 4 may be benzyl.
  • R 4 may be 4-methoxybenzyl.
  • R 4 is a C 3-6 carbocycle. In some embodiments, R 4 is a C 3-6 cycloalkyl.
  • R 4 may be cyclohexyl optionally substituted with e.g ., OH, halo, C 1-6 alkyl, etc.
  • R 4 may be 2-hydroxycyclohexyl.
  • R is H.
  • R is unsubstituted C 1-3 alkyl or unsubstituted C 2-3 alkenyl.
  • R 4 may be -CH 2 CH(OH)CH 3 or -CH 2 CH(OH)CH 2 CH 3 .
  • R is substituted C 1-3 alkyl, e.g ., CH 2 OH.
  • R 4 may be -CH 2 CH(OH)CH 2 OH.
  • R 2 and R 3 together with the atom to which they are attached, form a heterocycle or carbocycle. In some embodiments, R 2 and R 3 , together with the atom to which they are attached, form a 5- to 14- membered aromatic or non-aromatic heterocycle having one or more heteroatoms selected from N, O, S, and P. In some embodiments, R 2 and R 3 , together with the atom to which they are attached, form an optionally substituted C 3-20 carbocycle ( e.g., C 3-18 carbocycle, C 3-15 carbocycle, C 3-12 carbocycle, or C 3-10 carbocycle), either aromatic or non-aromatic.
  • C 3-20 carbocycle e.g., C 3-18 carbocycle, C 3-15 carbocycle, C 3-12 carbocycle, or C 3-10 carbocycle
  • R 2 and R 3 together with the atom to which they are attached, form a C 3-6 carbocycle.
  • R 2 and R 3 together with the atom to which they are attached, form a C 6 carbocycle, such as a cyclohexyl or phenyl group.
  • the heterocycle or C 3-6 carbocycle is substituted with one or more alkyl groups ( e.g., at the same ring atom or at adjacent or non-adjacent ring atoms).
  • R 2 and R 3 together with the atom to which they are attached, may form a cyclohexyl or phenyl group bearing one or more C 5 alkyl substitutions.
  • the heterocycle or C 3-6 carbocycle formed by R 2 and R 3 is substituted with a carbocycle groups.
  • R 2 and R 3 together with the atom to which they are attached, may form a cyclohexyl or phenyl group that is substituted with cyclohexyl.
  • R 2 and R 3 together with the atom to which they are attached, form a C 7-15 carbocycle, such as a cycloheptyl, cyclopentadecanyl, or naphthyl group.
  • R 4 is selected from -(CH 2 ) n Q and -(CH 2 ) n CHQR.
  • Q is selected from the group consisting of -OR, -OH, -O(CH 2 ) n N(R) 2 , -OC(O)R, -CX 3 , -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O) 2 R, -N(H)S(O) 2 R, -N(H)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(H)C(O)N(R) 2 , -N(H)C(O)N(H)(R), -N(R)C(S)N(R) 2 , -N(H)C(S)N(R) 2 , -N(H)C(S)N(H)(R), and a heterocycle
  • R 2 and R 3 together with the atom to which they are attached, form a heterocycle or carbocycle.
  • R 2 and R 3 together with the atom to which they are attached, form a C 3-6 carbocycle, such as a phenyl group.
  • the heterocycle or C 3-6 carbocycle is substituted with one or more alkyl groups ( e.g., at the same ring atom or at adjacent or non-adjacent ring atoms).
  • R 2 and R 3 together with the atom to which they are attached, may form a phenyl group bearing one or more C 5 alkyl substitutions.
  • the pharmaceutical compositions of the present disclosure is selected from the group consisting of: and salts or stereoisomers thereof.
  • the compound of Formula (I) is selected from the group consisting of Compound 1-Compound 147, or salt or stereoisomers thereof.
  • Amine moieties of the lipid compounds disclosed herein can be protonated under certain conditions.
  • the central amine moiety of a lipid according to formula (I) is typically protonated ( i.e., positively charged) at a pH below the pKa of the amino moiety and is substantially not charged at a pH above the pKa.
  • Such lipids may be referred to ionizable amino lipids.
  • the ionizable amino lipid is Compound 18.
EP22204799.5A 2016-05-18 2017-05-18 Polynucleotides codant l'interleukine-12 (il12) et leurs utilisations Pending EP4186518A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662338483P 2016-05-18 2016-05-18
US201762443693P 2017-01-07 2017-01-07
EP17726458.7A EP3458083B1 (fr) 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations
PCT/US2017/033422 WO2017201350A1 (fr) 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP17726458.7A Division EP3458083B1 (fr) 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4186518A1 true EP4186518A1 (fr) 2023-05-31

Family

ID=58794205

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22204799.5A Pending EP4186518A1 (fr) 2016-05-18 2017-05-18 Polynucleotides codant l'interleukine-12 (il12) et leurs utilisations
EP17726458.7A Active EP3458083B1 (fr) 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP17726458.7A Active EP3458083B1 (fr) 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations

Country Status (22)

Country Link
US (5) US10646549B2 (fr)
EP (2) EP4186518A1 (fr)
JP (2) JP7246930B2 (fr)
KR (2) KR20220159479A (fr)
CN (1) CN109195621A (fr)
AU (1) AU2017268397B2 (fr)
CA (1) CA3024470A1 (fr)
DK (1) DK3458083T3 (fr)
ES (1) ES2941411T3 (fr)
FI (1) FI3458083T3 (fr)
HR (1) HRP20230050T1 (fr)
HU (1) HUE061077T2 (fr)
IL (1) IL262501A (fr)
LT (1) LT3458083T (fr)
MX (2) MX2018013509A (fr)
PL (1) PL3458083T3 (fr)
PT (1) PT3458083T (fr)
RS (1) RS63912B1 (fr)
RU (1) RU2769316C2 (fr)
SG (1) SG11201809381XA (fr)
SI (1) SI3458083T1 (fr)
WO (1) WO2017201350A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2935960C (fr) 2014-01-08 2023-01-10 Bart Lipkens Dispositif d'acoustophorese avec double chambre acoustophoretique
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
SI3718565T1 (sl) 2015-10-22 2022-08-31 Modernatx, Inc. Cepiva za respiratorni virus
JP7114465B2 (ja) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
DK3458083T3 (da) 2016-05-18 2023-01-30 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018107088A2 (fr) * 2016-12-08 2018-06-14 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
AU2018234692B2 (en) * 2017-03-15 2022-06-02 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3055653A1 (fr) * 2017-03-15 2018-09-20 Modernatx, Inc. Formulation de nanoparticules lipidiques
DK3596042T3 (da) 2017-03-15 2022-04-11 Modernatx Inc Krystalformer af aminolipider
WO2018187590A1 (fr) 2017-04-05 2018-10-11 Modernatx, Inc. Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
CA3063723A1 (fr) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides codant pour des polypeptides d'interleukine-12 (il12) ancres et leurs utilisations
EP3638215A4 (fr) 2017-06-15 2021-03-24 Modernatx, Inc. Formulations d'arn
EP3668971B1 (fr) 2017-08-18 2024-04-10 ModernaTX, Inc. Variants d'arn polymérase
EP3668977A4 (fr) 2017-08-18 2021-04-21 Modernatx, Inc. Procédés analytiques par hplc
WO2019036685A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Procédés pour analyse par clhp
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
US20210155928A1 (en) * 2018-05-31 2021-05-27 Beth Israel Deaconess Medical Center Rna-aided immunotherapeutics
US20200080106A1 (en) 2018-06-06 2020-03-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
WO2020051223A1 (fr) 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Compositions et procédés pour l'administration spécifique d'un organe d'acides nucléiques
JP2021535226A (ja) * 2018-09-04 2021-12-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
AU2019338535A1 (en) * 2018-09-14 2021-04-15 Modernatx, Inc. Methods and compositions for treating cancer using mRNA therapeutics
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
US11026894B2 (en) 2019-01-10 2021-06-08 Massachusetts Institute Of Technology Lipid nanoparticles and use thereof to deliver RNA polynucleotides
SG11202110007VA (en) * 2019-03-14 2021-10-28 Engene Inc Reversible coating of chitosan-nucleic acid nanoparticles and methods of their use
CN109932511B (zh) * 2019-03-22 2020-02-04 南昌大学第二附属医院 用于肝癌筛查的尿液外泌体磷脂标志物及其试剂盒
WO2020209934A1 (fr) * 2019-04-11 2020-10-15 Massachusetts Institute Of Technology Nouveaux récepteurs antigéniques chimériques et banques
AU2020280105A1 (en) 2019-05-22 2022-01-20 Massachusetts Institute Of Technology Circular RNA compositions and methods
MX2022003269A (es) 2019-09-19 2022-07-04 Modernatx Inc Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos.
ES2961245T3 (es) 2019-12-04 2024-03-11 Orna Therapeutics Inc Composiciones y métodos de ARN circular
AU2021222036A1 (en) * 2020-02-19 2022-09-22 University Of Florida Research Foundation, Incorporated Multilamellar RNA nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors
MX2022010084A (es) * 2020-02-21 2022-12-07 Combined Therapeutics Inc Composiciones y métodos para la expresión y modulación protectoras de órganos de ácidos ribonucleicos codificantes.
EP4077272A1 (fr) 2020-04-09 2022-10-26 Suzhou Abogen Biosciences Co., Ltd. Compositions de nanoparticules lipidiques
TW202204622A (zh) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 針對冠狀病毒之核酸疫苗
JP2023526408A (ja) 2020-05-17 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 調節された遺伝子治療のためのウイルスベクター及び核酸
WO2022020811A1 (fr) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Nanoparticule de nanoparticule lipidique comprenant des nucléotides modifiés
AR124599A1 (es) 2021-01-08 2023-04-12 Strand Therapeutics Inc Constructos de expresión y usos de estos
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
CA3188711A1 (fr) * 2021-05-06 2022-11-10 Yunsong CAI Lipide
AU2022336209A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN116829578A (zh) * 2021-10-08 2023-09-29 苏州艾博生物科技有限公司 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法
WO2023073228A1 (fr) 2021-10-29 2023-05-04 CureVac SE Arn circulaire amélioré pour exprimer des protéines thérapeutiques
CN116179549A (zh) 2021-12-08 2023-05-30 南京吉迈生物技术有限公司 通过5’utr序列变体修饰基因转录和翻译效率
CN114957027B (zh) * 2022-01-13 2023-05-19 北京悦康科创医药科技股份有限公司 一种阳离子脂质化合物、包含其的组合物及用途
WO2023144330A1 (fr) 2022-01-28 2023-08-03 CureVac SE Inhibiteurs de facteurs de transcription codés par un acide nucleique
WO2023196988A1 (fr) * 2022-04-07 2023-10-12 Modernatx, Inc. Procédés d'utilisation d'arnm codant pour il-12
CN116621965A (zh) * 2022-05-06 2023-08-22 珠海丽凡达生物技术有限公司 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
CN114994331B (zh) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 一种检测蛋白表达水平的试剂盒及其制备方法和应用
WO2023227608A1 (fr) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli

Citations (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
WO1999024595A1 (fr) 1997-11-12 1999-05-20 The Brigham And Women's Hospital, Inc. Element amplificateur de traduction du gene de la proteine precurseur amyloide humaine
WO2000018778A1 (fr) 1998-09-29 2000-04-06 Phylos, Inc. Synthese d'acides nucleiques fondee sur une generation aleatoire de codons
WO2001055371A1 (fr) 2000-01-28 2001-08-02 The Scripps Research Institute Procedes pour identifier des elements regulateurs transcriptionnels et translationnels synthetiques, et compositions correspondantes
US6617106B1 (en) 1990-10-09 2003-09-09 Steven Albert Benner Methods for preparing oligonucleotides containing non-standard nucleotides
US20050032730A1 (en) 2001-06-05 2005-02-10 Florian Von Der Mulbe Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
US20050059005A1 (en) 2001-09-28 2005-03-17 Thomas Tuschl Microrna molecules
US20050261218A1 (en) 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
US20070048776A1 (en) 2005-08-24 2007-03-01 The Scripps Research Institute Translation enhancer-element dependent vector systems
US20070117112A1 (en) 2005-06-30 2007-05-24 Diener John L Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
WO2007081740A2 (fr) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Méthodes et compositions basés sur des micro-arn et s'appliquant au diagnostic et au traitement de cancers solides
WO2007113648A2 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polythérapie à base d'un anticorps anti-ctla4
US20080046192A1 (en) 2006-08-16 2008-02-21 Richard Lathrop Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same
US20080076161A1 (en) 2002-04-01 2008-03-27 The Government Of The United States, As Represented By The Secretary Of The Army Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
WO2008054828A2 (fr) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Signature de l'expression de microarn pour la prédiction de la survie et des métastases dans le carcinome hépato-cellulaire
US7378262B2 (en) 2001-12-03 2008-05-27 Roche Molecular Systems, Inc. Reversibly modified thermostable enzymes for DNA synthesis and amplification in vitro
US7384739B2 (en) 2001-11-14 2008-06-10 Toyo Boseki Kabushiki Kaisha Compositions for enhancing DNA synthesis, DNA polymerase-related factors and utilization thereof
WO2008073915A2 (fr) 2006-12-08 2008-06-19 Asuragen, Inc. Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
WO2008078180A2 (fr) 2006-12-22 2008-07-03 Archemix Corp. Matériaux et procédés pour la génération de transcrits comprenant des nucléotides modifiés
WO2008154098A2 (fr) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Réactifs et procédés permettant une analyse d'expression d'arnmi et identification de biomarqueurs de cancer
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
US20090131348A1 (en) 2006-09-19 2009-05-21 Emmanuel Labourier Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2009070653A1 (fr) 2007-11-30 2009-06-04 The Ohio State University Research Foundation Profilage et criblage d'expression de micro-arn dans du sang périphérique dans un cancer du poumon
WO2009075886A1 (fr) 2007-12-11 2009-06-18 The Scripps Research Institute Compositions et procédés concernant des éléments activateurs de traduction de l'arnm
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
WO2009100430A2 (fr) 2008-02-08 2009-08-13 Asuragen, Inc Micro arn (mirna) exprimés différentiellement dans des nœuds lymphoïdes prélevés chez des patients atteints d’un cancer
EP2112235A1 (fr) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions et procédés pour le profilage de l'expression de microARN du carcinome du nasopharynx
WO2010018563A2 (fr) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions et procédés de pronostic d'un lymphome
US20100120024A1 (en) 2005-06-30 2010-05-13 Sharon Cload Materials and methods for the generation of transcripts comprising modified nucleotides
US20100129877A1 (en) 2005-09-28 2010-05-27 Ugur Sahin Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency
US20100286232A1 (en) 2006-03-02 2010-11-11 The Ohio State University Microrna expression profile associated with pancreatic cancer
US20100293625A1 (en) 2007-09-26 2010-11-18 Interexon Corporation Synthetic 5'UTRs, Expression Vectors, and Methods for Increasing Transgene Expression
US20110082055A1 (en) 2009-09-18 2011-04-07 Codexis, Inc. Reduced codon mutagenesis
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2011076142A1 (fr) 2009-12-24 2011-06-30 Fudan University Compositions et procédés pour le profilage de l'expression de micro-arn dans un plasma d'un cancer colorectal
WO2011076143A1 (fr) 2009-12-24 2011-06-30 Fudan University Compositions et méthodes de profilage du cancer du poumon par expression de microarn
WO2011095623A2 (fr) 2010-02-05 2011-08-11 Febit Holding Gmbh Miarn dans le diagnostic du cancer ovarien
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2011157294A1 (fr) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions destinées à être utilisées dans le traitement ou la prévention de cancer, de cancer du sein, de cancer du poumon, de cancer de l'ovaire, de métastase, d'insuffisance cardiaque, de remodelage cardiaque, de myocardiopathie dilatée, de maladies auto-immunes ou de maladies ou de troubles apparentés
WO2012009644A2 (fr) 2010-07-16 2012-01-19 Arizona Board Of Regents Procédés pour identifier des éléments d'arn synthétiques et naturels qui améliorent la traduction des protéines
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US20120053224A1 (en) 2008-12-10 2012-03-01 Universitat Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
WO2012081756A1 (fr) 2010-12-15 2012-06-21 주식회사 롤팩 Film co-extrudé d'emballage sous vide antimicrobien possédant une structure à sept couches et procédé de fabrication associé
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
WO2012122444A1 (fr) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combinaison de thérapies immunomodulatrices locales et systémiques pour l'amélioration du traitement du cancer
US8278036B2 (en) 2005-08-23 2012-10-02 The Trustees Of The University Of Pennsylvania RNA containing modified nucleosides and methods of use thereof
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
US20120264626A1 (en) 2009-05-08 2012-10-18 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
US20120283310A1 (en) 2008-02-28 2012-11-08 Croce Carlo M MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CLL) and Uses Thereof
WO2012151212A1 (fr) 2011-05-01 2012-11-08 University Of Rochester SCHÉMAS D'EXPRESSION DU microARN DANS LE CARCINOME HÉPATOCELLULAIRE MULTIFOCAL ET LEURS UTILISATIONS
US20120316081A1 (en) 2010-01-29 2012-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of Identifying Myelodysplastic Syndromes
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2013011378A1 (fr) 2011-07-15 2013-01-24 Leo Pharma A/S Profilage diagnostique de microarn dans le lymphome cutané à cellules t (ctcl)
US8367328B2 (en) 1998-04-23 2013-02-05 Takara Bio Inc. Method for synthesizing DNA
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
US20130053263A1 (en) 2009-12-30 2013-02-28 Febit Holding Gmbh miRNA FINGERPRINT IN THE DIAGNOSIS OF COPD
US8389210B2 (en) 2006-01-05 2013-03-05 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2013033640A1 (fr) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Procédés et compositions pour la détection du cancer sur la base de profils d'expression de miarn
US8401798B2 (en) 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
WO2013039857A1 (fr) 2011-09-12 2013-03-21 modeRNA Therapeutics Acides nucléiques modifiés et leurs procédés d'utilisation
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
WO2013052523A1 (fr) 2011-10-03 2013-04-11 modeRNA Therapeutics Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
WO2013066678A1 (fr) 2011-10-26 2013-05-10 Georgetown University Profilage de l'expression du microarn du cancer de la thyroïde
US20130183718A1 (en) 2010-09-21 2013-07-18 RibpxX GmbH Method for Synthesizing RNA using DNA Template
US8519110B2 (en) 2008-06-06 2013-08-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College mRNA cap analogs
US20130259923A1 (en) 2012-04-02 2013-10-03 modeRNA Therapeutics Modified polynucleotides for the production of secreted proteins
WO2013173223A1 (fr) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Immunothérapie anticancéreuse par rupture de la signalisation pd-1/pd-l1
US8609089B2 (en) 2008-08-25 2013-12-17 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2014028429A2 (fr) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes et polymérases destinées à la synthèse d'arn
WO2014093924A1 (fr) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Molécules d'acide nucléique modifiées et leurs utilisations
US20140200261A1 (en) 2013-01-17 2014-07-17 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20140228558A1 (en) 2002-12-23 2014-08-14 Geneart Ag Method and device for optimizing a nucelotide sequence for the purpose of expression in a protein
WO2014164253A1 (fr) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Régions non traduites hétérologues pour arnm
US20140341917A1 (en) 2011-11-28 2014-11-20 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US8900587B2 (en) 2007-06-18 2014-12-02 Merck Sharp & Dohme Corp. Antibodies to human programmed death receptor PD-1
WO2015024667A1 (fr) 2013-08-21 2015-02-26 Curevac Gmbh Procédé pour augmenter l'expression de protéines codées par l'arn
US20150079109A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
WO2015062738A1 (fr) 2013-11-01 2015-05-07 Curevac Gmbh Arn modifié à propriétés immunostimulantes réduites
WO2015095249A1 (fr) * 2013-12-18 2015-06-25 Intrexon Corporation Acides nucléiques d'il-12 monocaténaires, polypeptides d'il-12 monocaténaires, et leurs utilisations
WO2015101414A2 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Molécules d'acides nucléiques artificielles
WO2015101415A1 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Molécules d'acides nucléiques artificielles
WO2016170176A1 (fr) * 2015-04-22 2016-10-27 Curevac Ag Composition contenant de l'arn pour le traitement de maladies tumorales
WO2017049245A2 (fr) 2015-09-17 2017-03-23 Modernatx, Inc. Composés et compositions pour l'administration intracellulaire d'agents thérapeutiques

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
CA2268276A1 (fr) 1996-10-18 1998-04-30 Jeff Nordstrom Expression de genes, systemes d'apport et utilisations
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
CA2309766C (fr) 1997-11-20 2008-09-30 Vical Incorporated Traitement du cancer au moyen de polynucleotides exprimant la cytokine et compositions prevues a cet effet
WO2000015249A1 (fr) 1998-09-15 2000-03-23 Genetics Institute, Inc. Traitement de la maladie de kaposi avec il-12
DE60113805T2 (de) 2000-01-20 2006-07-13 Universität Zürich Institut für Medizinische Virologie Intratumorale Verabreichung nackter IL-12 codierender Nucleinsäuremoleküle
ES2164011B1 (es) 2000-02-25 2003-05-16 Inst Cientifico Tecnol Navarra Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
CN1281748C (zh) 2000-03-15 2006-10-25 格纳西尼有限公司 为改善IL－12活性而突变的IL－12p40亚基基因及其作为DNA疫苗佐剂的用途
KR20020010206A (ko) 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신
US6875611B2 (en) 2001-07-03 2005-04-05 University Of Utah Research Foundation Soluble steroidal peptides for nucleic acid delivery
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
DE10248141B4 (de) 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
CA2527869A1 (fr) 2003-05-30 2004-12-23 University Of South Florida Methode de traitement de tumeurs malignes
GB0329146D0 (en) 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
EP1640018A1 (fr) 2004-09-24 2006-03-29 Universität Zürich Thérapie combinatoire pour le traitement du cancer
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
JP5175214B2 (ja) 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 改良された安定性を有するインターロイキン−１２ｐ４０変種
US7833754B2 (en) 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
KR101241477B1 (ko) 2006-01-27 2013-03-08 엘지이노텍 주식회사 질화물 반도체 발광소자 및 그 제조 방법
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
EP3293266A1 (fr) 2007-05-04 2018-03-14 University Health Network Immunothérapie par il-12 pour le cancer
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
TWI359030B (en) 2007-08-24 2012-03-01 Univ Nat Taiwan Treatment of cellular proliferative disorders
PT2201100E (pt) 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
WO2009039198A2 (fr) 2007-09-17 2009-03-26 The Trustees Of The University Of Pennsylvania Production d'arnm hyperstables
EP2205282A2 (fr) * 2007-09-24 2010-07-14 Bar-Ilan University Nanoparticules de polymère revêtues d'oxyde métallique magnétique et utilisations de celles-ci
EP2072618A1 (fr) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Utilisation d'ARN pour la reprogrammation de cellules somatiques
EP2224912B1 (fr) * 2008-01-02 2016-05-11 TEKMIRA Pharmaceuticals Corporation Compositions et procédés améliorés pour la délivrance d'acides nucléiques
NZ588583A (en) * 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
WO2009140206A1 (fr) 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Expression améliorée d'hétérodimères de la famille il-12
WO2009149539A1 (fr) 2008-06-10 2009-12-17 Université de Montréal Amplification de la réponse de lymphocytes t cd8+ spécifiques d’un antigène à l’aide d’arnm d’irf‑7
US9074206B2 (en) 2008-11-13 2015-07-07 Fudan University Compositions and methods for micro-RNA expression profiling of colorectal cancer
EP2424887B1 (fr) 2009-04-30 2015-09-30 The U.S.A. as represented by the Secretary, Department of Health and Human Services Interleukine-12 inductible
CN104873464B (zh) 2009-06-10 2018-06-22 阿布特斯生物制药公司 改进的脂质制剂
CN105255881A (zh) 2009-07-31 2016-01-20 埃泽瑞斯公司 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna
EP2281579A1 (fr) 2009-08-05 2011-02-09 BioNTech AG Composition de vaccin comportant un ADN modifié 5'-Cap
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
WO2012072096A1 (fr) 2010-12-03 2012-06-07 Biontech Ag Procédé pour l'expression cellulaire d'arn
WO2012103985A2 (fr) 2010-12-16 2012-08-09 Steve Pascolo Composition pharmaceutique à base d'arn qui comprend un métal alcalin en tant que contre-ion et formulé avec des dications
WO2012116714A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des patients âgés
US9281930B2 (en) 2011-05-02 2016-03-08 Lg Electronics Inc. Method for transmitting/receiving data in wireless access system and base station for same
SI2717893T1 (sl) 2011-06-08 2019-10-30 Translate Bio Inc Sestavki lipidnih nanodelcev in postopki za dostavo mRNA
ES2888249T3 (es) 2011-10-11 2022-01-03 Univ Zuerich Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral
KR102101819B1 (ko) 2011-12-12 2020-04-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
EP2623121A1 (fr) 2012-01-31 2013-08-07 Bayer Innovation GmbH Composition pharmaceutique comportant un complexe de chargement de porteur polymérique et un antigène
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
EP2672197A1 (fr) 2012-06-06 2013-12-11 Hörmann Energietechnik GmbH & Co. KG Agencement de montage pour le montage sur le toit de corps de surface sur une construction
JP6561378B2 (ja) 2012-06-08 2019-08-21 トランスレイト バイオ， インコーポレイテッド 非肺標的細胞へのｍＲＮＡの経肺送達
EP3536787A1 (fr) 2012-06-08 2019-09-11 Translate Bio, Inc. Polynucléotides résistant aux nucléases et leurs utilisations
US20140020675A1 (en) 2012-07-18 2014-01-23 Chandrashekhar Sonwane Solar receiver
CN102876684B (zh) * 2012-09-17 2014-10-08 青岛康立泰药业有限公司 人白细胞介素-12的编码基因、真核宿主细胞和表达方法
WO2014071963A1 (fr) 2012-11-09 2014-05-15 Biontech Ag Procédé pour l'expression d'arn cellulaire
ES2921623T3 (es) * 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EP2929035A1 (fr) 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Nanoparticules lipidiques pour administration de marn
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
US10124065B2 (en) 2013-03-08 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3495505A1 (fr) 2013-03-14 2019-06-12 Translate Bio, Inc. Évaluation quantitative de l'efficacité de coiffe d'arn messager
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
AU2014239184B2 (en) 2013-03-14 2018-11-08 Translate Bio, Inc. Methods and compositions for delivering mRNA coded antibodies
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
WO2014152940A1 (fr) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Compositions thérapeutiques à base d'arnm et leur utilisation pour traiter des maladies et des troubles
WO2014152513A1 (fr) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Acides ribonucléiques ayant des nucléotides 4'-thio-modifiés et procédés associés
BR112015022505A2 (pt) 2013-03-14 2017-10-24 Shire Human Genetic Therapies avaliação quantitativa para eficiência do cap de rna mensageiro
EP2972360B1 (fr) 2013-03-15 2018-03-07 Translate Bio, Inc. Stimulation synergique de l'administration d'acides nucléiques par le biais de formulations mélangées
US20160367651A1 (en) 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
AU2014337156A1 (en) 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
CA2928078A1 (fr) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Formulations de lipide pour l'administration d'arn messager
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SG11201608798YA (en) * 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
PL3766916T3 (pl) * 2014-06-25 2023-02-27 Acuitas Therapeutics Inc. Nowe lipidy i formulacje nanocząstek lipidowych do dostarczania kwasów nukleinowych
SG11201702295UA (en) 2014-09-22 2017-04-27 Intrexon Corp Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
WO2016123573A1 (fr) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Matériaux péritumoraux et intratumoraux pour traitement anticancéreux
CA2985087C (fr) 2015-05-19 2021-02-16 Morphogenesis, Inc. Vaccin contre le cancer comportant un arnm codant pour une proteine du type m
US10682401B2 (en) 2015-05-19 2020-06-16 Morphogenesis, Inc. Multi-indication mRNA cancer immunotherapy
EP3205356A1 (fr) 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Vecteur d'expression plasmidique codant l'interleukine humain 12 sous le contrôle transcriptionnel d'un promoteur p21 et sans la résistance aux antibiotiques pour la thérapie génique du cancer et d'autres utilisations
EP3211000B1 (fr) 2016-02-25 2019-01-30 Provecs Medical GmbH Nouveau système de vecteur immunostimulant
DK3458083T3 (da) 2016-05-18 2023-01-30 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
JP2019532648A (ja) 2016-10-07 2019-11-14 ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム がんの治療のための膜係留ｉｌ−１２を発現しているｔ細胞

Patent Citations (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US6617106B1 (en) 1990-10-09 2003-09-09 Steven Albert Benner Methods for preparing oligonucleotides containing non-standard nucleotides
WO1999024595A1 (fr) 1997-11-12 1999-05-20 The Brigham And Women's Hospital, Inc. Element amplificateur de traduction du gene de la proteine precurseur amyloide humaine
US6310197B1 (en) 1997-11-12 2001-10-30 The Brigham And Women's Hospital, Inc. Translation enhancer element of the human amyloid precursor protein gene
US6849405B2 (en) 1997-11-12 2005-02-01 The Brigham And Women's Hospital, Inc. Translation enhancer element of the human amyloid precursor protein gene
US8367328B2 (en) 1998-04-23 2013-02-05 Takara Bio Inc. Method for synthesizing DNA
WO2000018778A1 (fr) 1998-09-29 2000-04-06 Phylos, Inc. Synthese d'acides nucleiques fondee sur une generation aleatoire de codons
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
US7183395B2 (en) 2000-01-28 2007-02-27 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
US20090093049A1 (en) 2000-01-28 2009-04-09 The Scripps Research Institute Methods of Identifying Synthetic Transcriptional and Translational Regulatory Elements, and Compositions Related to Same
WO2001055369A1 (fr) 2000-01-28 2001-08-02 The Scripps Research Institute Sites d'entree internes du ribosome de synthese et procedes d'identification correspondants
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
US7456273B2 (en) 2000-01-28 2008-11-25 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
WO2001055371A1 (fr) 2000-01-28 2001-08-02 The Scripps Research Institute Procedes pour identifier des elements regulateurs transcriptionnels et translationnels synthetiques, et compositions correspondantes
US20050032730A1 (en) 2001-06-05 2005-02-10 Florian Von Der Mulbe Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
US20050059005A1 (en) 2001-09-28 2005-03-17 Thomas Tuschl Microrna molecules
US7384739B2 (en) 2001-11-14 2008-06-10 Toyo Boseki Kabushiki Kaisha Compositions for enhancing DNA synthesis, DNA polymerase-related factors and utilization thereof
US7378262B2 (en) 2001-12-03 2008-05-27 Roche Molecular Systems, Inc. Reversibly modified thermostable enzymes for DNA synthesis and amplification in vitro
US20080076161A1 (en) 2002-04-01 2008-03-27 The Government Of The United States, As Represented By The Secretary Of The Army Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
US20140228558A1 (en) 2002-12-23 2014-08-14 Geneart Ag Method and device for optimizing a nucelotide sequence for the purpose of expression in a protein
US20050261218A1 (en) 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
US20100120024A1 (en) 2005-06-30 2010-05-13 Sharon Cload Materials and methods for the generation of transcripts comprising modified nucleotides
US20070117112A1 (en) 2005-06-30 2007-05-24 Diener John L Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US8278036B2 (en) 2005-08-23 2012-10-02 The Trustees Of The University Of Pennsylvania RNA containing modified nucleosides and methods of use thereof
US8748089B2 (en) 2005-08-23 2014-06-10 The Trustees Of The University Of Pennsylvania RNA containing modified nucleosides and methods of use thereof
US8835108B2 (en) 2005-08-23 2014-09-16 The Trustees Of The University Of Pennsylvania RNA containing modified nucleosides and methods of use thereof
US20070048776A1 (en) 2005-08-24 2007-03-01 The Scripps Research Institute Translation enhancer-element dependent vector systems
WO2007025008A2 (fr) 2005-08-24 2007-03-01 The Scripps Research Institute Systemes de vecteurs dependant d'elements d'activation traductionnelle
US20110124100A1 (en) 2005-08-24 2011-05-26 The Scripps Research Institute Translation enhancer-element dependent vector systems
US20100129877A1 (en) 2005-09-28 2010-05-27 Ugur Sahin Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency
US8389210B2 (en) 2006-01-05 2013-03-05 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
US20120214699A1 (en) 2006-01-05 2012-08-23 The Ohio State University Methods for Diagnosing Breast Cancer Using MicroRNA Signatures
WO2007081740A2 (fr) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Méthodes et compositions basés sur des micro-arn et s'appliquant au diagnostic et au traitement de cancers solides
US20110171646A1 (en) 2006-03-02 2011-07-14 The Ohio State University Research Foundation Microrna expression profile associated with pancreatic cancer
US20100286232A1 (en) 2006-03-02 2010-11-11 The Ohio State University Microrna expression profile associated with pancreatic cancer
WO2007113648A2 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polythérapie à base d'un anticorps anti-ctla4
US20080046192A1 (en) 2006-08-16 2008-02-21 Richard Lathrop Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same
US20090131348A1 (en) 2006-09-19 2009-05-21 Emmanuel Labourier Micrornas differentially expressed in pancreatic diseases and uses thereof
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008054828A2 (fr) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Signature de l'expression de microarn pour la prédiction de la survie et des métastases dans le carcinome hépato-cellulaire
US20120329672A1 (en) 2006-11-01 2012-12-27 Croce Carlo M MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma
WO2008073915A2 (fr) 2006-12-08 2008-06-19 Asuragen, Inc. Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
US20090092974A1 (en) 2006-12-08 2009-04-09 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
WO2008078180A2 (fr) 2006-12-22 2008-07-03 Archemix Corp. Matériaux et procédés pour la génération de transcrits comprenant des nucléotides modifiés
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
WO2008154098A2 (fr) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Réactifs et procédés permettant une analyse d'expression d'arnmi et identification de biomarqueurs de cancer
US8900587B2 (en) 2007-06-18 2014-12-02 Merck Sharp & Dohme Corp. Antibodies to human programmed death receptor PD-1
US20100293625A1 (en) 2007-09-26 2010-11-18 Interexon Corporation Synthetic 5'UTRs, Expression Vectors, and Methods for Increasing Transgene Expression
WO2009070653A1 (fr) 2007-11-30 2009-06-04 The Ohio State University Research Foundation Profilage et criblage d'expression de micro-arn dans du sang périphérique dans un cancer du poumon
US20100323357A1 (en) 2007-11-30 2010-12-23 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
EP2610341A1 (fr) 2007-12-11 2013-07-03 The Scripps Research Institute Compositions et procédés concernant des éléments activateurs de traduction de l'ARNm
US20090226470A1 (en) 2007-12-11 2009-09-10 Mauro Vincent P Compositions and methods related to mRNA translational enhancer elements
EP2610340A1 (fr) 2007-12-11 2013-07-03 The Scripps Research Institute Compositions et procédés concernant des éléments activateurs de traduction de l'ARNm
WO2009075886A1 (fr) 2007-12-11 2009-06-18 The Scripps Research Institute Compositions et procédés concernant des éléments activateurs de traduction de l'arnm
US20130177581A1 (en) 2007-12-11 2013-07-11 The Scripps Research Institute Compositions and Methods Related to mRNA Translational Enhancer Elements
WO2009100430A2 (fr) 2008-02-08 2009-08-13 Asuragen, Inc Micro arn (mirna) exprimés différentiellement dans des nœuds lymphoïdes prélevés chez des patients atteints d’un cancer
US20090263803A1 (en) 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
US20120283310A1 (en) 2008-02-28 2012-11-08 Croce Carlo M MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CLL) and Uses Thereof
EP2112235A1 (fr) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions et procédés pour le profilage de l'expression de microARN du carcinome du nasopharynx
US8401798B2 (en) 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
US8519110B2 (en) 2008-06-06 2013-08-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College mRNA cap analogs
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
WO2010018563A2 (fr) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions et procédés de pronostic d'un lymphome
US8609089B2 (en) 2008-08-25 2013-12-17 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
US20120053224A1 (en) 2008-12-10 2012-03-01 Universitat Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
US20120264626A1 (en) 2009-05-08 2012-10-18 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
US20110082055A1 (en) 2009-09-18 2011-04-07 Codexis, Inc. Reduced codon mutagenesis
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011076143A1 (fr) 2009-12-24 2011-06-30 Fudan University Compositions et méthodes de profilage du cancer du poumon par expression de microarn
WO2011076142A1 (fr) 2009-12-24 2011-06-30 Fudan University Compositions et procédés pour le profilage de l'expression de micro-arn dans un plasma d'un cancer colorectal
US20130053263A1 (en) 2009-12-30 2013-02-28 Febit Holding Gmbh miRNA FINGERPRINT IN THE DIAGNOSIS OF COPD
US20130053264A1 (en) 2009-12-30 2013-02-28 Febit Holding Gmbh Mirna fingerprint in the diagnosis of prostate cancer
US20120316081A1 (en) 2010-01-29 2012-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of Identifying Myelodysplastic Syndromes
US20120309645A1 (en) 2010-02-05 2012-12-06 Febit Holding Gmbh miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2011095623A2 (fr) 2010-02-05 2011-08-11 Febit Holding Gmbh Miarn dans le diagnostic du cancer ovarien
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011157294A1 (fr) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions destinées à être utilisées dans le traitement ou la prévention de cancer, de cancer du sein, de cancer du poumon, de cancer de l'ovaire, de métastase, d'insuffisance cardiaque, de remodelage cardiaque, de myocardiopathie dilatée, de maladies auto-immunes ou de maladies ou de troubles apparentés
WO2012009644A2 (fr) 2010-07-16 2012-01-19 Arizona Board Of Regents Procédés pour identifier des éléments d'arn synthétiques et naturels qui améliorent la traduction des protéines
US20130183718A1 (en) 2010-09-21 2013-07-18 RibpxX GmbH Method for Synthesizing RNA using DNA Template
WO2012081756A1 (fr) 2010-12-15 2012-06-21 주식회사 롤팩 Film co-extrudé d'emballage sous vide antimicrobien possédant une structure à sept couches et procédé de fabrication associé
US20120263677A1 (en) 2011-03-10 2012-10-18 Provectus Pharmaceuticals, Inc. Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
WO2012122444A1 (fr) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combinaison de thérapies immunomodulatrices locales et systémiques pour l'amélioration du traitement du cancer
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2012151212A1 (fr) 2011-05-01 2012-11-08 University Of Rochester SCHÉMAS D'EXPRESSION DU microARN DANS LE CARCINOME HÉPATOCELLULAIRE MULTIFOCAL ET LEURS UTILISATIONS
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
WO2013011378A1 (fr) 2011-07-15 2013-01-24 Leo Pharma A/S Profilage diagnostique de microarn dans le lymphome cutané à cellules t (ctcl)
WO2013033640A1 (fr) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Procédés et compositions pour la détection du cancer sur la base de profils d'expression de miarn
WO2013039857A1 (fr) 2011-09-12 2013-03-21 modeRNA Therapeutics Acides nucléiques modifiés et leurs procédés d'utilisation
US20130115272A1 (en) 2011-10-03 2013-05-09 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013052523A1 (fr) 2011-10-03 2013-04-11 modeRNA Therapeutics Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
WO2013066678A1 (fr) 2011-10-26 2013-05-10 Georgetown University Profilage de l'expression du microarn du cancer de la thyroïde
US20140341917A1 (en) 2011-11-28 2014-11-20 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013151671A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines et de peptides cosmétiques
US20130259923A1 (en) 2012-04-02 2013-10-03 modeRNA Therapeutics Modified polynucleotides for the production of secreted proteins
WO2013173223A1 (fr) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Immunothérapie anticancéreuse par rupture de la signalisation pd-1/pd-l1
WO2014028429A2 (fr) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes et polymérases destinées à la synthèse d'arn
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
WO2014093924A1 (fr) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Molécules d'acide nucléique modifiées et leurs utilisations
US20140200261A1 (en) 2013-01-17 2014-07-17 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014164253A1 (fr) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Régions non traduites hétérologues pour arnm
WO2015024667A1 (fr) 2013-08-21 2015-02-26 Curevac Gmbh Procédé pour augmenter l'expression de protéines codées par l'arn
US20150079109A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
WO2015062738A1 (fr) 2013-11-01 2015-05-07 Curevac Gmbh Arn modifié à propriétés immunostimulantes réduites
WO2015095249A1 (fr) * 2013-12-18 2015-06-25 Intrexon Corporation Acides nucléiques d'il-12 monocaténaires, polypeptides d'il-12 monocaténaires, et leurs utilisations
WO2015101414A2 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Molécules d'acides nucléiques artificielles
WO2015101415A1 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Molécules d'acides nucléiques artificielles
WO2016170176A1 (fr) * 2015-04-22 2016-10-27 Curevac Ag Composition contenant de l'arn pour le traitement de maladies tumorales
WO2017049245A2 (fr) 2015-09-17 2017-03-23 Modernatx, Inc. Composés et compositions pour l'administration intracellulaire d'agents thérapeutiques

Non-Patent Citations (119)

* Cited by examiner, † Cited by third party
Title
A. R. GENNARO: "Remington: The Science and Practice of Pharmacy", 2006, LIPPINCOTT, WILLIAMS & WILKINS
ALEXOPOULOU ET AL., NATURE, vol. 413, 2001, pages 732 - 738
AL-ZOGHAIBI ET AL., GENE, vol. 391, no. 1-2, 2007, pages 130 - 9
ANANDCHERESH, CURR OPIN HEMATOL, vol. 18, 2011, pages 171 - 176
ANDREAS M REICHMUTH ET AL: "mRNA vaccine delivery using lipid nanoparticles", THERAPEUTIC DELIVERY, vol. 7, no. 5, 1 May 2016 (2016-05-01), GB, pages 319 - 334, XP055401839, ISSN: 2041-5990, DOI: 10.4155/tde-2016-0006 *
ANDRIES ET AL., J. CONTROL. RELEASE, vol. 217, 2015, pages 337 - 344
ANDRIES ET AL., MOL. PHARM., vol. 9, no. 8, 2012, pages 2136 - 2145
ASSELIN-PATUREL, C., CANCER, vol. 91, 2001, pages 113 - 122
BAR M ET AL., STEM CELLS, vol. 26, 2008, pages 2496 - 2505
BARTEL, CELL, vol. 136, 2009, pages 215 - 233
BONAUER ET AL., CURR DRUG TARGETS, vol. 11, 2010, pages 943 - 949
BOROS ET AL., J. PHOTOCHEM. PHOTOBIOL. B., vol. 129, 2013, pages 93 - 99
BOROS ET AL., PLOS ONE, vol. 10, no. 6, 2015, pages e0131141
BRIEBA ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 5144 - 5149
CHAPPELL ET AL., PNAS, vol. 101, 2004, pages 9590 - 9594
CHENG ET AL., PNAS, vol. 91, 1994, pages 5695 - 5699
CHIU ET AL., J. VIROL., vol. 79, no. 13, 2005, pages 8303 - 8315
CHUNG ET AL., BIOCHEMISTRY, vol. 37, no. 46, 1998, pages 16298 - 16306
CHUNG ET AL., BMC SYSTEMS BIOLOGY, vol. 6, 2012, pages 134
COMERONAGUADE, J. MOL. EVOL., vol. 47, 1998, pages 268 - 74
CONTRERASRAO, LEUKEMIA, vol. 26, 20 December 2011 (2011-12-20), pages 404 - 413
COUGHLIN, C. M., CANCER RES, vol. 57, 1997, pages 2460 - 2467
CROWLEY ET AL., GENE THER, 30 June 2015 (2015-06-30)
DAUBENDIEK ET AL., JACS, vol. 117, 1995, pages 7818 - 7819
DIEBOLD ET AL., EUR. J. IMMUNOL., vol. 36, 2006, pages 3256 - 3267
DIEBOLD ET AL., SCIENCE, vol. 303, 2004, pages 1526 - 1529
DWYER ET AL., J. NEUROCHEM., vol. 66, no. 2, 1996, pages 1335 - 1343
FERIZI ET AL., LAB CHIP, vol. 15, no. 17, 2015, pages 3561 - 3571
FOXERIL, DNA RES, vol. 17, no. 3, 2010, pages 185 - 96
FREEMAN ET AL., BIOTECHNIQUES, vol. 26, no. 1, 1999, pages 112 - 22,124-5
FROLOVSCHLESINGER, J. VIROL., vol. 70, no. 12, 1996, pages 1182 - 1190
GANRHOADS, J. BIOL. CHEM., vol. 271, no. 2, 1996, pages 623 - 626
GARNEAU ET AL., J. VIROL., vol. 82, no. 2, 2008, pages 880 - 892
GATELY, MK ET AL., ANNU REV IMMUNOL, vol. 16, 1998, pages 495 - 521
GENTNERNALDINI, TISSUE ANTIGENS, vol. 80, 2012, pages 393 - 403
GOFF LA ET AL., PLOS ONE, vol. 4, 2009, pages e7192
GRIMSON AFARH KKJOHNSTON WKGARRETT-ENGELE PLIM LPBARTEL DP, MOL CELL, vol. 27, no. 1, 6 July 2007 (2007-07-06), pages 91 - 105
GUSTAFSSON ET AL., JOURNAL/TRENDS BIOTECHNOL, vol. 22, 2004, pages 346 - 53
GUSTAFSSON ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 83, 2012, pages 37 - 46
HANSSON ET AL., J. BIOL. CHEM., vol. 290, no. 9, 2015, pages 5661 - 5672
HEMMI ET AL., NATURE, vol. 408, 2000, pages 740 - 745
HERBST ET AL., J CLIN ONCOL, vol. 31, 2013, pages 3000
HOLCIKLIEBHABER, PNAS, vol. 94, no. 6, 1997, pages 2410 - 2414
HOLDENHARRIS, VIROLOGY, vol. 329, no. 1, 2004, pages 119 - 133
HOLTKAMP ET AL., BLOOD, vol. 108, no. 13, 2006, pages 4009 - 4017
IKEMURA, J. MOL. BIOL., vol. 151, no. 3, 1981, pages 389 - 409
INNIS ET AL., PNAS, vol. 85, 1988, pages 9436 - 9440
ISMAIL M. MERAZ ET AL: "Adjuvant Cationic Liposomes Presenting MPL and IL-12 Induce Cell Death, Suppress Tumor Growth, and Alter the Cellular Phenotype of Tumors in a Murine Model of Breast Cancer", MOLECULAR PHARMACEUTICS, vol. 11, no. 10, 6 October 2014 (2014-10-06), US, pages 3484 - 3491, XP055388647, ISSN: 1543-8384, DOI: 10.1021/mp5002697 *
IZQUIERDOCUEVZA, BIOCHEM. J., vol. 346, 2000, pages 849 - 855
IZQUIERDOCUEVZA, MOL. CELL. BIOL., vol. 17, no. 9, 1997, pages 5255 - 5268
JIE CHEN ET AL: "Production and clinical development of nanoparticles for gene delivery", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 3, 1 January 2016 (2016-01-01), GB, pages 16023, XP055656178, ISSN: 2329-0501, DOI: 10.1038/mtm.2016.23 *
JIMA DD ET AL., BLOOD, vol. 116, 2010, pages e118 - e127
JUNJIE LI ET AL., CURRENT BIOLOGY, vol. 15, 23 August 2005 (2005-08-23), pages 1501 - 1507
K ANWER ET AL: "Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer", GENE THERAPY, vol. 17, no. 3, 24 December 2009 (2009-12-24), GB, pages 360 - 369, XP055656177, ISSN: 0969-7128, DOI: 10.1038/gt.2009.159 *
KANG, W. K. ET AL., HUMAN GENE THERAPY, vol. 12, 2001, pages 671 - 684
KARIKO ET AL., IMMUNITY, vol. 23, 2005, pages 165 - 175
KARIKO ET AL., MOL. THER., vol. 16, no. 11, 2008, pages 1833 - 1840
KARIKO ET AL., MOL. THER., vol. 20, no. 5, 2012, pages 948 - 953
KARIKO ET AL., NUCLEIC ACIDS RES, vol. 39, no. 21, 2011, pages e142
KAUFFMAN KEVIN J ET AL: "Materials for non-viral intracellular delivery of messenger RNA therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 240, 21 December 2015 (2015-12-21), pages 227 - 234, XP029759407, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2015.12.032 *
KEDDE ET AL.: "A Pumilio-induced RNA structure switch in p27-3'UTR controls miR-221 and miR-22 accessibility", NATURE CELL BIOLOGY, vol. 12, no. 10, 2010, pages 1014 - 20
KHLEIF, PROCEEDINGS FROM THE EUROPEAN CANCER CONGRESS 2013, 27 September 2013 (2013-09-27)
KIM ET AL., NATURE, vol. 350, no. 6324, 1991, pages 331 - 92
KNIRSCHCLERCH, BIOCHEM. BIOPHYS. RES. COMMUN., vol. 272, no. 1, 2000, pages 164 - 168
KORE ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, 2013, pages 4570 - 4574
KORMANN ET AL., NAT. BIOTECHNOL., vol. 29, no. 2, 2011, pages 154 - 157
KORMANN ET AL., NATURE BIOTECHNOLOGY, vol. 29, 2010, pages 154 - 157
KUPPUSAMY KT ET AL., CURR. MOL MED, vol. 13, no. 5, 2013, pages 757 - 764
LANDGRAF ET AL., CELL, vol. 129, 2007, pages 1401 - 1414
LASEK W. ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 63, 2014, pages 419 - 435,424
LEONARD, J. P. ET AL., BLOOD, vol. 90, 1997, pages 2541 - 2548
LIZARDI ET AL., NATURE GENETICS, vol. 19, 1998, pages 225 - 232
MANDALROSSI, NAT. PROTOC., vol. 8, no. 3, 2013, pages 568 - 582
MATSUDA ET AL., PLOS ONE, vol. 11, no. 5, 2010, pages e15057
MATSUDAMAURO, PLOS ONE, vol. 5, 2010, pages 11
MEIJER HA ET AL., SCIENCE, vol. 340, 2013, pages 82 - 85
MELLMAN ET AL., NATURE, vol. 472, no. 7344, 2011, pages 499 - 503
MORIN RD ET AL., GENOME RES, vol. 18, 2008, pages 610 - 621
NASTALA, C. L. ET AL., J IMMUNOL, vol. 153, 1994, pages 1697 - 1706
NORBURY: "Cytoplasmic RNA: a case of the tail wagging the dog", NATURE REVIEWS MOLECULAR CELL BIOLOGY, 29 August 2013 (2013-08-29)
OCHMAN ET AL., GENETICS, vol. 120, no. 3, 1988, pages 621 - 623
P CHAROENSIT ET AL: "Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice", CANCER GENE THERAPY, vol. 17, no. 7, 23 April 2010 (2010-04-23), GB, pages 512 - 522, XP055388601, ISSN: 0929-1903, DOI: 10.1038/cgt.2010.12 *
PANEK ET AL.: "An evolutionary conserved pattern of 18S rRNA sequence complementarity to mRNA 5'UTRs and its implications for eukaryotic gene translation regulation", NUCLEIC ACIDS RESEARCH, 2013
POLEGANOV ET AL., HUM. GEN. THER., vol. 26, no. 11, 2015, pages 751 - 766
POLIDOROS ET AL., BIOTECHNIQUES, vol. 41, 2006, pages 35 - 42
QUERIDO ET AL., J. CELL SCI., vol. 124, 2014, pages 1703 - 1714
RAMUNAS ET AL., FASEB J, vol. 29, no. 5, 2015, pages 1930 - 1939
S TUGUES ET AL: "New insights into IL-12-mediated tumor suppression", CELL DEATH AND DIFFERENTIATION., vol. 22, no. 2, 5 September 2014 (2014-09-05), GB, pages 237 - 246, XP055285716, ISSN: 1350-9047, DOI: 10.1038/cdd.2014.134 *
SAHIN ET AL., NATURE REVIEWS DRUG DISCOVERY, 19 September 2014 (2014-09-19)
SANDHU ET AL., IN SILICO BIOL, vol. 8, no. 2, 2008, pages 187 - 92
SAUDEMONT, A. ET AL., LEUKEMIA, vol. 16, 2002, pages 1637 - 1644
SHARPLI, NUCLEIC ACIDS RES, vol. 15, no. 3, 1987, pages 1281 - 95
SJOBERG ET AL., BIOTECHNOLOGY (NY, vol. 12, no. 11, 1994, pages 1127 - 1131
STRONG ET AL., GENE THERAPY, vol. 4, 1997, pages 624 - 627
SUZUKI ET AL., DNA RES, vol. 15, no. 6, 2008, pages 357 - 65
TANAKA ET AL., INTERNATIONAL JOURNAL OF CANCER, vol. 36, no. 5, 1985, pages 549 - 55
THESS ET AL., MOL. THER., vol. 23, no. 9, 2015, pages 1456 - 1464
TOURIOL ET AL., BIOLOGY OF THE CELL, vol. 95, 2003, pages 169 - 178
VAZ C ET AL., BMC GENOMICS, vol. 11, 2010, pages 288
VIDIGAL JAVENTURA A, SEMIN CANCER BIOL, vol. 22, no. 5-6, 2012, pages 428 - 436
VILLALOBOS ET AL., JOURNAL/BMC BIOINFORMATICS, vol. 7, 2006, pages 285
VIVINUS ET AL., EUR. J. BIOCHEM., vol. 268, no. 7, 2001, pages 1908 - 1917
VOELLENKLE C ET AL., RNA, vol. 18, 2012, pages 472 - 484
WALKER ET AL., PNAS, vol. 89, 1992, pages 392 - 396
WANG ET AL., CANCER IMMUNOL RES, vol. 2, no. 9, 2014, pages 846 - 56
WANG ET AL., CURR. GENE THER., vol. 15, no. 4, 2015, pages 428 - 435
WANG ET AL., EMBO J, vol. 16, no. 13, 1997, pages 4107 - 4116
WANG ET AL., NAT. MED., vol. 10, 2004, pages 1366 - 1373
WARREN ET AL., CELL STEM CELL, vol. 7, no. 5, 2010, pages 618 - 630
WELCH, PLOS ONE, vol. 4, no. 9, 2009, pages e7002
WELLENSIEK ET AL.: "Genome-wide profiling of human cap-independent translation-enhancing elements", NATURE METHODS, 2013
WIEDMANN ET AL., PCR METHODS AND APPLICATION, vol. 3, no. 4, 1994, pages s51 - s64
YAKUBOV ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 394, no. 1, 2010, pages 189 - 193
YOO JK ET AL., STEM CELLS DEV, vol. 21, no. 11, 2012, pages 2049 - 2057
YU ET AL., VACCINE, vol. 25, no. 10, 2007, pages 1701 - 1711
ZANDBERG ET AL., ORAL ONCOL, vol. 50, 2014, pages 627 - 632
ZHOU ET AL., PNAS, vol. 102, 2005, pages 6273 - 6278
ZHU ET AL., NUCLEIC ACIDS RESEARCH, 2013
ZINCKGRAF ET AL., VACCINE, vol. 21, no. 15, 2003, pages 1640 - 9

Also Published As

Publication number Publication date
US20200376081A1 (en) 2020-12-03
EP3458083B1 (fr) 2022-11-02
PT3458083T (pt) 2023-03-06
RU2018144292A3 (fr) 2021-03-10
HRP20230050T1 (hr) 2023-03-03
FI3458083T3 (fi) 2023-03-01
US20220265774A1 (en) 2022-08-25
CA3024470A1 (fr) 2017-11-23
US10646549B2 (en) 2020-05-12
SG11201809381XA (en) 2018-12-28
LT3458083T (lt) 2023-02-10
WO2017201350A1 (fr) 2017-11-23
DK3458083T3 (da) 2023-01-30
RU2769316C2 (ru) 2022-03-30
US20190125839A1 (en) 2019-05-02
ES2941411T3 (es) 2023-05-22
US11000573B2 (en) 2021-05-11
KR102469450B1 (ko) 2022-11-22
US11571463B2 (en) 2023-02-07
EP3458083A1 (fr) 2019-03-27
US20210299221A1 (en) 2021-09-30
PL3458083T3 (pl) 2023-03-13
HUE061077T2 (hu) 2023-05-28
US20240024422A1 (en) 2024-01-25
JP2023072056A (ja) 2023-05-23
JP2019516710A (ja) 2019-06-20
JP7246930B2 (ja) 2023-03-28
MX2018013509A (es) 2019-03-28
IL262501A (en) 2018-12-31
CN109195621A (zh) 2019-01-11
MX2022008602A (es) 2022-08-11
AU2017268397B2 (en) 2023-07-06
KR20220159479A (ko) 2022-12-02
SI3458083T1 (sl) 2023-03-31
KR20190008890A (ko) 2019-01-25
RU2018144292A (ru) 2020-06-18
RS63912B1 (sr) 2023-02-28
US11311602B2 (en) 2022-04-26
AU2017268397A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US11311602B2 (en) Polynucleotides encoding interleukin-12 (IL12) and uses thereof
US11873327B2 (en) Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US20230323371A1 (en) Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
EP3458474B1 (fr) Combinaisons d'arnm codant pour des polypeptides de modulation immunitaire et leurs utilisations
EP3458105B1 (fr) Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1
US10993918B2 (en) Polynucleotides encoding citrin for the treatment of Citrullinemia type 2
US20190298657A1 (en) Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
WO2017201317A1 (fr) Polyribonucléotides contenant une teneur réduite en uracile et utilisations associées
EP3458107A1 (fr) Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221031

AC Divisional application: reference to earlier application

Ref document number: 3458083

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN